Oncology Global Development Unit
PKC412 (Midostaurin)
Clinical Protocol CPKC412E2301 / [STUDY_ID_REMOVED]
A phase III, randomized, double -blind study of 
chemotherapy wi th daunorubicin or idarubicin and 
cytarabine for induction and intermediate dose cy tarabine
for c onsolidation plus midostaurin (PKC 412) or 
chemotherapy p lus placebo in new ly diagnosed patients 
with FLT-3 mutation negativ e acute myeloid leukemia (AML)
Document type Oncology Clinical Tri al Protocol (Clean )
EUDRACT number 2017 -003540 -21
Version number 01(Amended Protocol)
Development phase III
Document status Final
Release date 08-Jun-2018
Property of [COMPANY_001]
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of [COMPANY_001]
Template version 06-Apr-2017

[COMPANY_001] Confidential Page 2
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table of contents
Table of contents ................................................................................................................. [ADDRESS_1018167] of abbreviations ............................................................................................................ 8
Glossary  of terms ............................................................................................................... 13
Protocol summary :
............................................................................................................. 14
Amendment 1 (08 -Jun-
2018) ............................................................................................ 22
1Background ........................................................................................................................ 24
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_5303] .............. 24
1.2 Introduction to investigational treatment(s) and other study treatment(s) ............. [ADDRESS_1018168] -consolidation therap y in AML: disease 
considerations ........................................................................................ [ADDRESS_1018169] assessment ............................................................................. 38
38
2.8 Risk and benefit ..................................................................................................... 39
3Objectives and endpoints ................................................................................................... 41
4Study  desig n
...................................................................................................................... 45
4.1 Description of stud y design ................................................................................... 45
4.2 Study  phase (details of dosing in section 6) .......................................................... [ADDRESS_1018170]-
consolidation phase....................................................................... 47
4.2.4 Follow -up phase .................................................................................... 47
4.3 Timing of interim anal yses and design adaptations ............................................... 48
4.4 Definition of end of study ...................................................................................... 48
4.5 Early study termination .......................................................................................... 48
5Population ................................ ................................ ................................ .......................... 48

[COMPANY_001] Confidential Page 3
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
5.1 Patient population ................................ ................................ ................................ ..48
5.2 Inclusion criteria .................................................................................................... 49
5.3 Exclusion criteria ................................................................................................... 49
6Treatment ........................................................................................................................... 51
6.1 Study  treatment ...................................................................................................... 51
6.1.1 Dosing regimen ..................................................................................... 51
6.1.2 Ancillary  treatments .............................................................................. 56
6.1.3
Rescue medication ................................................................................ 56
6.1.4 Guidelines for continuation of treatment .............................................. 56
6.1.5 Treatment duration ................................................................................ 56
6.2 Dose escalation guidelines ..................................................................................... 57
6.3 Dose modifications ................................................................................................ 57
6.3.1 Dose modification and dose delay ........................................................ 57
6.3.2
Dose adjustments for QTcF prolongation............................................. 62
6.3.3 Follow -up for toxicities ......................................................................... 62
6.4
Concomitant medications ...................................................................................... 63
6.4.1 Permitted concomitant therap y
............................................................. 63
6.4.2 Permitted concomitant therap y requiring caution and/or action ........... 64
6.4.3 Prohibited concomitant therap y
............................................................ 64
6.4.4 Use of Bisphosphonates (or other concomitant agents) ........................ 65
6.5
Patient numbering, treatment as signment or randomization ................................. 65
6.5.1
Patient numbering ................................................................................. 65
6.5.2 Treatme nt assignment or randomization ............................................... 65
6.5.3 Treatment blinding ................................................................................ 66
6.6 Study  drug preparation and dispensation ............................................................... 66
6.6.1 Study  treatment packaging and labeling ............................................... 67
6.6.2 Drug supply  and storage ........................................................................ 67
6.6.3 Study  drug compliance and account abilit y
........................................... 68
6.6.4 Disposal and destruction ....................................................................... 68
7Visit schedule and assessments ......................................................................................... 69
7.1 Study  flow and visit schedule ................................................................................ 69
7.1.1 Molecular p
re-screening ........................................................................ 90
7.1.2 Screening ............................................................................................... 90
7.1.3 Treatment period ................................................................................... 92
7.1.4 Discontinuation of study treatment ....................................................... 93
7.1.5 Withdrawal of consent .......................................................................... 94

[COMPANY_001] Confidential Page 4
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
7.1.[ADDRESS_1018171]....................................................... 116
8.2 Serious adverse events ......................................................................................... 116
8.2.1
Definitions........................................................................................... 116
8.2.2
Reporting............................................................................................. 117
8.3 Emergency  unblinding of treatment assignment ................................................. 118
8.4 Pregnancies .......................................................................................................... 118
8.5 Warnings and precautions .................................................................................... 119
8.6 Data Monitoring Committee ................................................................................ 119
8.7 Steering Committee ............................................................................................. 120
9Data collection and management ................................ ................................ ..................... 120
9.1 Data confidentiality ............................................................................................. 120
9.2 Site monitoring .................................................................................................... 121
9.3
Data collection..................................................................................................... 121
9.4 Database management and quality  control ................................ .......................... 122
10Statistical methods and data anal ysis.............................................................................. 122
10.1 Analy sis sets ........................................................................................................ 123
10.1.1 Full Anal ysis Set ................................................................................. 123
10.1.2 Safety  set............................................................................................. 123
10.1.3
Per-Protocol set ................................................................................... 123
10.1.4 Pharmacokinetic anal ysis set
............................................................... 123
10.2 Patient demographics/other baseline characteristics ........................................... 124

[COMPANY_001] Confidential Page 5
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
10.3 Treatments (stud y treatment, con comitant therapi[INVESTIGATOR_014], compliance) ..................... 124
10.4 Primary  objective ................................................................................................. 124
10.4.1 Statistical hy pothesis, model, and method of analy sis........................ 125
10.4.2 Handling of missing values/censoring/discontinuations ..................... 125
10.4.3 Supportive analy ses............................................................................. 125
10.5 Secondary  objectives ........................................................................................... 126
10.5.1 Key secondary  objective(s) ................................................................. 126
10.5.2 Other secondary  efficacy objectives ................................................... 127
10.5.3 Safety  objectives ................................................................................. 129
10.5.4 Pharmacokinetics ................................................................................ 131
10.5.5
Patient- reported outcomes ................................................................... 132
133
133
133
133
135
10.7 Interim anal yses................................................................................................... 135
10.7.1 Event free survival (EFS) .................................................................... 135
10.7.2 Key secondary  endpoint: Overall 
survival (OS) ................................. 137
10.8
Sample size calculation........................................................................................ 139
10.9 Power for analysis of key secondary  endpoint .................................................... 139
11Ethical considerations and administrative procedures .................................................... 139
11.1 Regulatory
 and ethical compliance ...................................................................... 139
11.2 Responsibilities of the investigator and IRB/ IEC/REB ....................................... [ADDRESS_1018172] keepi[INVESTIGATOR_5304]
..................... 141
11.7 Confidentiality  of study  documents and patient records ..................................... 142
11.8
Audits and inspections......................................................................................... 142
11.9 Financial disclosures ............................................................................................ 142
12Protocol adherence .......................................................................................................... 142
12.1 Amendments to the protocol ................................................................................ 142
13References (available upon request) ................................ ................................ ................ 144
14Appendices ...................................................................................................................... 147
14.1 Appendix 1 
–Concomitant medications .............................................................. 147

[COMPANY_001] Confidential Page 6
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
14.1.[ADDRESS_1018173] of prohibited medications ............................................................ 147
14.1.2 Permitted medications to be used with caution ................................... 147
14.2 Appendix 2 
–FACT -Leu questionnaire .............................................................. 149
14.3 Appendix 3 
–EQ-5D- 5L questionnaire ............................................................... 152

[COMPANY_001] Confidential Page 7
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
List of Figures
Figure 4-[ADDRESS_1018174] of tables
Table 3
-1 Objectives and related endpoints .......................................................... 41
Table 6
-1 Dose and treatment schedule................................................................. 54
Table 6
-2 Criteria for dose reduction/interruption and re -initiation of 
midostaurin/placebo, daunorubicin/idarubicin and cy tarabine 
treatment for adverse drug reactions ................................ ..................... 59
Table 6-3 Dispensing and preparation ................................................................... 67
Table 6
-4 Supply  and storage of study  treatments ................................................ 68
Table 7
-1 Visit evaluation schedule ...................................................................... 70
Table 7
-2 Response classification in AML  at a given evaluat ion time (Cheson 
2003, EL N 2017 / Döhner et al 2017) ................................................... [ADDRESS_1018175] hematologic diagnostics ....................................................... 103
Table 7
-7 Local ECG assessment monitoring schedule ...................................... 106
Table 7
-8 Pharmacokinetic blood collection log for Midostaurin, CGP52421 
and CGP62221 – Full PK collection (N=60) ...................................... 107
Table 7
-9 Pharmacokinetic blood collection log for Midostaurin, CGP52421 
and CGP62221 – Sparse PK collection ............................................... 109
110
Table 7
-11 Biomarker sample collection plan ....................................................... 111
Table 10
-1 Noncompartmental pharmacokinetic parameters ................................ 132
Table 10-2 Simulated cumulative probabilities to stop for efficacy  or futility  
by [CONTACT_941] 1stinterim (IA1), the 2ndinterim (I A2) or the final EFS (FA) 
analyses............................................................................................... 137
Table 10
-3 Simulated probabilities to stop for efficacy  on overall survival at 
2ndEFS interim (1stOS interim (IAOS1)), final EFS (2ndOS 
interim (IAOS2)) anal ysis or final OS anal ysis (FAOS ) .................... 138

[COMPANY_001] Confidential Page 8
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
List of abbreviations
ADR Adverse Drug Reaction
AdSM Advanced systemic mastocytosis
AE Adverse Event
AESI Adverse event of special interest
AHNMD Associated hematologic non -mast cell lineage disorder
ALP Alkaline phosphatase
ALT Alanine aminotransferase
AML Acute myeloid leukemia
ANC Absolute Neutrophil Count
APL acute promyelocytic leukemia
AR Allelic Ratio
ASM Aggressive systemic mastocytos is
AST Aspartate aminotransferase
ATC Anatomical Therapeutic Chemical
AUC Area under the curve
AV Atrioventricular
BCRP Breast cancer resistant protein
BCS Biopharmaceutics classification system
BM Bone Marrow
BMA Bone marrow aspi[INVESTIGATOR_744321] B
CBF Core binding factor
CID Cumulative incidence of death
CIR Cumulative incidence of relapse
CIVI Continuous intravenous infusion 
CMO&PS Chief Medical Office and Patient 
CMV Cytomegalovirus
CNS Central Nervous System

[COMPANY_001] Confidential Page 9
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
CPO Country Pharma Organization
CR Complete remission
CRi Morphologic complete remission with out hematopoietic recovery
eCRF Electronic Case Report/Record Form; the term CRF can be applied to either EDC
or Paper
CRO Contract Research Organization
CSF Cerebrospi[INVESTIGATOR_744322] (CSR) that captures all the additional 
information that is not included in the CSR
CTCAE Common Terminology Criteria for Adverse Events
CV Coefficient of variation
CYP3A4 cytochrome P450 3A4 enzyme
DILI Drug -induced liver injury
DFS Disease-free survival
DMC Data Monitoring Committee
EBV Epstein -Barr Virus
EC Ethic committee
ECG Electrocardiogram
ECHO Echocardiogram
ECOG Eastern Cooperative Oncology Group
EDC Electronic Data Capture
EDD Expected Delivery Date
EFS Event -free survival
ELN European LeukemiaNet
EOT End of Treatment
EQ-5D EuroQol - [ADDRESS_1018176] -Leu Functional assessment of cancer therapy -leukemia
FAS Full analysis set

[COMPANY_001] Confidential Page 10
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
FDA Food and drug administration
FGFR Fibroblas t growth factor receptor
FLT3 FMS- like tyrosine kinase
FLT-3 MN (SR<0.05) FLT-3 Mutation Negative (FLT -[ADDRESS_1018177] Hematopoietic Stem Cell Transplantation
HSV Herpes simplex virus
IB Investigator’s Brochure
ICF Inform consent form
ICH International Conference on Harmonization
ICMJE International Committee of Medical Journal Editors
IDAC Intermediate dose of Ara -C/Cytarabine
IEC Independent Ethics Committee
IN Investigator notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology that includes Interactive Voice Response System
and Interactive Web Response System
ITD Internal Tandem duplication
IUD Intrauterine Device
IUS Intrauterine System
I.V Intravenous(ly)
IWG International Working Group
LAIP Leukemia -Associated ImmunoPhenotypes
LFT Liver function tests
LPLV Last patient last visit
LLOQ Lower limit of quantitation 

[COMPANY_001] Confidential Page 11
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
LVEF Left Ventricular Ejection Fraction
MAR Missing -at-random
MCL Mast cell leukemia
MDS Myelodysplastic Syndrome
MedDRA Medical dictionary for regulatory activities
MFC multi -parameter flow cytometry 
MI Myocardial Infarction
MMRM Mixed models for repeated measures
MR Minor Response
MRD Minimal /Measurable Residual Disease
MRP2 Multi -drug resistance associated protein [ADDRESS_1018178] level
OS Overall Survival
PAS Pharmacokinetic Analysis Set
PD Pharmacodynamic
PDGFR Platelet-derived growth factor receptor
P-gp P-glycoprotein
PHI Protected Health Information
 
PK Pharmacokinetic
PML- RARA Promyelocyte Leukemia -Retinoic Acid Receptor Alpha Rearrangement
p.o. per os/by [CONTACT_1966]/orally
PopPK Population pharmacokinetic analysis
PPS Per-Protocol Set
PR Partial remission
PRO Patient reported outcome
PT Prothrombin time

[COMPANY_001] Confidential Page 12
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
aPTT activated partial thromboplastin time
QT/QTcF QT interval/QT interval corrected with Fridericia’s formula
RATIFY Randomized AML Trial In FLT3+ patients <60 Years (Study A2301)
REB Research Ethics Board
RT Radiotherapy
SAE Serious Adverse Event
SAP Statistical Analysis Plan
SC Steering Committee
SD Standard deviation
SDAC Standard dose of Ara -C/Cytarabine
SM Systemic Mastocytosis
SR Signal Ratio
SS Safety set
SSD Study specification document
S[LOCATION_003]R Suspected unexpected serious adverse reations
TBIL Total bilirubin
TdP Torsades de Pointes
TKD Tyrosine Kinase Domain
ULN Upper limit of normal
VAP Validation and planning
VAS Visual analogue scale
VEGFR Vascular endothelial growth factor
WBC White blood cell
WHO World Health Organization

[COMPANY_001] Confidential Page 13
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Glossary  of terms
Assessment A procedure used to generate data required by [CONTACT_64058] A biological speci men including, for ex ample, blood (plas ma, serum), bone 
marrow, saliva, tissue, urine, stool, etc. t aken fr om a study su bject or study 
patient
Cycles Number and timing or recommended repetitions of therapy are usually 
expressed as number of days (e.g.: 28 days)
Enrollment Point/time of patient entry into the study; the point at which informed consent 
must be obtained (i.e. prior to starting any of the procedures described in the 
protocol)
FLT3-Mutation Negative (MN ) For the purpose of this study FLT3- MNis defined as the absence of ITD 
mutation and absence of TKD activating mutation at codons D835 and I836 in 
the FLT3 gene (FMS -like tyrosine kinase 3 gene) , based on mutant to wild 
type signal ratio below the 0.05 clinical cutoff.
Investigational drug The study treatment whose properties are being tested in the study; this 
definition is consistent with US CFR 21 Section 312.3 and is synonymous with 
“investigational new drug.”
Investigational treatment Drug whose properties are being tested in the study as well as their 
associated placebo and active treatment controls (when applicable). This also 
includes approved drugs used outside of their indication/approved dosage, or 
that are tested in a fixed combination. Investigational treatment generally does 
not include other study treatments administered as concomitant background 
therapy required or allowed by [CONTACT_79583]/dosage
Medication number A unique identifier on the label of each study treatment package which is 
linked to one of the treatment groups of a study
Other study treatment Any drug administered to the patient as part of the required study procedures 
that is not included in the investigational treatment
Subject number (Subject No.) A unique identifying number assigned to each patient/subject/healthy 
volunteer who enrolls in the study
Period A subdivision of the study timeline; divides stages into smaller functional 
segments such as screening, induction, consolidation, post-consolidation, 
follow -up for e fficacy or survival.
Personal Data Subject information collected by [CONTACT_221963]. This data includes subject identifier 
information, study information and biological samples.
Randomization number A unique treatment identification code assigned to each randomized patient, 
corresponding to a specific treatment arm assignment
Stop study participation Point/time at which the patient came in for a final evaluation visit or when 
study treatment was discontinued whichever is later
Study treatment Midostaurin or placebo in sequential combination with daunorubicin/idarubicin 
and cytarabine induction, in sequential combination with intermediate dose 
cytarabine consolidation, and as single agent post -consolidation therapy.
Study treatment discontinuation Point/time when patient permanently stops taking study treatment for any 
reason
Treatment group A treatment group defines the dose and regimen o fthe combination .
Variable Identif ier used in the data analysis; derived directly or indirectly from data 
collected using specified assessments at specified timepoints.
Withdrawal of cons ent Withdrawal of consent from the study occurs only when a subject does not 
want to participate in the study any longer, and does not allow any further 
collection of personal data

[COMPANY_001] Confidential Page 14
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Protocol summary :
Title A phase III, randomized, double -blind study of chemotherapy with daunorubicin or 
idarubicin and cytarabine for induction and intermediate -dose cytarabine for 
consolidation plus midostaurin (PKC412) or chemotherapy plus placebo in newly 
diagnosed patients with FLT3 -mutation negative acute myeloid leukemia (AML) 
Brief title A global study of the efficacy and sa fety of midostaurin + chemotherapy in newly 
diagnosed patients with FLT3 -MN AML
Sponsor and clinical 
phase[COMPANY_001] ,  Phase III
Investigation type Drug
Study type Interventional
Purpose and rationale The purpose of this study is to confirm the preliminary evidence from early clinical trials 
that midostaurin may provide clinical benefit not only to AML patients with the FLT3 -
mutation sbut also in FLT3 -MN (SR<0.05) AML (FLT3 mutant to wild type signal ratio 
below the 0.05 clinical cut- off).
This s tudy will evaluate the efficacy and safety of midostaurin in combination with 
daunorubicin or idarubicin and cytarabine forinduction andintermedia te-dose 
cytarabine for consolidation, and midostaurin single agent post-consolidation therapy in 
newly diagn osed patients with FLT3 -MN (SR<0.05) AML.
Primary objective(s) 
and key secondary 
objectivePrimary Objective: To determine if the addition of midostaurin to standard induction and 
consolidation therapy, followed by [CONTACT_744348] -consolidation therapy improves 
event -free survival (EFS) in patients with newly diagnosed FLT3 -MN (SR<0.05) AML.
Key Secondary Objec tive: To determine if the addition of midostaurin to standard 
induction and consolidation therapy, followed by [CONTACT_744348] -consolidation 
therapy improves overall survival (OS ) in patients with newly diagnosed FLT3 - MN 
(SR<0.05) AML.
Secondary objecti ves Objective 1: To compare the rate of complete remission (CR + CR iwith adequate blood 
count recovery) in the two treatment groups.
Objective 2: To compare the percentage of patients who reached MRD negative status 
in the two treatment groups .
Objective 3: To compare the pe rcentage of patients with MRD negative status in the 
post-consolidation phase in the two treatment groups .
Objective 4: To compare the time to MRD negative status bone marrow between the 
two tr eatment groups .
Objective 5: To compare disease -free survival ( DFS), as well as the cumulative 
incidence of relapse (CIR) and cumulative incidence of death (CID) in the two treatment 
groups.
Objective 6: To compare the time to CR or CRi with adequate blood count recovery in 
the two treatment groups.
Objective 7: To compare the time to neutrophil recovery in the two treatment groups .
Objective 8: To compare the time to platelet recovery in the two treatment groups .
Objective 9: To assess the safety and tolerability of mido staurin in combination with 
chemotherapy and as monotherapy during post -consolidation.
Objective 10: To further characterize the pharmacokinetics of midostaurin, CGP52421 
and CGP62221.
Objective 11: To assess the impact of midostaurin on health related qua lity of life and 
AML symptom reduction .
 
 

[COMPANY_001] Confidential Page 15
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
 
 
 
Study design This is a multi -center, multinational, randomized, double-blind Phase III study using a 
group sequential design with two interim analyses.  The primary endpoint is EFS as per 
investigator assessment and is defined as the time from randomization to failure to 
achieve CR or CRi with adequate blood count recovery (i.e.,neutrophils ≥1.0 x 109/L 
and platelets ≥50 x 109/L) in induction phase , relapse from CR or CRi with adequate
blood count recovery or death due to any cause whichever occurs first.
Overall surv ival ( OS)is the key secondary endpoint and is defined as the time from 
randomization to death due to any cause . OS will be hierarchically tested if the EFS 
shows significant improve ment inthesecond interim analys is or in the final analysis.
Patients will be stratified according to 
Age (<60 vs . ≥60 years)
Patients within each stratum will be randomized in a 1:1 ratio into one of two treatment 
arms:
Midostaurin + chemotherapy
or
Placebo + chemotherapy
The stud ywill consist of the following phases:
Screening/randomization phase:
Patients having signed informed consent will be screened for eligibility criteria. 
Patients will start treatment with chemo therapy at day 1 and will be randomized at day 
8.
Induction phase:
All patients will receive at least one cycle of induction therapy with continuous infusion 
cytarabine and daunorubicin or idarubicin (induction 1) . Patients not achieving CR or 
CRiwith a dequate blood count recovery after Induction 1 will receive a second cycle 
with intermediate -dose cytarabine and daunorubicin or idarubicin (induction 2) .
Patients not achieving CR or CRiwith adequate blood recovery after induction 2 will 
discontinue study treatment and will be followed for survival.
Patients achieving CR or CRi with a dequate blo od count recovery after induction 2 will 
enter the consolidation phase.
Consolidation phase : 
Patients achiev ingCRor CRi with a dequate blood count recovery after induction with 
one or two cycles will proceed to consolidation therapy with either 3 or 4 cycles of 
intermediate -dose cytarabine, or to Hematopoietic Stem Cells Transplantation (HSCT )
with or without preceding consolidation cycles.
Post-consolidati on phase: 
Patients achieving CR or CRi with adequate blood count recovery at the end of the 
consolidation phase will receive 12 cycles (28 days/cycle) of continuous therapy with 
midostaurin or placebo twice daily at [ADDRESS_1018179] -transplant therapy, 
continuously, for up to 12 cycles (28 days/cycle). Post HSCT post -consolidation therapy 
will begin >[ADDRESS_1018180].
Follow -up phase:

[COMPANY_001] Confidential Page 16
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
All patients enrolled to the study will be followed through the treatment period and until 
relapse/treatment failure, thereafter for start of new line of therapy and survival. 
Population The study will include 502 adult (male and female) patients 18 years with newly 
diagnosed FLT3 -MN (SR<0.05) AML.
Inclusion criteria Patients eligible for inclusion in this study have to meet all o f the following criteria:
Diagnosis of AML ( ≥20% blasts in the bone marrow based on World Health 
Organization ( WHO) 2016 classification ). Patients with acute promyelocytic leukemia 
APL with a PML-RARA rearrangement are not eligible .
Suitability for intensive induction chemotherapy in the judgment of the investigator
based on patient’s performance status and comorbidities
Documented absence of an internal tandem duplication ( ITD)and tyrosine kinase 
domain ( TKD)activating mutation at codons D835 and I836 in the FLT3 gene, with 
clinical cutoff of 0.05 mutant to wild type signal ratio.
Age  18 years 
Laboratory values that indicate adequate organ function assessed locally at the 
screening visit:
Aspartate aminotransferase (AST) ≤ 3 times upper limit of normal (ULN)
Alanine aminotransferase (ALT) ≤ [ADDRESS_1018181]
Serum total bilirubin ≤ 1.[ADDRESS_1018182], except in the setting of isolated Gilbert syndrome
Estimated (by [CONTACT_3158] -Gault) creatinine clearance ≥ 30ml/min
Written informed consent 
Exclusion criteri a Patients eligible for this study must not meet any of the following criteria:
Central nervous system ( CNS )leukemia
Therapy -related secondary AML 
Isolated extramedullary leukemia
Prior therapy for leukemia or myelodysplasia with the following exceptions:
Emergency leukapheresis
Emergency treatment for hyperleukocytosis with hydroxyurea or low -dose cytarabine
for  7 days
Cranial radiotherapy (RT) for CNS leukostasis (one dose only)
Hematopoietic Growth factor/cytokine support
Other supportive therapy including antibiotics at the discretion of the investigator
AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., 
azacytidine or decitabine)
Any investigational agent within 30 days or 5 half -lives, whichever is greater
Prior treatment with a FLT3 inhibitor
Strong CYP3A4/5 enzyme inducing drugs (see Appendix 1 ) unless they can be 
discontinued or replaced prior to enrollment. 
Any other known disease or concurrent severe and/or uncontrolled medical condition 
that could compromise participation in the study.
Abnormal chest X -ray with corresponding clinical symptoms or findings that indicate an 
active infection, or other pulmonary conditions that are currently clinically significant. 
Intestina l malabsorption
Known human immunodeficiency virus (HIV) infection or active viral hepatitis
Cardiovascular abnormalities, including any of the following:
History of myocardial infarction (MI), angina pectoris, coronary artery by[CONTACT_9292] 
(CABG) within 6 months prior to starting study treatment
Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia), complete left 
bundle branch block, high -grade atrioventricular ( AV)block (e.g., bifascicular block, 
Mobitz type II and third degree AV b lock)
Uncontrolled congestive heart failure

[COMPANY_001] Confidential Page 17
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Left ventricular ejection fraction of <50%
Poorly controlled hypertension
Pregnant or nursing (lactating) women
Women of child -bearing potential, defined as all women physiologically capable of 
becoming pregnant, unless they are using highly effective methods of contraception 
during dosing and for at least 4 months after stoppi[INVESTIGATOR_88794].
Sexually active males unless they use a condom during intercourse 
Unwillingness or inability to comply with the protocol.
Known hypersensitivity to midostaurin, cytarabine or idarubicin / daunorubicin or to any 
of the excipi[INVESTIGATOR_744323]/placebo, cytarabine or idarubicin / daunorubicin.
Investigational and 
reference therapyMidostaurin or placebo in sequential combination with daunorubicin/idarubicin and 
cytarabine induction, in sequential combination with intermediate dose cytarabine 
consolidation, and as single agent post -consolidation therapy .Treatment switching is 
not an option in this trial.
Efficacy asse ssments Efficacy assessment will be determined by [CONTACT_89944]:
Blast count in bone marrow, peripheral blood specimens (platelet count, neutrophils 
and blasts), evaluation of extramedullary disease and assessment of red blood cell and 
platelet transfusion. 
Entry of response evaluations in the case report form (CRF )will be according to the 
International Working Group (IW G) criteria for AML ( Cheson et al., 2003, ELN 2017 / 
Döhner et al 2017 ) as per investigator assessment. The response to treatment and 
relapse will not require confirmation by a repeated test.
Response assessment will be done at the following time points:
End of each induction cycle, end of each consolidation cycle, every cycle during post -
consolidation phase and every [ADDRESS_1018183] 
a response assessment performed (for a maximum of 2- 3 additional weeks) upon blood 
recovery .
Moreover, disease assessment will be performed any time in case of suspected 
relapse.
For details please see Section 7.2.1 .
Safety assessments Safety assessment will include AEs with severity, relationship to study treatment and 
seriousness , physical examination, Eastern cooperative oncology group (ECOG) PS, 
vital signs, 12 -lead electrocardiogram (ECG), local measurements of QTc ≥480ms will 
be centrally verified on a copy of a high quality recording that includes time and voltage 
scales, multigated acquisition scan (MUGA), echocardiogram (ECHO) and laboratory 
assessments including hematology, chemistry, coagulat ion and urinalysis
Other assessments PK parameters 
Plasma concentrations of midost aurin and its activemetabolites C GP62221 and
CGP52421 
 
 
 
Patient reported outcome assessment using EuroQol -5 Dimension (EQ -5D), Functional 
assessment of cancer therapy -general (FACT-G) with FACT -leukemia (FACT-Leu)
 

[COMPANY_001] Confidential Page 18
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Statistical methods and 
data analysesPopulations:
The Full Analysis Set (FAS) comprises all patients to whom study drug has been 
assigned by [CONTACT_17628]. According to the intent to treat principle, patients will be 
analyzed according to the treatment and stratum they have been assigned to during the 
randomizatio n procedure.
The Safety Set (SS) includes all patients who received at least one dose of study 
treatment starting at day [ADDRESS_1018184] 
one dose of that treatment. 
Primary efficacy and key secondary endpoints:
EFS and OS are the primary and key secondary endpoints, respectively. Therefore, 
family wise type I error rate associated with efficacy analyses for testing EFS and OS 
will be controlled by [CONTACT_744349]. 
Event Free Survival (EFS):
The study is designed to test the following statistical hypothesis for EFS using a 
stratified log -rank test (stratified according to randomization stratification factor of age 
(<60 vs. ≥ 60 years )) at the one -sided 2.5% level of significance: 
H01: θ1≥ 1 vs. H a1: θ1< [ADDRESS_1018185] ratio (Midostaurin treatmen t arm vs. placebo arm) of EFS.
The primary efficacy endpoint EFS will be analyzed at the interim looks and final look of 
a group sequential design based on the FAS population according to the treatment 
group patients were randomized and the strata they wer e assigned at randomization 
(i.e. age < 60 vs. >=60 years). EFS will be estimated using the Kaplan -Meier method. 
The median EFS along with 95% confidence intervals will be presented by [CONTACT_6490]. 
Under the proportional hazards assumption, a test bas ed on the stratified log -rank test 
provides an asymptotically equivalent result as that of the stratified Cox regression 
model which will be used to estimate the hazard ratio (HR) of EFS, along with 95% 
confidence interval (using the same strata informatio n as above). 
The final analysis will be performed when there are approximately 285 EFS events. 
Two interim analyses will be performed when approximately 114 and 214 of the 285 
EFS events ( approximately 40% and 75% information fraction respectively) have b een 
documented .
These analyses are expecte d to take place around [ADDRESS_1018186] patient randomized in the study assuming an increasing recruitment 
rate to reach 30 patients / month in month 6. The primary intent of the first interim 
analysis is to allow the study to stop early for lack of ef ficacy (futility). There is no intent 
to carry out an analysis to declare superior efficacy at the time of the first interim 
analysis. At least, 283 patients (56%) are expected to be randomized at the time of the 
interim futility analysis, i.e., when appro ximately [ADDRESS_1018187] been randomized.
A user -define d gamma spending function ( γ = -1.2) will be used as a beta -spending 
function to determine the non -binding futility boundary at the time of the 1stinterim 
analysis. The futility boundary at the first interim is calculated as hazard ratio of 0.97. 
The observed (i.e., nominal) p -value has to be greater than p=0.44 (one-sided) to 
conclude futility. Since the observed number of EFS events at the interim analyses may 
not exactly be equal to the planned number of events, the futility boundary will need to 
be re -calculated (or updated) bas ed on the actual number of observed events. 
Therefore, the observed p -value (or Z -test statistic) at the first interim analysis will be 
compared with the updated futility boundary.
A Haybittle -Peto stoppi[INVESTIGATOR_744324] (Peto et al 1976 ). At the second interim analysis, the observed p -value has to 
be less than p=0.0001 (i.e. HR<0.6 01) in order to conclude superior efficacy. If the 
study continues, the f inal analysis will be performed when approximately [ADDRESS_1018188] . The final analysis criteria will be determined based 

[COMPANY_001] Confidential Page 19
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
on the actual number of events observed such that the overall significance level across 
all analyses is maintained at 0.025. It is estimated that the observed hazard ratio ( HR)
needs be less than 0. 793to declare statistical significance at the final EFS analysis.
The following table represents the operational characteristics of this design. These are 
based on simulations in the software package East version 6.4 . The following are a few 
key operational characteristics: The cumulative probability to detect an efficacious 
treatment by [CONTACT_744350] 90%; while the cumulative probability of 
erroneously detecting a non -efficacious treatment by [CONTACT_744351] 2.4%. If the 
null hypothesis is true then cumulative probability to stop the trial at the first interim 
analysis for lack of efficacy is 5 5.8%.
Hazard 
ratioAnalysis Avera
ge 
sampl
e sizeEFS 
(information 
fraction)Average
Time
(months)Simulated cum. Prob 
stop due to
Efficacy Futility
0.675IA 1
IA 2
FA282
502
502114 (40%)
223 (78%)
285 (100%)11.9
20
38.80.0149 *
0.1983
0.9000.025
NA
NA
0.8375IA1
IA2
FA264
502
502123 (43 %)
240(84%)
285 (100%)11.3
20
310.0003 *
0.009
0.3120.213
NA
NA
1.0IA1
IA2
FA249
502
502114 (40%)
255 (89%)
285 (100%)10.8
20
26.50
0.0001
0.0240.558
NA
NA
*Although the probability to stop for efficacy at IA1 is provided, t here is no intent to stop 
for efficacy at IA1.
Overall Survival (OS):
OS is the key secondary endpoint. A hierarchical testing procedure will be adopted and 
analysis of OS will be performed only if the primary null hypothesis for EFS is rejected. 
The analysis of OS will be based on FAS following a separate group-sequential plan.
Two interim analyses and a final analysis for OS may be performed in this study. A 
Haybittle -Peto boundary (Peto et al 1976 ), independent of the Haybittle -Peto boundary 
used for EFS , along with the testing strategy outlined below wi ll be used to maintain the 
overall type I error probability . Timing of two interim OS analyses will be at the same 
time as the second interim and final EFS analyses. The OS analysis will compare 
midostaurin+chemotherapy with placebo+chemotherapy (H 02: θ2≥1 vs. H a2: θ2< [ADDRESS_1018189] ratio (m idostaurin treatment arm vs. placebo arm) of OS). The 
median OS in the control treatment arm is expected to be around 30 months. It is 
hypothesized that midostaurin treatment arm will result in a 28.6% reduction in the 
hazard rate for overall survival (corresponding to an increase in median survival by 12 
months (from 30 to to 42 months) under the exponential model assumption). If the true 
hazard ratio is [ADDRESS_1018190] 80% 
power at an one -sided overall 2.5% level of significance to reject the null hypotheses 
(HR≥1) using a log -rank test and a 3-look group sequential design. Under the 
assumptions mentioned abov e, approximately 79and 190 survival events (28% and 
68% information fraction respectively) are expected to occur at the time of the first and 
second interim OS analysis, respectively. The final analysis for OS will be conducted 
when [ADDRESS_1018191] patient to be randomized. 
The following table provides expected time at which interim and final analyses for EFS 
and OS will be performed.  These estimates are based on the assumptions used for 
determining the study design:

[COMPANY_001] Confidential Page 20
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Analysis Expected 
number of 
randomized 
patientsNumber of events Expected 
time***
(month)EFS
(information 
fraction)OS**
(information 
fraction)
EFS First interim 283 114(40%) - 12
Second EFS 
interim/first OS 
interim502 223(78%) 79(28%) 20
EFS final/Second 
OS interim502 285(100%) 190(68%) 39
OS final 502 - 278(100%) 64
** Analyses performed in case EFS is significant
*** Expected time after FPFV.
The interim analyses for EFS and the first interim analysis of OS will be performed by 
[CONTACT_55467]. 
Results from the EFS interim analysis will not be communicated to clinical team, the 
study steering committee (SC) or any party involved in the study conduct (apart from 
the independent statistician and independent data monitoring committee ( DMC )
members) or external parties including Health Authority and investigators until EFS is 
found to be significant or study needs to be terminated due to safety or lack of efficacy. 
Unblinded results from the OS interim analysis will not be communicated to clinical 
team or any party involved in the study conduct (apart from the independent statistician 
and DMC members) or external parties, until OS is found to be significant or until the 
final OS analysis or the study needs to be terminated due to any cause.  Note that the 
DMC will also conduct regular safety looks which may include on -study deaths.
Other secondary endpoints:
Other secondary efficacy varia bles include CR or CRi with adequate blood count 
recovery rate, DFS, C umulative I ncidence of Relapse (CIR), and C umulative I ncidence 
of Death (CID) . The assessment of these endpoints will be based on the I WG for AML 
(Cheson et al 2003, ELN 2017 / Döhner et al 2017 ), per investigator assessment. 
CR or CRi with adequate blood count recovery rates will be analyzed using Cochran -
Mantel -Haenszel test based on strata at ran domization. Estimated CR or CRi with 
adequate blood count recovery rate salong with corresponding 95% confidence 
intervals will be presented by [CONTACT_1570].
Median DFS, Time to CR or CRi with adequate blood count recovery, Cumulative 
Incidence of Relapse (CIR) and C umulative Incidence of Death (CID) along with 
corresponding 95% confidence intervals will be presented by [CONTACT_1570].
The rate of CR or CRi with adeq uate blood count recovery and time to CR or CRi with 
adequate blood count recovery will be analyzed based on the FAS. However, DFS, 
Cumulative Incidence of Relapse (CIR) and Cumulative I ncidence Death (CID) will be 
analyzed based on data from responders (CR or CRi with adequate blood count 
recovery) in the FAS. Assessment of relapse from CR or from CRi with adequate blood 
count recovery, DFS, C umulative Incidence of Relapse (CIR) , and Cumulative
Incidence of Death (CID) will not consider whether a patient received HSCT.
The median time to platelet and to neutrophil recovery along with their corresponding 
95% confidence intervals will be presented by [CONTACT_1570].
In addition safety, pharmacokinetic, patient reported outcome (PRO) data will be 
analyzed.  For PRO, The FACT -Leu will be scored.  For each treatment group, 
calculated score and change from baseline will be analyzed.  Effects of treatment on 
overall HRQL will be assessed.  
Sample size
The assumpt ion of median EFS of 12.0 months for the control treatment arm for sample 
size calculations is based on available data for patients with FLT -MN Hoenekopp
(Bacher et al 2008 ). It is expected that treatment with test treatment arm will result in a 

[COMPANY_001] Confidential Page 21
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
37.5% reduction in the hazard rate (corresponding to an increase in median PFS from 
12.[ADDRESS_1018192] 90% 
power at an one -sided overall 2.5% level of significance to reject the null hypothesis 
(HR= 1) using a log -rank test and a 3 -look group sequential design with Haybittle -Peto 
boundary to determine effica cy boundary and gamma spending function (γ = -1.2 ) to 
determine the non -binding futility boundary. Considering a recruitment period of 
approximately 20 months assuming an increasing recruitment rate to reach 30 patients 
/ month in month 6, 502 patients wil l need to be randomized to the two treatment arms 
in a 1:1 ratio. Assuming about 10% patients will be lost to follow-up for EFS, a total of 
[ADDRESS_1018193] 6.4 .
For details of the statistical methods, please see section 10 .
Key words PKC412, midostaurin, cytarabine, daunorubicin ,idarubicin, acute myeloid leukemia, 
FLT3 -MN (SR<0.05) , combination treatment, induction failure, event free survival , 
measurable residual disease.

[COMPANY_001] Confidential Page 22
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Amendment 1 (08-Jun -2018 )
Amendment rationale
At the time of this protocol amendment, patient shave not yet been enrolled in the trial .  
Due to the implementation of the Global Data Protection Regulation (GDPR) on 25- May-
2018, corresponding changes have been made tothe ICF and protocol. 
Additional text ha sbeen added to the screening section in order to clarify  that a t sites that also 
participate in the CPKC412A2220 (A2220) trial (aiming at patients with FLT3 mutated AML), 
patients who are screened in the A2220 trial and confirmed to be 
FLT3 mutation negative 
(SR<0.05) may be offered the opportunity  to join the E2301 trial provided they also meet all 
other inclusion criteria. As the majority  of patients diagnosed with AML are FLT3 mutation 
negative, this will allow that a considerable number of patients, who have gone through 
complex screening proced ures and who would remain without study  treatment , can be offered 
the opportunity  to be treated within the E2301 clinical trial .
Further text has been added to outline that blood will be taken to collect information on some 
enzy me activity  (pharmacogenomic anal ysis) to under stand how the drug is broken down, and 
to address a Regulatory  
Authority  request.
Additional changes were implemented based on Health Authority  recommendations. 
Changes to the protocol 
Minor ty pos and grammatical errors were updated throughout the protoc ol. 
1.List of Abbreviations updated. 
2.Glossary  of terms: Updated ‘Personal data’ and ‘withdrawal of consent’ to coincide with 
GDPR guidelines .
3.All: Correction of typosand formatting to include Pgp to P -gp, 109/L to 109. Bone 
marrow samples ‘on’ day 21
-28 changed to “between” day  21-28. Updated to CTCAE 
version 5.0
.
4. Section 2.2.2: A nalyses of OS update d ‘indicates’ to ‘suggests’.
5. Section 4.2.2: Updated timing for Study  treatment interruption before HSCT .
6. Section 4.4: Clarified the time to End of study .
7. Sec tion 4.5: Further defined e arly termination.
8. Section 5.3: Exclusion criterion #16 updated.
9. Section 5.3: Exclusion criterion #18 added ‘ Known hy persensitivity  to IMP’.
10.Section [IP_ADDRESS]: Clarification on study  drug characteristics.
11. Section 6.3.2 and Table 6.2:Clarified dose modification s .
12.Table 6.2: Dose modifi cations for idarubicin included.
13. Section 6.4.2: Permitted Concomitant medication updated. 
14.Table 7.1 and Table 7.6: Cytogenetics updated to reflect new AML testing guidelines .
15.Table 7.1: Update 30 day  follow up assessments.

[COMPANY_001] Confidential Page 23
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
16. Section 7.1.2 : Screening section updated to capture inclusion of A2220 FLT3 mutation 
negative patients and to clarify  the sample collection and timing of AML diagnosis . 
17.Section [IP_ADDRESS]: Clarification on FL T3 data collection. 
18.Section 7.1.3 : Updated dur ation of each cycle length . 
19.
Section 7.1.5: Withdrawal of consent updated to align with GDPR .
20.
Section [IP_ADDRESS]: Physical exam definition updated .  
21. Section [IP_ADDRESS] and 11.3: F ertility  information updated.
23.Section 7.2.4 and Table 7.11: Biomarker tests clarified. 
24.Section [IP_ADDRESS]: MRD negative status updated .
25. Section 10.5.4 and Table 10-1: Updated pharmacokinetic sand PK parameters. 
26.References : Addition of ‘Thiede et al 2002 ’citation .
27.Appendix 1 : Prohibited concomitant medication updated for clarit y.  
Changes to specific sections of the protocol are shown in the track changes version of the 
protocol using 
strike through red font for deletions and red underlined for insertions.
IRBs/IECs 
A copy of this amended protocol will be sent to the Institutional Review Board 
(IRBs)/Independent Ethics Committee (I ECs) and Health Authorities. 
The changes described in this amended protocol require IRB/IEC approval prior to 
implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for 
approval a revised Informed Consent that takes into account the changes describ ed in this 
protocol amendment. 

[COMPANY_001] Confidential Page 24
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
1 Background
1.1 Overview of disease pathogenesis, epi[INVESTIGATOR_744325] m yeloid leukemia ( AML )is one of the most common ty pes of leukemia in adults. I t is a 
heterogeneous disease that is characte rized by [CONTACT_744352][INVESTIGATOR_744326]. Risk stratification in 
AML is evolving as a consequence of characterizing cy togenetic abnormalities and mutational 
profiling, and the latter is especially  important in patients lacking karyotypic abnormalities 
(Döhner et al 2017 ).
Currently , the most generall y recognized approach to classify ing AML and predicting its 
prognosis considers the (co)occurrence of specific cytogenetic abnormalities together with 
mutations such as NPM1, FLT3-ITD and CEBPA. However other mutations such as 
DNMT3A and TP53 are also increasingl y recognized to impact clinical outcome 
(Papaemmanuil et 
al 2016 ; Arber et al 2016). The European LeukemiaNet (ELN) guidelines 
have provided updated recommendations for prognostic determination (Döhner et al 2017). 
Favorable prognosis AML includes that with FLT3 -ITDlowallelic ratio or FLT3 -ITD -negative 
genot ype combined with a NPM1- mutation, or the presence of core binding factor (CBF) 
alterations. Adverse prognos is is associated with karyotypes such as monosomy  5  o r 
monosomy  7, NPM1- WT genot ype with FLT3 -ITDhighallelic ratio, or the t(6;9) or t(9;22) 
translocations, among others. The remainder is classified as intermediate risk disease. For the 
complete ELN risk groups including all genetic and genomic risk markers please refer to the 
2017 guidelines ( Döhner et al 2017 ).
Approximately  30% of patients with newly  diagnosed AML  have an activating mutation in 
the FLT3 gene, usuall y either an ITD mutation, in approximately  20% of AML  patients, or an 
activating point mutation in the activating loop of the TKD, approximately  6-8% of AML 
patients) (Kayser and Levis 2014); rarely, both occur in the same leukemia. The FLT3 gene 
encodes a protein in the class III t yrosine kinase receptor family , and it serves a key  role in the 
proliferation and differentiation of normal hematopoietic progenitor cells. FLT3 -ITD 
mutations, particularly  when they are present at a high allelic ratio relative to FLT3 -MN 
(FLT3 -wildy
pe), are associated with poor prognosis (Kottaridis et al 2001 , Bacher et al 2008, 
Thiede et 
al 2002, Pratcorona et al 2013). In patients with newly  diagnosed AML, the 
complete remission (CR) rates in patients with FLT3 mutations are generally  similar, or only 
slightly  lower, than in those without FLT3 mutations. However, FLT3 -ITD mutations have 
been shown to be associated with inferior DFS and OS, 
with a higher risk of relapse 
(Kottaridis et al 2001, Bacher et al 2008 , Thiede et al 2002). The prognostic significance of 
the FLT3 -TKD mutation has not been co nsistent in reports.
Initial therap y for AML  inyounger patients (<60 y ears) to induce remission has changed little 
in the past three decades, and for patients with 
an adequate performance status it frequentl y 
comprises the “7 + 3” remission induction regimen with daunorubicin and cytarabine, 
followed by [CONTACT_744353]. The 5-year survival rate with 

[COMPANY_001] Confidential Page 25
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
this approach is 30 to 40% in patients under the age of 60 years, and less than 15% in older 
patients ( Stone et al 2005 ).
Patients with poor prognostic features of AML are recommended to enroll into clinical trials 
and/or to undergo HSCT following achievement of remission with standard induction 
chemotherap y (Schiller 2014). Significant improvements in OS and DFS for AML patients 
harboring FLT3-ITD mutations have been reported with allo -HSCT compared to 
chemotherap y or autologous HSCT (DeZern et al 2011, Brunet et al 2013), especiall y for 
patients with 
high FLT3 -ITD allelic ratios (Schlenk et al 2014 ). However, these patients 
remain at high risk of relapse post-HSCT compared to patients without FLT3 -ITD mutations, 
with a higher 2-year relapse incidence (30% vs 16%; p=0.006) and lower leukemia free 
survival (58% vs 71%; p=0.04), respectivel y (Brunet et al 2012 )
.
The ability  to delay  or prevent relapses in transplant candidates who experience complete 
remission could allow more eligible patients to undergo a HSCT. This benefit of a longer time 
window in remission would particularl y apply to those patients who require an unrelated 
donor, because [ADDRESS_1018194] 
an improved EFS when comparing with historical contro ls. 
1.2 Introduction to investigational treatment(s) and other study  
treatment(s)
1.2.1 Overview  of Midostaurin
Midostaurin (Rydapt®, PKC412, CGP41251) is an orally bioavailable staurosporine analog 
with potent activity  against both ITD-and TKD -mutant as well as against FLT3 -MN, and 
these observations informed the decision to pursue its development in patients with FLT3 -
mutated AML. In addition, it inhibits other molecular targets including several isoforms of 
protein kinase C, KIT, vascular endothelial growth factor receptor (VEGFR -2), platelet -
derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR) , and 
multi
-drug resistance gene products, which are thought to be important for the pathogenesis of 
AML  or its sensitivity  to standard therapie s. Furthermore, midostaurin inhibits kinases with 
mutations that confer resistance to other tyrosine kinase inhibitors such as imatinib.
The anti-proliferative effects of midostaurin were demonstrated in in vitro assay s with cells 
expressing FLT3-ITD or FLT3 -TKD mutations (Weisberg et al 2002). Synergistic inhibitory 
activity  of midostaurin in combination with daunorubicin or cy tarabine was observed in AML 
patie nt cell lines. Moreover, a related FLT3 inhibitor provided enhanced but 
sequence 
dependent cell cytotoxicity  when administered simultaneously  with or immediately  following 
cytarabine, and the combinatorial activity  of the FLT3 inhibitor with daunorubicin was also 
demonstrated ( Levis et al 2004
).
The potential clinical activity  of midostaurin in patients with FLT3-Wildty peAML is 
supported by [CONTACT_744354]-based studies. Midostaurin potently  inhibits the activity  of 
the purified FLT3 -MN tyrosine kinase with an IC50 of 19.8 nM, and it binds to the purified 

[COMPANY_001] Confidential Page 26
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
FLT3 -MN kinase with a dissociation constant of 11 nM. Midostaurin inhibits the proliferation 
of the M07e leukemia cell line (FLT3 -MN) with an IC50 of 183 16 nM ([COMPANY_001] internal 
data). Moreover, midostaurin inhibits protein tyrosine phosphory lation of FLT3 -MN-
expressing Ba/F3 hematopoietic cells stimulated with FLT-ligand at midostaurin doses in the 
range of 0.01 -1 µM ( Weisberg et al 2002 ).
[IP_ADDRESS] Non
-clinical experience 
Pharmacokinetics and drug meta bolism in animals
The oral absorption of [14C]midostaurin in all species was moderate to high, and the 
bioavailability  was low to moderate. Given midostaurin’s low aqueous solubility  (<0.001 
mg/mL) and its high absorption in human (>90%), midostaurin is classified as a 
Biopharmaceutics classification system (BCS )II drug. In rats, dogs and rabbits, the total 
systemic plasma clearance (0.24 - 0.98 L/h/kg) andthe volume of distribution at steady  state 
(1.20 - 3.77 L/kg) were moderate. The half-life was relativel y short in animals (3.2-7.3 h). In 
human the apparent terminal half- life was relatively  long (~20 h) following a single oral dose.
Radioactivity  derive d from [14C]midostaurin was extensively  distributed into tissues in the rat. 
The concentrations in most tissues were higher than that in blood. Radioactivity  crossed the 
blood brain barrier. After multiple doses, the radioactivity  in tissues was 2 -10-fold higher than 
that after a single dose. [14C]midostaurin showed a high protein binding in the rat, dog and 
human (>98 -99%). The protein binding was independent of concentration in animals. In 
human, a concentration dependent increase in fraction unbound was observed over a 
concentration range of 100-20,000 ng/mL. The two major metabolites of midostaurin, 
[14C]CGP52421 and [3H]CGP62221, showed a similar plasma protein binding to midostaurin.
Midostaurin was extensively  metabolized in the rat, dog, rabbit and human. The primary 
biotransformation pathway s observed included hydroxylation, 
O-demethy lation, N-
demethy lation and amide hy drolysis. The major circulating components were midostaurin and 
CGP52421 (two epi[INVESTIGATOR_744327]) in all species. CGP62221 (the O-demethy lation product) was also a 
major human circulating metabolite and detectable in the dog and rabbit. The total recovery  of 
radioactivity  was high in the rat, rabbit, dog and human (81.5% -99.4%). In all these species, 
radioactivity  was mainl y excreted via fecal excretion. Renal excretion was apparentl y very 
minor (<4%).
Based on recombinant enzy mes and human liver microsomes, the CYP3A4 is the major 
enzy me involved in midostaurin oxidative metabolism. Midostaurin, CGP52421 and 
CGP62221 were found to inhibit the following cytochromes in-vitro: CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, CYP2E1 and CYP3A4. It also induces the following 
cytochromes: CYP1A2, CYP2C8, CYP2C9 ,CYP2B6 and CYP3A4. The results of the net 
effect model suggest that an impact of midostaurin and/or CGP52421 and CGP62221 is 
expected on the following CYP: CYP3A4, CYP2C8 and CYP2B6. 
In vitro experiments demonstrated as well that midostaurin, CGP52421 and CPG62221 can 
potentially  inhibit P-glycoprotein (P-gp) inhibitor with an IC50value of 1.7 M, breast cancer 
resistant protein (BCRP)(IC50=0.23 M) and OATP1B1 (IC50=1.25 M). Thus, its 
concomitant use with P-gp, BCRP or OATP1B1 substrates could lead to clinical drug-drug 

[COMPANY_001] Confidential Page 27
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
interactions. Midostaurin drug transport inhibition experiments indicated that midostaurin is 
not likely  to be a substrate of P-gp, multi- drug resistance associated protein 2 (MRP2 ), and is 
not actively  taken up into the liver.
Preclinical toxicology
Midostaurin has been extensively  evaluated in various in vitro systems and in vivo models. 
Studies relevant to clinical dosing of midostaurin include repeat dose toxicology  studies with 
durations of up to [ADDRESS_1018195] been 
performed with the combination of midostaurin and daunorubicin/cy tarabine. No 
carcinogenicity  studies have been performed.
Overall, the effects of treatment with midostaurin observed in the toxicology  studies have 
been essentiall y limited to those expected from an inhibitor of cell proliferation. The no 
observable effect level (NOEL) in the 12-month toxicity  studies was 3 mg/kg in rat and 1 
mg/kg in dog. In-vitro and in-vivo mutagenicity tests revealed no genotoxicity . There was no 
teratogenic effect noted from embry o
-fetal development studies in rats and rabbits. 
Developmental toxicity  was seen at 10 mg/kg or higher. NOEL for fertility  and general 
reproductive toxicity  was defined at 30 mg/kg.
Treatment with midostaurin at doses ≥3 mg/kg in dogs and ≥10 mg/kg in rats at durations up 
to 12 months was associated with effects on proliferating tissues, especially  the intestine 
(mucosal alteration), testes (degenerated spermatogonia), and bone marrow (hypocellularity). 
The effect on thebone marrow was accompanied by [CONTACT_744355] (decreased total 
white cells, ly mphocy tes and ery throcy tic parameters).
Please, refer to the Investigators Brochure for additional information.
[IP_ADDRESS] Clinical experience
Clinical pharmacokinetics
PK character istics
Midostaurin is a BCL  class II compound with good absorption and poor solubility . Two of its 
metabolites demonstrated pharmacological activities (CGP52421 and CGP62221). Following 
multiple doses, thePK of midostaurin and CGP62221 was time-dependent with an initial 
increase observed the first week followed by a decline of concentrations until reaching a 
steady -state on D28. CGP52421 concentrations do not appear to decline significantl y as for 
midostaurin and CGP62221. Midostaurin is rapi[INVESTIGATOR_21590], with 
peak plasma concentrations observed at 1-[ADDRESS_1018196] dose. Midostaurin has an apparent 
volume of distribution of 95 L and is highl y bound to protein, including albumin, alpha -
glycoprotein and lipoprotein, with a free fractio n of about 2%. 
Midostaurin is predominantly metabolized by [CONTACT_097]3A4 into two major active circulating 
metabolites, CGP62221 (via O-demeth ylation) and CGP52421 (via hy droxy lation). The major 
circulating components in plasma are CGP52421, CGP62221 and midosta urin, accounting for 
38, 
28, and 22% of area under the curve AUC0 -168h, respectivel y. The compound related 
materials are mainly  distributed to plasma, and minimally  to red blood cells. The median 

[COMPANY_001] Confidential Page 28
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
terminal half-lives of midostaurin -, CGP62221 and CGP52421 in plasma are approximately  
20.5, 32.3 and 471hours, respectivel y. The midostaurin mean apparent plasma clearance 
(CL/F) was 2.4-3.1L/h in healthy  subjects. In AML  and advanced systemic mastocy tosis ( SM)
patients, popPK estimates for clearance of midostau rin at stead y-state was 5.9 L /h and 4.4 L/h, 
respectivel y. The Human Mass Balance study  results indicated that faecal excretion is the 
major route of excretion (78% of the dose), and mostly  as metabolites (73% of the dose), 
while unchanged midostaurin accounts for 3% of the dose. Only 4% of the dose is recovered 
in urine.
Drug -drug interactions
Strong CYP3A4 inhibitors 
Overall, strong CYP3A4 inhibitors increase exposure of midostaurin. The potential impact of
these agents on the pharmacokinetics of midostaurin was assessed across the midostaurin 
clinical program since many  of these agents are commonly  used as standard of care antifungal 
prophy laxis in patients with AML .
In the Phase 3 study  A2301, a high propor tion of patients received a strong CYP3A4 inhibitor 
mostly  during induction chemotherap y (62%), and using routine antifungal proph ylaxis. 
Patients receiving concomitant strong CYP3A4 inhibitors had 1.44- fold higher exposure to 
midostaurin compared to patie nts not receiving strong CYP3A4 Inhibitors. However, 
increases in midostaurin exposure following co-administration of strong CYP3A4 inhibitors 
were off-set by [CONTACT_744356], resulting in relativel y small 
changes in the exposure to the sum of active moieties at stead y state, consisting of 1.22 fold 
higher exposure in patients receiving strong CYP3A4 inhibitors. Analy sis of the grade 3
-4 
AEs demonstrated that although differences were noted between patients treated with strong 
CYP3A4 inhibitors compared to those without, there was no definite pattern. For example, for 
patients treated with strong CYP3A4 inhibitors, a slightly  higher incidence of sepsis and 
febrile neutropenia was observed; yet patients who did 
not receive strong CYP3A4 inhibitors 
had a slightl y higher incidence of neutropenic infection Nevertheless, different approaches 
were taken to further assess the impact of strong CYP3A4 inhibitors on the PK of midostaurin. 
In a pooled analysis across advanced systemic mastocy tosis (AdSM )and AML  patients 
receiving midostaurin as single –agent therapy , there was maximum of 2.7-fold increase of 
midostaurin exposure (Cmin) at steady  state upon co-administration with strong CYP3A4 
inhibitors. 
When exposure to the sum of active moieties was compared, the geometric mean 
Cmin increased by  76% upon co -administration with CYP3A4 inhibitors. In Study  A2104E2, 
AML  patients who were concomitantly  administered the strong CYP3A4 inhibitor 
itraconazole (n=7) with midostaurin 50 mg (twice daily)in the combination arm had a 2.09 -
fold increase in midostaurin Cmin at steady  state compared to when they  received midostaurin 
50 mg twice daily alone , CGP52421, CGP62221 and the sum of the active moieties were 
increased by 16%, 33% and 18% respe ctivel y. A similar finding was confirmed through 
popPK analy sis for AML patients.
Of note, in the Phase III Study  A2301, no dose-reduction of midostaurin/placebo was 
recommended with concomitant strong CYP3A4 inhibitors. Based on these data, no dose 
adjust ment is required when midostaurin is co-administered with CYP3A4 inhibitors. 
However, caution should be advised when administering medicinal products that are strong 

[COMPANY_001] Confidential Page 29
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
inhibitors of CYP3A4 concomitantly  with midostaurin, and alternative therapeutics that do 
not strongl y inhibit CYP3A4 activity  should be considered. In situations where satisfactor y
therapeutic alternatives do not exist -for example with the use of routine antifungal
prophy laxis with azole antifungals during induction/cons olidation chemotherap yfor AML, 
patients should be closely monitored due to the potential for increase in exposure.
Strong CYP3A4 inducers: In the healthy  volunteer study  A2110, midostaurin concentrations 
decreased by [CONTACT_3450] 10-fold (90% decrease) when co-administered with rifampi[INVESTIGATOR_2513], a 
CYP3A4 inducer. In the single -agent midostaurin studies D2201, A2213 and A2104E1, there 
were no difference in plasma Cmin between patients who received CYP3A4 inducers and 
those who did not forany of the active moieties or sum of active moieties. Of note, none of 
the patients were adminis
tered a strong CYP3A4 inducers at least 7 day s prior to a PK sample.
Therefore, concomitant administration of medicinal products that are strong inducers of 
CYP3A4 with midostaurin should be avoided, and a lternative therapeutics that do not strongl y 
induce CYP3A4 should be considered.
CYP3A4 induction related to midostaurin administration: The PK of a single dose of 
midazolam (sensitive CYP3A4 probe substrate) was not affected in a clinically  meaningful 
manner following four dosing days of midostaurin administration inhealthy subjects (Study 
A2112). The geomean Cmax and AUCinf of midazolam decreased by9% and 5%, 
respectivel y.However, it cannot be excluded that midostaurin may  be an inducer of CYP3A4, 
as the dose of midazolam was administered only  after four dosing day s of midostaurin and not 
at stead ystate. Based on a physiologicall y-based PK analy sis, the simulated results indicate 
that themidazolam geometric mean ratio of AUC could be reduced by 25%at steady -state 
levels of midostaurin, as compared to the value observed in Study  A2112 (Day  8).
Medicinal products with a narrow therapeutic range that are CYP3A4 substrates should be
used with caution when administered concomitantly  with midostaurin, and may need dose
adjustment to maintain optimal exposure.
Clinical efficacy  in AML
Irrespective of activating mutations of FL T3 which are present in 30%, FLT3 is constitutively  
overexpressed in 70% or more of AML patients. As detailed in section 1.2.1 t he potential 
clinical activity  of midostaurin in patients with FLT3 -MN AML is supported by [CONTACT_744357]-based studies (Weisberg et al 2002). Accordingl y, some of the early clinical trials 
with mido staurin in AML  included not only patients with FLT3 mutated AML but also 
patients with FLT3 -MN AML .
The [CPKC412A2104 -E1]phase II trial evaluated midostaurin (single agent) in patients with 
AML  or high-risk MDS with either FLT3-mutated or FLT3 -MN disease. Among the [ADDRESS_1018197] 
response was MR in nine (15.8%) patients, and blast reduction (with or without MR) was 
observed in 23 (40.4%) patients. The results overall indi cated evidence of clinical activity  and 
also supported the evaluation of midostaurin in combination with standard chemotherap y in 
patients with previously  untreated AML . In the [CPKC412A2104 -E2]phase II trial in the 
same patient population, midostaurin wa s either dose escalated or combined with itraconazole 
to pharmacologicall y enhance drug exposure. 

[COMPANY_001] Confidential Page 30
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Of note, one patient in the [CPKC412A2104- E2]trialwith FLT3-MN AML who was enrolled 
inthe midostaurin+itraconazole arm obtained aminor response with blas t reduction from Day 
[ADDRESS_1018198]. 
The [CPKC412A2106 ]phase IB trial evaluated midostaurin administered sequentially  or 
concomitantly  with daunorubicin and cytarabine in 69 patients with AML. Among patients 
treated at 50 mg twice daily , 11/13 (84.6%) patients with FLT3 mutation positive AML  and 
16/27 (59.3%) patients with FLT3-MN AML obtained a CR. The median time to CR was 
similar in FLT3 -mutated and FLT3-MN patients Kaplan –Meier OS probabilities at 1 and 2 
years, respectively , were 0.85 (95% CI: 0.65–1.0) and 0.62 (95% CI: 0.35–0.88) in patients 
with FLT3-mutated AML, and 0.78 (95% CI: 0.62–0.93) and 0.52 (96% CI: 0.33–0.71) in 
patients with FLT3–WT AML . Kaplan –Meier DFS probabilities at 1 year for FLT3 -mutated
and FLT3 –WT patients were 0.50 (95% CI: 0.22–0.78) and 0.60 (95% CI: 0.39–0.81), 
respectivel y. 
The Cancer and Leukemia Group B10603 (CALGB10603 )
([CPKC412A2301 ], RATIFY ) 
trial, hereafter referred to as Study  [A2301] ,enrolled patients in North America and Europe < 
60 years of age with newly  diagnosed FLT3 -mutated acute myeloid leukemia (AML ), 
Midostaurin combined with standard induction and consolidation therapy  following by [CONTACT_744358] . Study  [A2301]
is a randomized, double -blind, multi- center, placebo -controlled Phase III study  conducted in 
717 in patients with newly  diagnosed FLT3 mutation positive (ITD or TKD) AML according 
to WHO criteria. The prim ary efficacy  endpoint was OS non-censored at the time of HSCT, 
and the key secondary  endpoint was EFS non-censored at the time of HSCT. The study  met 
its primary  endpoint; a significant improvement in OS was demonstrated with a HR of 0.77 
(95% CI: 0.629, 0.953), corresponding to a 23% reduction in risk of death in favor of the 
midostaurin arm. The result was statistically  significant with a p-value of 0.0078 at a one -
sided alpha of 0.0239. Because the OS primary  analysis was statisticall y significant, the key 
secondary  endpoint EFS was tested in a confirmatory  setting. The median EFS was 8.2 
months for patients in the midostaurin arm compared to 3.0 months for patients in the placebo 
arm (HR=0.78; 95% CI 0.662, 0.930); this was statistically  significant (p=0 .0024) at a one-
sided alpha level of 0.025. Subgroup analysis demonstrated that the benefit in OS and EFS 
was of similar magnitude for FLT3 ITD mutated patients with low allelic ratio (allelic ratio 
AR < 0.7) compared to high allelic ratio (> 0.7). In addition the OS & EFS benefit for FLT3 
TKD mutated patients, who have disease prognosis closer to wild type patients also showed a 
similar benefit compared to FLT3 ITD with AR > 0.7, suggesting that the observed treatment 
benefit may not only be driven by [CONTACT_744359]3 mutated AML  clones but 
midostaurin may  have activities on FL T3 WT AML.
Based on data from the [A2301] study , midostaurin has been approved by [CONTACT_744360] ( FDA )for the treatment of patients with newl y diagnosed FLT3 m utated AML, 
in combination with standard cytarabine and daunorubicin induction and cytarabine 
consolidation.
The multi
-kinase inhibitor sorafenib inhibits FLT3 and other kinases. In a phase III evaluation 
of sorafenib versus placebo added to standard chemotherapy  in patients with newly  diagnosed 

[COMPANY_001] Confidential Page 31
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
AML , patients with either FLT3 -MN or FLT3 -mutated AML  were enrolled. Although full 
quantitative information about mutation subgroups has not been presented publicly , an 
analysis in which patients with FLT3 -ITD mutations were excluded showed that increases in 
EFS and RFS remained statistically  significant; however, an analysis of patients with FLT3-
MN disease was not reported (Röllig et al 2015). These data suggest that multikinase 
inhibition may be useful 
in AML more broadl y and not just among patients with FLT3 -
mutated AML.
Summary  of safety in clinical studies
Midostaurin has been extensively  studied in both oncology  and 
non-oncology  indications as 
well as in a large number of health y volunteers over the past two decades. Taken together, 
midostaurin has been evaluated inan extensive clinical program including more than 1800 
subjects, including one large, placebo -controlled study  of midostaurin incombination with 
chemotherap y in FLT3 -mutated AML, two Phase 2 studies in advanced SM, nine Phase 1-2 
studies conducted in var ious indications, and 11 clinical pharmacology  studies
The safet y profile of midostaurin is well characterized, with predictable, primar y 
gastrointestinal (nausea, 
vomiting) events and cytopenias that are generally manageable with 
the use of anti -emetic th erapy and dose adjustment/temporary interruption. 
The largest portion of the midostaurin clinical safety  experience has been in two indications:
As a single agent in patients with AdSM [formerly  aggressive s ystemic mastocy tosis 
(ASM) or mast cell leukemia (MCL ) with or without an associated hematologic non -mast 
cell lineage disorder (AHNMD)]
In combination with standard chemotherap y in patients with newly diagnosed FLT3 -
mutated AML
When administered to AML patients in combination with standard “7+3” chemot herap y in the 
pi[INVESTIGATOR_303651] [A2301] trial, most of the AEs, AEs suspected to be related to study  drug, 
serious adverse events (SAEs )and AEs leading to discontinuation occurred at similar 
frequencies in both midostaurin and placebo control groups. The most frequent adverse events 
reported in the combination setting included predominantly  cytopenias (thrombocy topenia, 
anemia, neutropenia) and gastrointestinal events (nausea, vomiting) compared with patients 
receiving midostaurin monotherapy , as expected from the known toxicities of the backbone 
“7+3” chemotherap y regimen.
In Study  [A2301] , the safety  profile (overall) for both the midostaurin and placebo groups was 
consistent. The median duration of exposure to midostaurin and placebo was 42.0 day s (range
2-576 days) and 34.0 days (range 1-465 days), respectivel y. As expected, the most frequent 
grade 3/4 AEs in both groups were related to myelosuppression 
(neutropenia, anemia, 
thrombocy topenia, febrile neutropenia) and occurred in nearl y all patients during the 
induction/consolidation phases. The addition of midostaurin did not prolong the time to 
platelet or neutrophil recovery  in the induction and consolidation phases.
The most frequent non-hematologic grade 3/4 AEs in the midostaurin group were infection s 
(device -related), diarrhea, and exfoliative dermatitis; and for the placebo arm, hypokalemia, 
diarrhea, and pneumonia. AEs 
were generall y balanced between the two arms, with the 
exception of exfoliative dermatitis and transaminase elevations, which occur red more 

[COMPANY_001] Confidential Page 32
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
frequentl y in midostaurin -treated patients. Please refer to the Investigators Brochure for 
additional information.
2 Rationale
2.1 Stud y rationale and purpose
The available preclinical and clinical evidence suggesting a potential clinical activity  of 
midostaurin in patients with FLT3-MN AML is summarized in Section 1.2.
A[A2301] subgroup analy sis compared the benefit in OS and EFS in patients with different 
ratios of FLT3-mutated and FLT3 -MN (allelic ratio). This subgroup analy sis demonstrated 
that the benefit in OS and EFS was of similar magnitude for FLT3 ITD mutated patients with 
low allelic ratio (AR < 0.7and AR < 0.5) compared to high allelic ratio ( ≥0.7). In addition 
the OS and EFS ben efit for FLT3 TKD mutated patients, who have disease prognosis closer to 
wild type patients also showed a similar benefit compared to FLT3 ITD with AR≥0.7, 
suggesting that the observed treatment benefit may not be driven by [CONTACT_324094]3-inhibition alone
but could be driven by [CONTACT_1604], such as the inhibition of the tyrosine- kinase activity  of 
overexpressed FLT3 -MN. Midostaurin is an ATP -
competitive inhibitor of multiple kinases 
including FLT3, KIT, protein kinase C, VEGFR, PDGFR and FGFR. These are molecular
targets implicated in the pathogenesis of AML and a variet y of other diseases. The relative 
contribution to efficacy  of the different mechanisms of action of midostaurin is currentl y not 
fully  understood.
The efficacy  of currently  available treatments is dissatisfy ing in both, AML  with FLT3 -
mutated as well as FLT3 -MN AML . Despi[INVESTIGATOR_444121], little improvement of the 
available therapy  forAML  was achieved during several decades of preclinical and clinical 
research. Approximately 35% to 40% of patients younger than 60 years of age may obtain 
long-term survival with current forms of treatment. However, there is a wide variation in 
outcome among genetically  distinguishable subsets of the disease, with some subty pes having 
a notoriously  poor outcome such as patients with genetic abnormalities that indicate adverse 
prognosis like monosomies, complex cytogenetic abnormalities, p53 mutations, RUNX1 
mutations, ASXL 1 mutations and others. Also, in older patients, the overall prognosis has 
remained highl y unsatisfactory . E.g. aclinical study  of intensive chemotherap y in 998 older 
patients with a median age of 71 years (range, 65 –89 y ears) demonstrated a CR rate of 45%, a 
death rate in induction of 29% and a median survival of 5.4 months. The 1-and 2-year 
survival rates were 30% and 16%, respectivel y (Kantarjian et al 2006).  Thus; there is an 
urgent unmet need for therapeutic improvements. 
This study  is designed to confirm the preliminary  evidence from early clinical trials that 
m
idostaurin may provide clinical benefit not only to AML patients with the FLT3 -mutation 
but also in FLT3 -MN (SR<0.05) AML . If midostaurin is active in this subgroup , patients 
could derive clinical benefit in multiple ways . For example ,a higher CR rate or a longer 
remission time that would widen the time window tosearch foran allogeneic HSC Tdonor or 
midostaurin may prolong the time in remission and overall survival in patients with and 
without HSC T. This study will also allow an increase in the preliminary  understanding of the 

[COMPANY_001] Confidential Page 33
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
prognostic potential of MRD assessments during treatment and follow -up and may contribute 
to the standardization of the required assay s.
2.2 Rationale for the study  design
The efficacy  of midostaurin at a dose of 50mg twice daily  in combination with the 7+3 
chemotherap y regimen for induction and with intermediate -dose cytarabine for consolidation 
will be evaluated in a 1:[ADDRESS_1018199] chemotherapy regimens. Randomization will be 
stratifi edaccording to age (<60 vs. 60 years).
After completion of consolidation therap y or after allogeneic HSCT ,patients will receive 
post-consolidation therapy  with midostaurin/placebo alone for twelve [ADDRESS_1018200] -consolidation therapy  in AML: disease 
considerations
The incorporation of post-consolidation therap y in the study  is based on high incidence of 
relapse after the completion of induction and consolidation chemotherapy .Additionally , in the 
[A2301] study , there was a trend for a reduction in the rate of relapses during the maintenance 
phase, followed by a  peak of early relapse observed among patients who discontinued or 
completed 12 cycles of midostaurin continuation therap y[A2301] (see Section 2.4, below) . 
This observation is consistent with the mechanistic 
observation that midostaurin, effective at 
blast reduction in the relapsed refractory  setting, may play a role, through its blast reduction 
of preventing the reappearance of clinical disease after the completion of consolidation 
treatment with intensive induction chemotherapy .The selection of a 12-month period of 
midostaurin/placebo post-consolidation was deemed appropriate based on theconsider able 
risk of relapse during this period even among patients who remained in CR through the 
induction and consolidation treatment phases. The 12-month duration is also consistent with 
the safet y experience with single -agent midostaurin. 
In sum mary , patient s who still have measurable residual disease experience rapid relapse once 
chemotherap y is completed. Thus, the continued administration of an oral, non -cytotoxic drug 
such as midostaurin after completion of chemotherapy  might continue to inhibit the outgr owth 
or even eliminate residual leukemic blasts that are present at the end of a routine course of 
chemotherap y, potentially  prolonging DFS. The observation of anti-leukemic activity  when 
midostaurin was used as a single agent in patients with relapsed/ref ractory  FLT3-mutated and 
FLT3 -MN AML provided a supporting rationale.
2.2.[ADDRESS_1018201] -consolidation therapy
Data from Study  [A2301] in patients with FL T3-mutated AML suggest that single agent post-
consolidation therapy for 12 cycleswas an important factor in t
he overall success of the study .
However, A2301 evaluated patients with AML  withFLT3 mutations and the results of 2301 
cannot be extrapolated to AML with FLT3 -MN (SR<0.05) . The results of MRD 
measurements during the post-consolidation phase of Study  [E2301] may support the 

[COMPANY_001] Confidential Page 34
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
hypothesis that post-consolidation treatment with midostaurin in AML with FLT3 -MN 
(SR<0.05) is effective as well.
In A2301, the analysis of OS (non-censored for HSCT) from the start of the post-
consolidation phase shows a survival benefit for patients treated with midostaurin compared 
to placebo (HR=0.802, 95% CI: 0.504, 1.276) . This analy sis included 205 patients (120 
patients in the midostaurin arm, and 85 patients in the placebo arms). A comparison of 
baseline demographic and disease characteristics for these patients did not identify  any 
imbalance between the midostaurin and placebo groups that would have influenced the OS 
assessment . Of note, the study  was not sufficiently powered to test for statistical signific ance
[AML  Summary  of Clinical Efficacy -Section 3.2.5] .
The OSKaplan -Meier curves show clear separation between m
idostaurin and placebo during 
the first [ADDRESS_1018202]-consolidation phase in CR (194 patients; 115 in 
the midostaurin armand 79 in the placebo arm). Patients were censored at the end of the 12-
month post-consolidation phase . In this analysis, the HR was 0.714 (95% CI 0.430, 1.184), 
showing benefit for midostaurin post -consolidation therap yover placebo .
Taken together, the analy ses of OS from the start of post-consolidation andDFS during post-
consolidation are consistent, and suggest a treatment b
enefit of post -consolidation therapy .Of 
note, the observations above do not follow a secondary  randomization and rely  on few events, 
so conclusions must be drawn cautiously .
[IP_ADDRESS] Safety  and tolerability of midostaurin post -consolidation therapy
When the post-
consolidation phase (single agent midostaurin or placebo) was assessed 
separately , a difference in the type and severity  of adverse drug reactions (ADRs )was 
observed compared to the phases of combined treatment with chemotherapy  i.e. induction and 
consolidation phase. The overall incidence of ADRs during the post-consolidation phase was 
generall y lower. ADR during the post-consolidation phase with at least ≥5% difference 
between the midostaurin and placebo arms were: nausea (46.4% vs 17.9%), hypergl ycaemia 
(20.2% vs 12.5%), vomiting (19% vs 5.4%) and lymphopenia (16.7% vs 8.9%). Most of the 
hematological abnormalities reported occurred during the induction and consolidation phase 
when the patients received midostaurin or placebo in combination with chemotherap y. The 
most frequent grade 3/[ADDRESS_1018203]-
consolidation phase with midostaurin and placebo respe ctivel ywere absolute neutrophil count 
decrease (20.8% vs 18.9%) and leukopenia (7.5% vs 5.9%). Overall, ADRs reported during 
the post-consolidation phase were of mild to moderate intensit y and led to very few 
discontinuations (8.1% for midostaurin arm and5.4% for placebo arm). The median duration 
of exposure in the post-consolidation phase was the same in both treatment groups (336 days) 
[Study  A2301- Table 12-2], demonstrating the tolerability  of midostaurin monotherap y 
following chemotherap y for previous ly untreated AML . 

[COMPANY_001] Confidential Page 35
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
2.[ADDRESS_1018204] chemotherap yforAML was established intheclinical trials described in
Section 2.4.
The currently  approved midostaurin dosing regimen in FLT3 positive AML  patients during 
the induction/consolidation cycles is 50 mg twice daily  at day 8 
– 21, i.e.,the midostaurin 
regimen that was evaluated in [A2301] .In E2301, midostaurin will be dosed at [ADDRESS_1018205] day of the subsequent cycle of chemotherap y. The 
reasons for this change are detailed below. 
An exposure -response analy sis of the pi[INVESTIGATOR_2397]  [A2301] showed a positive relationship of 
dose intensity  of midostaurin with efficacy  endpoints including complete response rates in 
cycle 1, EFS and OS. Although a modest increase of the probability  of grade 3/[ADDRESS_1018206] importantly  an increased exposure with the active metabolite CGP62221 was associated 
with an increased survival. Further considering that CGP62221 is a stronger inhibitor of 
mutated as opposed to wild type FLT3 a higher exposure with midostaurin in AML without 
FLT3 mutation is expected to be clinicall y beneficial in this indication. 
The proposed longer midostaurin dosing regimen is being used in study  ADE02 (newl y 
diagnosed AML with FLT3 mutation). The analy sis of interim ADE02 results from the first 
245 patients enrolled (median age: 53.6 years old, range 20 – 69) showed that an increased 
dose intensity  of midostaurin can be safel y achieved by [CONTACT_744361] [A2301] trial. Overal l the safet y and tolerability  of the 
treatment in ADE02T was very similar compared to[A2301] . Most importantly, the rate of 
death in patients up to 60 years old during induction and consolidation therap y was low in 
both trials (death during induction therapy was 3.4% and 3% in [A2301]   and ADE02T 
respectivel y). Therefore, in order to further optimize the risk-benefit relationship of the 
treatment of AML without FLT3 mutation the same dosing regimen of midostaurin will be 
applied in E2301 as was used in AD E02T.
2.4 Rationale for choice of combination drugs
For patients with newly diagnosed AML regardless of cytogenetic and molecular markers 
(except acute prom yelocytic leukemia), and who are judged to be fit, the most frequentl y used 
therap y has been the ‘7 + 3’remission induction regimen with cytarabine and daunorubicin, 
followed by [CONTACT_744353]. Studies showed that 
modification s of the components of the chemotherap y regimen and their timing and dosing 
resulted in little incremental benefit for patients of all risk categories, including patients with 
and without FLT3 -mutations. Therefore ,minor modifications or variants of this standard 
treatment approach that better reflect the existing variants of current standard of care and that 

[COMPANY_001] Confidential Page 36
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
are not expected to jeopardize the treatment homogeneity  in the study are allowed such as 
replacement of daunorubicin with an equivalent dose of idarubicin or the omission of a second 
induction chemotherap y cycle in patients who achieved CR alread y with the first induction 
cycle. Significant improvements in OS and DFS for AML  patients have been reported with 
HSCT compared to consolidation chemotherap y (Kayser et al 2010, DeZern et al 2011 ).
Therefore ,patients in this study  are allowed to undergo allogeneic or autolog ous HSCT at any 
time after induction therapy  and can thereafter resume treatment with the study  drug during
the 
post-consolidation phase of the stud y.
Midostaurin will be administered sequentially  with chemotherap y during each induction and 
consolidation treatment cycle. Midostaurin will be dosed at 50 mg twice daily. Study 
[CPKC412A2106] showed that in combination with chemotherap y the 50 mg twice daily .
midostaurin dose was better tolerated than was the 100 mg twice daily .dose, and the 
sequential regimen was better tolerated than was concomitant administration. The safet y of 
intensive c hemotherapy  combined with midostaurin was confirmed in the phase III study 
A2301 as described in section [IP_ADDRESS]. Moreover, in a leukemia cell culture model a related 
FLT3 tyrosine kinase inhibitor was shown to synergize with cytarabine when administered 
following this chemotherap y but antagonized anti-leukemic cytotoxicity  when administered 
before cytarabine ( Levis et al 2004 ).
Data suggest that the detection of measurable residual disease in AML patients predicts rapid 
relapse once chemotherapy  is completed. The continued administration of an oral, non-
cytotoxic drug such as midostaurin following chemotherapy  might continue to inhibit growth 
or even kill residual blasts present at the end of a routine course of chemotherapy , potentially 
prolonging DFS (Ivey et al) . Studies [CPKC412A2104] , [CPKC412A2104E1] and 
[CPKC412A2104E2] showed that midostaurin has single agent activi ty in relapsed or 
refractory  AML even in FLT3 -MN cases. 
In addition, the analy sis of [A2301] study  suggest sa protective effect against relapse during 
the [ADDRESS_1018207] on maintenance therap y, DFS was analyzed for the subset of patients who 
entered the maintenance phase in CR (194 patients; 115 in the midostaurin armand 79 in the 
placebo arm). 
Patients were censored at the end of the 12-month maintenance phase. In this 
analysis, the HR was 0.714 (95% CI 0.430, 1.184), showing benefit for midostaurin 
maintenance therapy  over placebo. DFS after completion of the mainte nance phase was 
analyzed using the subset of patients who remained in CR after completing the maintenance
phase. The DFS events (all relapses) in the midostaurin arm occurred early  (primaril y within 
the first 6 months after stoppi[INVESTIGATOR_121471] y), whereas in the placebo arm, the events were more 
distributed over time. The findings show that even after the completion of maintenance
therap y, the risk of disease relapse is substantial and it is supportive of the hypothesis that 
continued suppression of leukemic cell clones that survived induction and consolidation 
therap y is important even after completion of cytotoxic chemotherap y administration. The 
observations above do not follow a secondary randomization and rely on few events, so 
conclusions must be drawn cautiously . However, taken together, the analy ses of OS from the 
start of maintenance , DFS during maintenance , and DFS after maintenance , are consistent, 
and indicate a clear treatment benefit of maintenance therapy in AML with mutated FLT-3. 

[COMPANY_001] Confidential Page 37
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Similarly , suppre ssion of the kinase activity  in residual leukemic blasts in AML  with non-
mutated but overexpressed FLT3 during [ADDRESS_1018208] and relapses occur at substantial frequencies 
(Christopeit et al 2014). The interim analy sis of a single arm study  in AML  FLT3-mutated 
demonstrated that midostaurin can be safely  administered after allogeneic transplant. Patients 
received midostaurin during induction, consolidation and after transplant. EFS at 2 years after 
start of treatment was substantially  improved from 25% to 34.6% compared to historical 
controls. The relative contribution of each phase of treatment (induction, consolidation if 
applicable, HSCT and post-consolidation
) could not be determined (PKC412ADE02T Interim 
Study  Report June 2016, on file). In thisstudy  patients can start post-consolidation treatment
after allogeneic HSCT and recovery  from the procedure. MRD measurements during and after 
post-consolidation treatment may help to determine whether midostaurin can reduce the 
residual leukemic disease load in MRD -positive patients after allogeneic transplant and 
convert the MRD status to negative and/or reduce the rate of molecular and hematologic 
relapses in MRD -negative transplanted patients
. Such findings would support the hypothesis 
that midostaurin after alloge neic HSCT could ultimately  result in a longer DFS after 
transplant.
The study  design will assess the use of midostaurin in combination with standard remission 
induction chemotherap y, with intermediate dose cytarabine during consolidation, and as a 
single agent during [ADDRESS_1018209] AML without 
a FLT3 mutation (neither ITD nor TKD per clinical cut-off SR<0.05) will be randoml y 
assigned in a 1:1 ratio to midostaurin or placebo arm . 
Patients will be treated with one or two cycles of remission induction therapy  with cytarabine 
and daunorubicin or idarubicin , followed by [CONTACT_744362]. Patients who 
demonstrate a CR or CRi with adequate blood count recovery (neutrophils ≥1.0 x 109/L and 
platelets ≥50 x 109/L)will receive in consolidation therap ythree or four cycles of 
intermediate -dose cytarabine chemotherap y with sequential midostaurin/placebo as assigned. 
If a patient continues to be in remission, post-consolidation therapy for up to twelve 28-day 
cycles will be administered with midostaurin/placebo as assigned. Patients who receive HSCT 
can stay in the study  and will start midostaurin/placebo post-consolidation therap ybut will 
interrupt midostaurin during the procedure and recovery .
The safet yof the chemotherap y regimen combined with midostaurin was demonstrated in 
the
[A2301] study  (Stone et al 2017 ). This study  will comprise the first randomized placebo-
controlled evaluation of safet y and efficacy  of midostaurin chemotherap y regimen in FLT -
MN AML . 

[COMPANY_001] Confidential Page 38
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
2.5 Rationale for choice of comparators drugs 
Midostaurin will be added to the 7+[ADDRESS_1018210] combination regimen with daunorubicin (or 
idarubicin) and cytarabin efor induction and intermediate dose cytarabin efor consolidation. 
Because no standard treatment that combines chemotherap y with a kinase inhibitor exist, 
placebo added to the standard chemotherap y7+3will serve as comparator .
2.[ADDRESS_1018211] in AML refers to the presence ofleukemic cells at a sensitivity  of detection below the 
threshold of conventional morphologic methods. Patients who experience a CR or CRi 
according to morphologic assessment s (<5% blasts in the bone marrow), can potentiall y still 
harbor a large number of leukemic cells in the bone marrow ( up to 1010)which can confer a 
poor outcome. Detection of MRD (usuall y <0.1% bone marrow blasts) has shown prognostic 
relevance in several studies (Terwijn et al 2013; Ivey A et al, 2016 ), indicating that depth of 
leukemic clearance should be considered as a relevant prognostic endpoint in AML . The most 
frequentl y used methods for MRD assessment in AML  include multi-pa rameter flow 
cytometry  (MFC) to detect abnormal immunophenoty pesand PCR assay s to detect molecular 
alterations, including NPM1 mutations or genomic translocations (Hourigan CS et al, 2017) . 
While molecu lar methods are generally  more sensitive than MFC, they are currently  only 
suitably  to monitor MRD in the subset of patients harboring those genomic aberrations (40-
60% of all patients). In contrast, MFC is suitable for MRD monitoring in ~90% of all AML 
patients, making it the most adequate technology  currently  available to test the prognostic 
impact of MRD status in this trial.
MRD will be assessed during and after treatment using MFC for secondary  endpoint, to 
determine the treatment benefit of midostauri
n. Flow cytometry  assessments for leukemia -
associated immunophenoty pes (LAIP) will be used to monitor MRD at a sensitivity  of 0.1% 
in bone marrow aspi[INVESTIGATOR_4026].  
 
Monitoring of MRD will be performed at baseline, during treatment (including induction, 
consolidation and post-consolidation), post treatment and at relaps e to sensitively  assess the 
depth and duration of response and to provide prognostic information on risk of relapse.
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 39
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
2.8 Risk and benefit
The data available for midostaurin in AML , taken from early stage single agent and 
combination trials, indicated a favorable benefit-risk profile. This was confirmed in the 
randomized phase III [A2301] trial, which met its primary  endpoint of overall survival, 
whereb y patients receiving midostaurin had a 23% reduced risk of death compared to the 
placebo arm. The secondary  endpoints of CR rate, EFS and DFS were all superior in the 
midostaurin arm, with generall y balanced toxicities and no impact of midostaurin treatment 
on time to hematologic recovery , infections o r bleeding. The challenge in evaluating toxicities 
with this compound is separating out those associated with background chemotherap y seen in 
patients in trials, multiple concomitant medications or confounding factors due to 
complications of underly ing disease. Pooled data from completed studies indicated 
gastrointestinal events, consisting of nausea, vomiting and diarrhea are the most prevalent 
adverse events, and the most common causes for drug discontinuation. These events tended to 
be grades [ADDRESS_1018212] 

[COMPANY_001] Confidential Page 40
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
chemotherap y followed by 12 months of continuation therap y in patients with FLT3 -mutated 
AML .
This study  E2301 may demonstrate similar benefits as seen in [A2301] ,i.e., prolongation of 
the overall survival, event free survival and disease free survival compared to standard 
therap y. Since there is no other approved FLT3 -inhibitor available for AML  with FLT3WT 
current standard intensive induction and consolidation chemotherapy  with or without HSCT is 
the relevant alternative treatment for comparison of the benefit and risks of the study 
treatment . Moreover it is regarded unlikel y that the safety  and tolerability of Midostaurin in 
AML with FLT3 -MN (SR<0.05) AML will significantly  differ from those observed in 
[A2301] in FLT3-mutated AML .The risks of the study  treatment during induction and 
consolidation are expected to reflect mainl y those associated with the chemotherapy  backbone 
and to be similar compared to standard chemotherapy as was seen in the [A2301] trial. During 
the post -consol idation phase with midostaurin monotherapy  the adverse events expected to be 
observed more frequently  compared to placebo are mainly  grade [ADDRESS_1018213] common causes for drug 
disconti nuation. Overall it appears plausible that the risk profile associated with the study 
treatment in patients with AML with FLT3 -MN (SR<0.05) will not be significantly  different 
from the risks in AML -mutated.
No diagnostic procedures that are different from those in standard of care will be performed in 
E2301.
Appropriate eligibility  criteria as well as specific dose modification and stoppi[INVESTIGATOR_004], are 
included in this protocol. Recommended guidelines for proph ylactic or supportive 
management of study -drug induced adverse events are provided in Section 6.3. The risk to 
subjects in this trial may be minimized by [CONTACT_546260], as well as, close clinical monitoring, dose reduction recommendations for toxicity , 
stoppi[INVESTIGATOR_744328] y according to clinical standard of care. For the most 
current overview of known risks refer to the latest Investigator’s Brochure. There may be 
unforeseen risks which could be serious. In the large Phase III study  [A2301] in FLT3-
mutated AML, midostaurin at a dose of 50mg twice dailywas overall well tolerated in 
combination
In summary , the collective ly available clinical data support a positive benefit risk assessment 
addressing important unmet medical needs in in patien ts with AML -FLT3 -MN (SR<0.05) .

[COMPANY_001] Confidential Page 41
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
[ADDRESS_1018214]-consolidation
therapy improves EFS in patients with newly 
diagnosed FLT3 -MN (SR<0.05) AML.EFS is defined as the time from randomization to failure to obtain a CR or 
CRi with adequate blood count recovery in induction, relapse after CRor 
CRi with adequate blood count recover yor death due to any cause, 
whichever occurs first as assessed by [CONTACT_093] .  
Key secondary Refer to Section 10.5.[ADDRESS_1018215]-consolidation 
therapy improves OS in patients with newly 
diagnosed FLT3 -MN (SR<0.05) AML.Overall survival is defined as the time from randomization to date of 
death due to any cau se. 
Other secondary
To compare CR + CRi with adequate blood count 
recover y rate in the two treatment groups.CR and CRi with adequate blood count recover y rate according to the 
International Working Group (IWG) for AML (Cheson et al 2003, ELN 
2017 / Döhner et al 2017
) as per investigator assessment.Refer to Section [IP_ADDRESS]
To compare the percentage of patients who 
reached MRD negative status in the two 
treatment groups .Percentage of patients with MRD negative status .Refer to Section [IP_ADDRESS]

[COMPANY_001] Confidential Page 42
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Objective Endpoint Analysis
To compare the percentage of patients with MRD 
negative status in the post -consolidation phase
in the two treatment groups .Perce ntage of patients with MRD negative status during post-
consolidation phase
To compare the time to MRD negative bone 
marrow between the two treatment arms in the 
two treatment groups .Number of day s from date of randomization to first documented MRD -
To compare DFS, as well as the Cumulative 
Incidence of Relapse (CIR) and Cumulative 
Incidence of Death (CID) in the two treatment 
groups.DFS, as measured from the date of first CR or CRiwith adequate blood 
count recovery to relapse or death from any cause, whichever occurs 
first. 
CIR is defined for patients with CR or CRi with adequate blood count 
recover y: time from achieving CR or CRi with adequate blood count 
recover y until onset of relapse. Patients without relapse are censored at 
the last adequate response assessment. Patients who died without 
relapse are counted as a competing cause of failure. 
CID is defined for patients with CR or CRi with adequate blood count 
recover y: time from achieving CR or CRi with adequate blood count 
recover y until death. Patients who did not die are censored at the last 
contact [CONTACT_568]. Patients who relapsed are counted a s a competing cause of 
failure. Refer to Section [IP_ADDRESS]
To co mpare the time to CR or CRi with adequate 
blood count recover y in the two treatment 
groups.Number of days from date of randomization to first documented CR or 
CRi with adequate blood count recover y. Refer to Section [IP_ADDRESS]
To compare the time to neutrophil recovery in the 
two treatment groups.Number of days from the first day of a chemotherapy cycle to first day 
neutrophils ≥0.5 x 109/L.
Number of days from day [ADDRESS_1018216] day 
neutrophils ≥1.0 x 109/L.Refer to Section 
[IP_ADDRESS]

[COMPANY_001] Confidential Page 43
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Objective Endpoint Analysis
To compare the time to platelet recovery in the 
two treatment groups.Number of days from the first day of a chemotherapy cycle to first day 
platelets ≥50 x 109/L.
Number of days from day1 of commencing induction therapy to first day 
platelets ≥100 x 109/L.
To assess the safety and tolerability of 
midostaurin in combination with chemotherapy 
and as monotherapy during post -consolidation. Frequenc y/severit y of AEs, and laborator y abnormalities. Refer to Section 10.5.[ADDRESS_1018217]- Leu and 
the EQ5 D-5L (visual analogue scale (VAS)) by [CONTACT_2939].Refer to Section 10.5.5
 
 
  
 
      
 
  
 
 

[COMPANY_001] Confidential Page 44
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Objective Endpoint Analysis
 
     
 

[COMPANY_001] Confidential Page 45
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
4 Study  design
4.1 Description of study  design
This is a randomized, double -blind, multi -center, placebo -controlled phase III study  of 
midostaurin (PKC412) or placebo in combination with idarubicin/ daunorubicin and 
cytarabine for induction therap y, intermediate -dose cytarabine for consolidation therap y, 
followed by [CONTACT_447]-consolidation therap y with midostaurin or placebo in adult patients with 
newly  diagnosed FLT3 -MN (SR< 0.05) AML, i.e., FLT3 mutant to wild type signal ratio 
below the 0.05 clinical cut-off. The study  is designed to evaluate the efficacy  and safet y of 
midostaurin combined with intensive chemotherapy  in this indication. 502 adult patients with 
newly  diagnose d AML  demonstrating FLT3 -MN (SR<0.05) as determin
ed bya [COMPANY_001]
designated lab orato rywillbe enrolled at approximately 1 50-180sites worldwide.
Figure 4 - 1 Study  Design
Eligible and consented patients are allowed to start with the 7+3 chemotherap y immediatel y 
after the unequivocal diagnosis of AML; the day of the first dose of chemotherap y is defined 
as Day  1.
Patients will be tested for the absence of FLT3 -ITD and FLT-TKD mutations, using a 
validated clinical trial assay  in a [COMPANY_001] designated laboratory .Absence of mutation is 
defined as ITD and TKD activating mutations at codons D835 and I836 in the FLT3 gene, 
below the clinical cutoff of 0.05 mutant to wild ty pe signal ratio.

[COMPANY_001] Confidential Page 46
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Patients with confirmed FLT3-MN (SR<0.05) AML will be randomly  assigned 1:1 to 
midostaurin or placebo by [CONTACT_2329] a stratified randomization according to age (<60 vs. 60 
years), Patients will be randomized on D ay 8, i.e., the day of the first dose of midostaurin or 
placebo. Patients with a FLT3 mutation or with an unknown FLT3 mutation status by [CONTACT_744363] 8will be considered as molecular screening failures and cannot be randomized .
Provided that FLT3 -MN (SR<0.05) status has been confirmed, patients meeting all other 
eligibility  crite ria will start the administration of midostaurin or placebo on
Day 8.
4.2 Stud y phase (details of dosing in section 6)
The study  contains three treatment phases:
Induction treatment phase
Consolidation treatment phase and,
Post-consolidation treatment phase
A patient has to meet the following criteria to continue with the next treatment phase:
A patient achieves CR at end of an y treatment phase OR patient achieves CRi at end of 
any treatment phase with adequate blood count recovery defined as the following:
Complete Recovery  in neutrophil count (1 x 10 E9/L)
Minimal recovery in platelet count ( 50 x 10E 9/L)
Of note, a patient not meeting the above criteria up to 93days after start of induction phase is 
considered as “ induction failure ”
.For details please se e Section [IP_ADDRESS].
The planned duration of a
n induction and consolidation cycle is 28 days.  Upon adequate 
blood count recovery after day 28, midostaurin is stopped immediately  (e.g., the evening dose 
of midostaurin or placebo on th atday is not taken).  Forty-eight hours thereafter is Day 1 (and 
start of chemotherap y) of the next cycle (Induction 2, Consolidation 1-4).  At the end of the 
last consolidation cycle, i.e., prior to start of the post-consolidation cycle 1, midostaurin or 
placebo will not be interrupted. The duration of each post- consolidation cy cle is [ADDRESS_1018218] one cycle of induction therap ywith continuous infusion 
cytarabine and idarubicin/ daunorubicin. Patients not achieving CR nor CRi with adequate 
blood count recovery after i
nduction 1 will receive a second cycle with intermediate -dose 
cytarabine and daunorubicin/idarubicin (the latter only in patients under 60yearsof age ).
Daunorubicin may  be replaced by  [CONTACT_744364]. 
The dose of idarubi cin would be one fifth of the planned daunorubicin dose. Midostaurin will 
start on day [ADDRESS_1018219] consolidation cy cle. 
Patient sachiev ingCRor CRi with adequate blood count recovery with induction cycle 1will
go directl y to consolidation therap y (4 cycles) without a second cycle of induction therap y.
Patients who do not achieve CRnor CR i with adequate blood count recovery  with one cycle 

[COMPANY_001] Confidential Page 47
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
of induction will receive a second induction cycle with intermediate dose cytarabin eand 
daunorubicin/idarubicin.
Patients achieving CR or CRi with adequate blood count recovery  with 2 cycles of induction 
will go directl y to consolidation therap y (3 cycles) .
Patients not achieving CRnor CR iwith adequate blood count recovery after induction 2 (i.e. 
up to 93 days after start of induction phase ) will discontinue study  treatment and will be 
followed for 
survival. 
4.2.[ADDRESS_1018220] with or without preceding 
consolidation cy cles. Patients may  undergo transplantation at the d iscretion of the Investigator 
(refer to [ADDRESS_1018221] and 2016 National Comprehensive Cancer Network (NCCI )
recommendations). In patients who are treated with allogeneic HSCT instead of consolidation 
therap y or after start of consolidation therapy  the conditioning regimen and management after 
transplantation will be according to local institutional standard s. Study treatment will be 
interrupted at least [ADDRESS_1018222]-consolidation therap y not earlier than 30 days after transplant but notlater than 
100 day s after trans plant.
P
atients will receive midostaurin (two 25 mg capsules) or placebo (2 capsules) twice daily 
orally from day 4until [ADDRESS_1018223] -consolidation phase
After adequate blood count recovery following the final cycle of consolidation therap y, 
patients will receive 12cycles (28 days/cycle) of continuous therap y with midostaurin or 
placebo twice dail y at [ADDRESS_1018224]-consolidation therapy , 
continuously , for up to 12cycles (28 days/cycle).Post HSCT post-consolidation therap y will 
begin >[ADDRESS_1018225] to follow -up. Data on anti-neoplastic thera pi[INVESTIGATOR_744329].

[COMPANY_001] Confidential Page 48
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
4.3 Timing of interim analy ses and design adaptations 
Two interim analy ses are planned when approximately  114 and 214of the 285 EFS events 
targeted for the primary analy sis (approximately  
40% and 75% information fraction, 
respectivel y) have been documented. The first interim analy sis is planned for a futility  
assessment. The study  can be stopped for efficacy  at the second interim analysis. These 
analyses are expected to take place around [ADDRESS_1018226] patient randomized in the study  assuming anincreasing recruitment rate to reach 30 
patients/month [ADDRESS_1018227] been documented (it is 
estimated that these [ADDRESS_1018228] patient) or [ADDRESS_1018229]-treatment or survival follow-up until the data cut-off 
date and all available data up to this cut- off date will be anal yzed.
4.5 Early study  termination 
The study  may be terminated at any time for any reason by [CONTACT_5343]. This may include 
reasons related to the benefit/ risk assessment of participating in the study , practical reasons 
(including slow enrollment), or for regulatory  or medical reasons. In taking this decision to 
terminate, [COMPANY_001] will alway s consider the subject ’swelfare and safety . Should this be 
necessary , patient sshould be seen as soon as possible for the End of Treatment (EOT) visit, 
and assessments for EOT as described in Section 7should be performed for discontinued or 
withdrawn patients . The investigator may  b e informed of additional procedures to be followed 
in order to ensure that adequate consideration is given to the protection of the patient’s 
interests. The investigator will be responsible for informing institutional review boards ( IRBs )
and/or ethics com mittees ( ECs) of the early termination of the trial.
In the event that the study  is terminated prematurely , e.g., due to futility  or overwhelming 
efficacy , patients still receiving study  treatment and who, according to investigator assessment, 
continue to benefit from the treatment, will be offered to complete study  treatment as per 
protocol.
5 Population
5.1 Patient population
The study  population will be comprised of male and female 
patients 18 yearsof age with 
newly  diagnosed FLT3 -MN (SR<0.05) (no ITD in the juxtamembrane domain or TKD 
activating mutation as defined in inclusion criteria) AML 
who are deemed by [CONTACT_744365] c hemotherapy .

[COMPANY_001] Confidential Page 49
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
All data for the Inclusion/Exclusion criteria must be verifiable in the patient’s source 
documents.
5.[ADDRESS_1018230] to meet all of the following criteria:
1.
Diagnosis of AML ( ≥20% blasts in the bone marrow based on WHO 2016 classification) . 
Patients with APL with PML -RARA are not eligible.
2.Suitability  for intensive induction chemotherap y in the judgment of the investigator
3. Documented absence of an ITD and TKD activating mutation at codons D83 5 and I836 in 
the FLT3 gene, as determined by  [CONTACT_744366] a [COMPANY_001] designated laboratory  using a 
validated clinical trial assay  with clinical cutoff of 0.05 mutant to wild ty pe signal ratio.
4.Age 18 years
5. L aboratory  values that indicate adequate organ function assessed locall yat the screening 
visit:
AST ≤ 3times UL N
Alanine aminotransferase (ALT) ≤ [ADDRESS_1018231]
Serum total bilirubin ≤ 1.5 times UL N , unless in case of h yperbilirubinemia due to an 
isolated Gilbert sy ndrome
Estimated (by  [CONTACT_3158]
-Gault) creatinine clearance ≥ 30ml/min
6.Written informed consent must be obtained prior to any  screening procedures.
5.[ADDRESS_1018232] not meet anyof the following criteria:
1.Central nervous s ystem (CNS) leukemia
2.Therap y-related secondary  AML 
3.Isolated extramedullary  leukemia
4. P rior therap y for leukemia or myelod ysplasia with the following exceptions:
a.Emergency  leukapheresis
b.Emergency  treatment for hy perleukocy tosis with hy droxyurea or low -dose cy tarabine
for 7 day s
c.Cranial RTfor CNS leukostasis (one dose onl y)
d.Hematopoietic Growth factor/cy tokine support
e.Other supportive therap y including antibiotics at the discretion of the investigator
5.AML  after antecedent my elody splasia (MDS) with prior cy totoxic treatment (e.g., 
azacy tidine or decitabine)
6. A ny investigational agent within 30 day s or 5 half -lives, whichever is greater, prior to Day  
1.An investigational agent is defined as an agent with no approved medical use in adults 
or in pediatric patients.
7. Prior treatment with a FLT 3 inhibitor (e.g. ,midostaurin, quizartinib, sorafenib)
8. S trong CYP3A4/5 enzyme inducing drugs ( see Appendix 1 )unless they  can be 
discontinued or replaced prior to enrollment . 

[COMPANY_001] Confidential Page 50
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
9. A ny other known disease or concurrent severe a nd/or uncontrolled medical condition (e.g., 
cardiovascular disease including congestive heart failure or active uncontrolled infection) 
that could compromise participation in the study .
10. A bnormal chest X -ray with corresponding clinical symptoms or findings that indicate an 
active infection , or other pulmonary  conditions that are currentl y clinicall y significant . 
11.
Impairment of gastrointestinal ( GI) function or GI disease that might alter significantl y the 
absorption of midostaurin.
12. K nown confirmed diagnosis ofHIV infection or active viral hepatitis (t esting is not 
mandatory  to exclude these viral infections).
13.Cardi ovascular abnormalities, including an y of the following:
History  of M I, angina pectoris, CABG within 6 months prior to starting study  
treatment
Clinically  uncontrolled cardiac arrh ythmias (e.g., ventricular tachy cardia), complete 
left bundle branch block, high -grade AV block (e.g., bifascicular block, Mobitz ty pe 
II and third degree AV block)
Uncontrolled c ongestive heart failure
Left ventricular e jection fraction of <50%,
Poorly  controlled h ypertension
14.Pregnant or nursing (lactating) women
15.Women of child
-bearing potential, defined as all women physiologicall y capable of 
becoming pregnant, unless they  are using highly  effective methods of contracept ion 
during dosing and for at least 4 months after stoppi[INVESTIGATOR_88794]. Highl y effective 
contraception methods include:
Total abstinence (when this is in line with the preferred and usual lifest yle of the 
subject ). Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y), total h ysterectomy, or tubal ligation at least six we eks before taking 
study  treatment. In case of oophorectom y alone, only  when the reproductive status of 
the woman has been confirmed by  [CONTACT_104]
Male sterilization (at least 6 months prior to screening). The vasectomized male 
partn er should be the sole partner for that subject
Use of oral, injected or implanted hormonal methods of contraception or placement of 
an intrauterine device (IUD) or intrauterine s ystem (IUS), or other forms of hormonal 
contraception that have comparable efficacy  (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception.
Midostaurin may  reduce the effectiveness of hormonal contraceptives; therefore, 
females using s ystemically  active hormonal contraceptives should add a barrier 
method of contraception. 
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile 
(i.e.,age appropriate, history  of vasomotor s ymptoms) 
or have had surgical bilateral 

[COMPANY_001] Confidential Page 51
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
oophorectom y (with or without hy sterectomy ), total hy sterectom y, or tubal ligation at 
least six weeks ago. In the case of oophorectomy alone, only  when the reproductive status 
of the woman has been confirmed b y follow up horm one level assessment is she 
considered not of child bearing potential.
16.Sexually  active males unless they  use a condom during intercourse while ta king the drug 
during treatment, and for at least [ADDRESS_1018233] y with the protocol.
18.Known hy persensitivity  to midostaurin, cy tarabine or daunorubicin /idarubicin or to any  of 
the excipi[INVESTIGATOR_744323]/placebo, cy tarabine or daunorubicin /idarubicin.
6 Treatment
6.1 Stud y treatment
In this study , the term “Study  drug ”refers to midostaurin/placebo labeled asPKC412/p
lacebo 
provided as 25 mg capsules which are packaged in blister packs and supplied by [CONTACT_744367] -blind supplies .
The term “Study  treatment” will indicate treatment with daunorubicin/idarubicin , cytarabine, 
or midostaurin/placebo. 
Induction chemotherap y will start on Day 1andthe randomization and treatment start with 
midostaurin/placebo will be done on D ay 8when (molecular) eligibility  has been confirmed 
based on the absence of a FLT3 mutation as determined by [CONTACT_744368] . 
If the patient does not have FLT3 test results qualify ing for eligibility by [CONTACT_2006] 8then the 
patient will be considered as a molecular screening failure and cannot be randomized .
6.1.[ADDRESS_1018234] dose of indu ction chemotherap y will be administered.
Daunorubicin/ idarubicin and cytarabine are approved drugs and will be sourced either 
according to local practice or centrall y. Please refer to the Package Insert for complete 
guidelines for administration and for s afety  monitoring guidelines.
The dosage of daunorubicin/idarubicin and cytarabine will be adjusted based on body  surface 
area (BSA) calculated before administration. To calculate BSA, the height at baseline and 
weight on the first day  of the respective tre atment cy cle will be used.
Dose modification for obese patients: 
There is no clearl y documented adverse impact of treatment of obese patients when dosing is 
performed according to actual body  weight. Therefore, all dosing is to be determined solel y 
by [CONTACT_15619]’s BSA as calculated from actual weight. This will eliminate the risk of 
calculation error and the possible introduction of variability  in dose administration. 

[COMPANY_001] Confidential Page 52
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
[IP_ADDRESS] Treatment regimen:
First Induction:
Cytarabine 200 mg/m2/day will be administered by  [CONTACT_119654] 
(CIVI) on Day s 1-7 (168 hour infusion).
Daunorubicin 60 mg/m2/day oridarubicin 12 mg/m2/day will be administered 
intravenously  by [CONTACT_27927] (IVP) or short (30 minutes) infusion on Day  1-3.
Study drug (midostau rin50 mg [two 25 mg capsules] or 
placebo [2 capsules]) will be 
administered twice per day  by [CONTACT_744369]  8 until 48 hrs prior to the start of next 
cycle(i.e.the morning of Day  27 if hematopoiesis recovers timely  (cycle length of 28
days)or later if the cy cle needs to be prolonged for blood count recovery ). Patients should 
take their doses at approximately  the same time each day , and approximately  [ADDRESS_1018235]
-dose PK samples, when instructed b y the study staff. Each daily 
dose should be given with food and a glass of water (~240 mL). Patients should be 
instructed to swallow capsules whole and not chew capsules. If vomiting occurs, no re -
dosing is allowed prior to the next scheduled dose. The soft capsules should be removed 
from the blister pack only shortly prior to administration . The capsules may  have an 
unpleasant odor, which disappears a few seconds after the blister foil is opened.
A bone marrow aspi[INVESTIGATOR_744330] 21-28 to determine 
the need for a second induction cycle. If the bone marrow aspi[INVESTIGATOR_744331] a 
determination of remission, then the bone marrow assessment should be repeated after about 
one week. 
A disease assessment will be performed at the end of induction 1 based on bone marrow and 
peripheral blood assessments. If the response isCR or CRi with adequate blood recovery  the 
patient will proceed to the consolidation phase. If the response is CRi without adequate blood 
count recovery , the patient will continue to be treated with Midostaurin/Placebo and observed 
up to 2 weeks to get the platelet ≥
50 x 109/L and neutrophil ≥1 x 109/L (i.e., adequate blood 
count recovery ) to be able to move to consolidation. In such cases a response assessment will 
be performed at day 42 (28 days plus the time window of 2 weeks for adequate blood count 
recovery )
If patients after induction 1 therap y still show ≥5% blasts (i.e., no CR or CRi) in their D21-
D28 bone marrow, then they require a second induction treatment. Dosing of 
midostaurin/placebo should be stopped immediatel y after knowledge of ≥5% blasts
persistence. 48 hours thereafter the second induction treatment should start.
Of note, Physicians should consider earlier bone marrow exams in patients whose peripheral 
blood counts are not recovering or recovering in an unexpectedly  slow manner. 
Secon d Induction:
Patients who still have more than ≥5% blasts in their bone marrow (no CR or CRi) after 
induction cycle 1 require a second induction treatment. Dosing of midostaurin/placebo should 
be stopped immediately. 48 hours thereafter the second induction treatment should start. 

[COMPANY_001] Confidential Page 53
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Intermediate -dose cytarabine (IDAC) 1500 mg/m2will be administered by  [CONTACT_744370] 3 hours every  12 hours on Day  1 to 3. Serial neurologic evaluations will be 
performed before and following the infusion of intermedi ate-dose cy tarabine. For 
patients of age 60 years or older at the time of study entry a dose of 1000 mg/m2 will 
be administered.
Daunorubicin 50 mg/m2/day oridarubicin 10 mg/m2/day will be administered 
intravenously  by [CONTACT_27927] (IVP) or short (30 minute) infusion on Day  1-3 for patients <60 
years onl
y. Patients  60 years at the time of study entry will not be given 
daunorubicin or idarubicin 
Study drug (midostaurin 50 mg [two 2 5 mg capsules] or placebo [2 capsules]) will be 
administered twice per day  by [CONTACT_744369]  4 until 48 hrs prior to start of next cy cle
(i.e. the morning of Day  27 if hematopoiesis recovers timely  (cycle length of 28 day s)or 
later if the cy cle needs to be prolonged for blood count recovery ).).
A bone marrow aspi[INVESTIGATOR_744330] 21-28 to determine if 
the patient can move to consolidation phase. If the response is CR, the patient will proceed 
immediately  after Day 28 totheconsolidation phase. If the response is CRi without adequate 
blood count recovery , the patient will continue to be treated with Midostaurin/Placebo and 
observed 3 additional weeks for an adequate blood recovery  to be able to move to 
consolidation. If no adequate blood count recovery will be achieved after these 3 additional 
weeks , the patient will be discontinued from treatment and followed for survival. Otherwise, 
the patient will move to consolidation. A response assessment will be performed at day  49(28 
days plus the time window of 3 weeks for adequate blood count recovery ).Patients who 
failed to achieve CR or CRi with adequate blood count recovery after a second induction 
will be discontinued from protocol therap y and followed for survival and post-study -
treatment therapi[INVESTIGATOR_014] (Section 7.1 ).
Consolidation (3 or 4 cy cles)
Patients achieving a CR or CRi with adequate blood count recovery after induction 1 will 
receive 4 cy cles of consolidation therapy  with midostaurin/placebo + chemotherapy . 
Patients achieving a CR or CRi with a dequate blood count recovery  only after induction 2 will 
receive 3 cy cles of consolidation therapy  with midosta urin/placebo and chemotherap y.
A bone marrow examination must be performed at each cycle of the consolidation phase to 
evaluate for relapsed AML. 
Intermediate -dose cytarabine (IDAC) 1500 mg/m2will be administered by  [CONTACT_744370] 3 hours ever y 12 hours on Day s 1 to 3. Serial neurologic evaluations will be 
performed before and following the infusion of intermediate -dose cy tarabine. For 
patients of age 60 years or older at the time of study entry a dose of 1000 mg/m2will 
be administered .
Study drug (midostaurin 50 mg [two 25 mg capsules] or 
placebo [2 capsules]) will be 
administered twice per day  by [CONTACT_744371] s 4 until 48 hrs prior to start of next 
consolidation cy cle(i.e. the morning of Day  27 if hematopoiesis recovers timely (cycle 
length of28 day s)or later if the cy cle needs to be prolonged for blood count recovery ). . 

[COMPANY_001] Confidential Page 54
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Post -consolidation therapy  (12 cy cles)
Patients who maintain CR or CRi with adequate blood recovery (by [CONTACT_744372][INVESTIGATOR_337]/biopsy  and peripheral blood evaluation) after completing consolidation therap y will 
receive 12 cy cles (28 days/cy cle) of midostaurin/placebo post -consolidation therapy .
Prior to initiation of midostaurin/placebo post-consolidation therap y, all significant acute 
toxicity  from consolidation therapy  must have resolved to <grade 2 or be stable except 
alopecia of any grade. Midostaurin/placebo post-consolidation therap y will begin after partial 
platelet recovery  (platelets ≥ 50,000/µL) from remission consolidation.
Study drug (midostaurin 50 mg [two 25 mg capsules] or 
placebo [2 capsules]) will be 
administered twice per day  by [CONTACT_5555] 28 consecutive day s. Patients should take their 
doses at approximately  the same time each day , and approximately  12 hours should elapse 
between the morning and evening doses. On day s that PK samples are obtained, the 
patient should take midostaurin/placebo during the clinic visit after the pre- dose PK 
samples and prior to post -dose PK samples, when instru cted by  [CONTACT_39802]. 
Hematopoietic stem cell transplantation
Patients who underwent HSCT after achieving CR or CRi with adequate blood count recover y
will receive midostaurin or placebo [ADDRESS_1018236]-consolidation therapy , 
continuously , fo
r up to 12 cycles (28 days/cycle). Post HSCT post-consolidation therap y will 
begin >[ADDRESS_1018237].
Table 6-1 Dose and treatment schedule
Study phase Study 
treatmentsPharmaceutical 
form and route of 
administrationDose Frequency 
and/or Regimen
Induction 1 Cytarabine CIVI 200 mg/m2/day Day 1 -7 (168 hour 
infusion)
Daunorubicin
OrIdarubicinIntravenously by [CONTACT_744373] (30 
minute) infusion
Intravenously by [CONTACT_744373] (30 
minute) infusion60mg/m2/day
(irrespective of 
age)
12mg/m2/day
(irrespective of 
age)Day 1 -3
Day 1 -3
Midostaurin /
PlaceboCapsules for oral 
use50mg/dose Twice daily on 
Day 8 until 48 hrs 
before start of 
next cycle   (i.e. 
the last dose of 
Midostaurin/Place
bo to be 
administered in 
the morning of 
Day 27 if the cycle 

[COMPANY_001] Confidential Page 55
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Study phase Study 
treatmentsPharmaceutical 
form and route of 
administrationDose Frequency 
and/or Regimen
length is 28 day s
or later if the c ycle 
needs to be 
prolonged for 
blood count 
recover y).
Induction 2 for 
patients without 
CR/CRi with 
adequate 
recover y after 
Induction 1Cytarabine Intravenously over 3 
hours1500 
mg/m2/dose for 
pts <60  years 
1000 
mg/m2/dose for 
pts 60  years 12-hour intervals 
on Day 1 -3
Daunorubicin
OrIdarubicin
No 
daunorubicin 
or Idarubicin
for pts 60 
yearsIntravenously by [CONTACT_744373] (30 
minute) infusion
Intravenously by [CONTACT_744373] (30 
minute) infusion50mg/m2/day
10mg/m2/dayDay 1 -3
Day 1 -3
Midostaurin /
PlaceboCapsules for oral 
use50mg/dose Twice daily on 
Day 4 until 48 hrs 
before start of 
next cycle (i.e. the 
last dose of 
Midostaurin/Place
bo to be 
administered in 
the morning of 
Day 27 if the cycle 
length is 28 day s
or later if the c ycle 
needs to be 
prolonged for 
blood count 
recover y)
Consolidation 
phaseCytarabine Intravenously over 3 
hours1500 
mg/m2/dose for 
pts <60  years 
1000 
mg/m2/dose for 
pts 60  years12-hour intervals 
on Day 1 -3

[COMPANY_001] Confidential Page 56
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Study phase Study 
treatmentsPharmaceutical 
form and route of 
administrationDose Frequency 
and/or Regimen
Midostaurin/
PlaceboCapsules for oral 
use50mg/dose Twice daily on 
Day 4 until 48 hrs 
before start of 
next 
chemotherapy 
cycle(i.e. the last 
dose of 
Midostaurin/Place
bo to be 
administered in 
the morning of 
Day 27 if the cycle 
length is 28 day s
or later if the c ycle 
needs to be 
prolonged for 
blood count 
recover y)
Post-
consolidation  
phaseMidostaurin/
PlaceboCapsules for oral 
use50mg/dose Twice daily for [ADDRESS_1018238] -
consolidation 
cycles required
6.1.2 Ancillary  treatments 
Not applicable .
6.1.3 Rescue medication 
Not applicable .
6.1.4 Guidelines for continuation of treatment 
See Section 6.3
6.1.5 Treatment duration
The treatment consists of 3 treatment phases and the maximum planned duration of treatment 
is 17cycles. P lanned durations of each treatment phase are:
Induction phase : 1 or 2 cy cles (daunorubicin /idarubicin , cytarabine and 
midostaurin/placebo). The maximum length of the first induction cy cle is 4 3days (28 day s 
plus potentially  up to 14 additional day s for adequate blood count recovery plus 1 day 
prior to the start of the next cy cle. Patients not achieving CR or CRi after Induction 1 will 

[COMPANY_001] Confidential Page 57
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
get a second cy cle of Induction. The maximum length of the second induction cy cle is 50 
days (28 day s plus potentially  up to 21 additional day s for adequate blood count recovery
plus 1 day  prior to the start of the next cy cle).
Consolidation phase : Patients who achieved CR or CRi with adequate blood count 
recovery  after induction 1therap y will receive 4cycles of consolidation (intermediate -
dose cy tarabine and midostaurin/placebo). Patients achiev ing CR or CRi with adequate 
blood count recovery only after induction 2 therapy  will receive 3 cy cles of consolidation .
One cy cle length is planned to be 28 day s whereas the maximum len gth of each 
consolidation cy cle is 50 days (28 day s plus potentially  up to 21 additional day s for 
adequate blood count recovery plus 1 day  prior to the start of the next cy cle)
. 
Post-consolidation phase : 12cycles (midostaurin/placebo). Each cy cle is 28 days.
Patients may be discontinued from treatment prior to completion of study  therap y for reasons 
of unacceptable toxicity , induction failure , relapse from CR/CR i with adequate blood count 
recovery , withdrawal of consent, failure to abide by [CONTACT_760], or at the discretion of the 
investigator.
6.2 Dose escalation guidelines 
Not applicable.
6.3 Dose modifications
6.3.1 Dose modification and dose delay
For patients who do not tolerate the protocol -specified dosing schedule, dose interruptions 
and/or reductions are either recommended or mandated in order to allow patient s to continue 
the study  treatment.
These dose modifications are summarized in Table 6-2. Deviations to mandatory  dose 
interruptions and/or reductions are not allowed. Permanent treatment discontinuation is 
mandatory  for specific event s indicated as such in Table [ADDRESS_1018239] be recorded on the appropriate CRF.
Study drug (midostaurin/placebo)
Table 6-2 describes toxicities (i.e.,adverse drug reactions) , laboratory  values, or other 
assessments that require interruption or dose modification of study  drug. Whether an AE that 
is not considered to be caused by [CONTACT_744374]. The need for modification in case of non-drug related AEs 
depends on the t ype of these AEs.
During induction and consolidation therapi[INVESTIGATOR_014], modifi cations must be done in case of non-
hematologic toxicities
,i.e.,ADR s(pulmonary , cardiac or other non -hematologic toxicities).
During post-consolidation therap y, modifications must be done in case of hematologic and 
non-hematologic toxicities (pulmonary ,cardiac or other non -hematologic toxicities).
If interruptions occur, missed doses of study  drug will not be made up.

[COMPANY_001] Confidential Page 58
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Study  drug interruptions of greater than [ADDRESS_1018240] as in that case the drug interruption can 
be longer than 28 consecutive days (please refer to section 6.1.1 for more detailed 
information) .
Cytarabine
Doses will be modified only  during the consolidation phase with intermediate -dose cy tarabine 
andin case of neurotoxicity , hematology  and non-hemat ology  toxicity . Please refer to Table 
6-2.
Idarubicin/ Daunorubicin
Doses will be modified during induction phase in case of hepatotoxicity , hematology  and non -
hematology  toxicity . Please refer to Table 6 -
2.

[COMPANY_001] Confidential Page 59
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412A2301
Table 6-2 Criteria for dose reduction/ interruption and re -initiation of midostaurin/placebo, daunorubicin /idarubicin and 
cytarabine treatment for adverse drug reactions
Dose modif ications for midostaurin/placebo
Hematologic toxicities
During induction and consolidation 
cyclesNo dose modifications are required for hematologic toxicity due to midostaurin/placebo during induction and 
consolidation therapy.
During post -consolidation cycles In the presence of grade [ADDRESS_1018241]-consolidation therapy, midostaurin/placebo must be held until 
Absolute Neutrophil Count (ANC )≥ 1.0 x 109/L.
Once ANC ≥ 1.0 x 109/L, then resume midostaurin/placebo at the previous dose. 
If neutropenia persists for more than two weeks, then discontinue midostaurin/placebo protocol therapy.
Non-Hematologic toxicities: 
Pulmonary toxicities
During induction, consolidation and 
post-consolidation cyclesFor ≥ grade 3 pulmonary infiltrate , midostaurin/placebo mu st be interrupted for the remainder of the cycle. 
Resume midostaurin/placebo at the same dose when infiltrate resolves to ≤grade 1.
Missed doses of midostaurin/placebo wi ll not be made up. If there is no improvement after [ADDRESS_1018242] be discontinued from study drug.
Cardiac Toxicity
During induction, consolidation and 
post-consolidation cyclesFor QTcF interval > 470 ms and ≤ [ADDRESS_1018243] any 
abnormalities. If possible, stop any medications that may prolong the QTcF interval. Decrease 
midostaurin/placebo to 50 mg once daily for the remainder of the cycle. Resume midostaurin/placebo at the 
initial dose in the next cycle provided that QTcF interval improves to ≤ 470 ms at the start of that cycle. 
Otherwise continue midostaurin/placebo 50 mg once daily.
For QTcF interval > 500 msand/or QTcF prolongation >[ADDRESS_1018244] any abnormalities. Hold or interrupt midostaurin/placebo for the remainder of the 
cycle, and, if possible, stop any medications that may  prolong the QTcF interval. If QTcF improves to ≤ [ADDRESS_1018245] prior to the next cycle, resume midostaurin/place bo at the initial dose. If QTcF interval is not improved to ≤ 
470 msin time to start the next cycle, midostaurin/placebo may be held up to [ADDRESS_1018246] be discontinued from study  drug .
Other Non-Hematologic toxicity

[COMPANY_001] Confidential Page 60
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412A2301
During induction and consolidation 
cyclesGrade 1/2: No dose modifications for any grade 1 or 2 non -hematologic toxicity.
Grade 3/4: If a patient experiences other grade 3/4 non- hematologic toxicity considered related to 
midostaurin/placebo, midostaurin/placebo will be interrupted until toxicity resolves to ≤ grade 1. If the toxicity 
resolves prior to day 21, then restart at same dose to complete current cycle. Missed doses of 
midostaurin/placebo will not be made up. A study drug interruption in excess of [ADDRESS_1018247] -consolidation cycles Grade 1/2: Persistent grade [ADDRESS_1018248] -consolidati ontherapy that patients deem to be 
unacceptable may prompt a study  drug interruption for as long as 28 days. A study  drug interruption in excess 
of 28 days will require discontinuation of study treatment.
Grade 3/4: For other grade 3/4 non- hematologic toxicities that are considered to be related to 
midostaurin/placebo, interrupt midostaurin/placebo. Resume midostaurin/placebo at the same dose when 
toxicity resolves to ≤grade 2. If midostaurin/placebo is held for more than 28 days, then discontinue 
midostaurin/placebo post-consolidation therapy.
Dose modifications for intermediate -dose cytarabine (I DAC) induction 2 if applicable and consolidation therapy
During Induction 2 if applicable and
consolidation cyclesDose reduction according to institutional guidelines except in case of neurotoxicity dose modifications as below:
Contributions of concomitant medications to neurotoxicity should be assessed and other medications discontinued 
if possible.
For neurotoxicity  ≥ grade 2 due to intermediate -dose cytarabine, discontinue cytarabine for the remainder of the 
cycle. Intermediate -dose cytarabine may be considered at the next consolidation therapy cycle with a dose 
modification from 1500m g/m2 to 1000mg in patients <60 years of age and from 1000m g/m2 to 600mg/mg2 in 
patients ≥60 of age if the toxicity has resolved to ≤ grade 1.
For a second occurrence of neurotoxicity ≥ grade 2, intermediate -dose cytarabine should be permanently 
discontinued.

[COMPANY_001] Confidential Page 61
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412A2301
Dose modifications for daunorubicin 
Dose reduction according to institutional guidelines except in case of hepatotoxicity dose modifications as below:
During induction c yclesTotal Bilirubin (mg/dL) % daunorubicin dose to administer
≤ 1.2 100%
> 1.2 –≤ 3.0 75% (25% dose reduction)
> 3.0 50% (50% dose reduction)
Dose modifications for idarubicin
Dose reduction accordi ng to Prescribing Information: 
Idarubicin should not be administered if t he serum bilirubin level exceeds 5 mg/100 ml. 
In patients with hepatic and/or renal impairment, a dose reduction of idarubicin should be considered.
Patients with serum creatinine concentrations of greater than 3 mg/dL should receive 50% of the usual daily daunorubicin dose.
All dose modifications should be based on the worst preceding toxicity. Common Toxicity Criteria for Adverse Events (CTCAE Version 5.0)

[COMPANY_001] Confidential Page 62
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
6.3.2 Dose adjustments for QTcF prolongation
In case of QTcF >500 ms, (or QTcF prolongation >60 ms from baseline)
1.Assess the quality  of the ECG recording and the QT value and repeat if needed
2.Interrupt stud y treatment
3.Determine the serum electroly te levels (in p articular hy pokalemia, hy pomagnesemia). If 
abnormal, correct abnormalities before resuming study  drug treatment.
4. Review concomitant medication associated with QT prolongation, including drugs with a 
“Known”, “Possible”, or “Conditional risk of Torsades de Pointes” , and drugs with the 
potential to increase the risk of study  drug exposure related QT prolongation 
5.Check study  drug dosing schedule and treatment compliance
6.
Consider collecting a time- matched PK sample, and record time and date of last study  
drug intake.
7.Note that measurements of QTc F≥480ms shall be centrall y verified on a copy  of the 
original high qualit y recording that includes time and voltage scales
After confirming ECG reading at site, if QTcF > 500 ms
Interrupt stud y treatment
Repeat ECG and confirm ECG diagnosis by  a cardiologist 
If QTcF confirmed > 500 ms:
Correct electrol ytes, eliminate culprit concomitant treatments, and identify  and 
address clinical conditions that could potentially  prolong the QT 
Consult with a cardiol ogist (or qualif ied specialist)
Increase cardiac monitoring as indicated, until the QTcF returns to ≤ 470 ms.
After resolution to 
≤ 470ms, consider re -introducing treatment at reduced dose, and 
increase ECG monitoring for the next treatment(s):
If QTcF remains ≤ 500 ms a fter dose reduction, continue planned ECG monitoring 
during subseq uent treatment
If QTcF recurs > [ADDRESS_1018249].
[IP_ADDRESS] Follow up on potential drug -induced liver injury (DILI) cases
Patients with transaminase increase combined with total bilirubin (TBIL )increase may be 
indicative of potential DILI, and should be considered as clinically  important events.
The threshold for potential DILI may depend on the patient’s baseline AST/AL T and TBIL 
value; patients meeting any of the following criteria will require further follow -up as outlined 
below:
For patients with normal ALT and AST andTBIL value at baseline: AST or ALT > 3.[ADDRESS_1018250] combined with TBIL > 2.0 x UL N

[COMPANY_001] Confidential Page 63
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
For patients with elevated AST or ALT or TBIL value at baseline: [AST or ALT > 2 x 
baseline AND > 3.[ADDRESS_1018251]] OR [AST or ALT > 8.[ADDRESS_1018252]], combined with [TBIL > 2 x 
baseline AND > 2.[ADDRESS_1018253]]
Medical review needs to ensure that liver test elevations are not caused by  [CONTACT_15014], defined 
as ALP elevation > 2.[ADDRESS_1018254] with R value < 2 in patients without bone metastasis, or 
elevation of ALP liver fraction in patients with bone metastasis.
Note: (The R value is calculated by [CONTACT_5358], using multiples of the ULN 
for both values. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R≥ 5), or mixed (R >2 and < 5 ) liver injury ).
In the absence of cholestasis, these patients should be immediately  discontinued from study 
drug treatment, and repeat liver function testing (LFT)as soon as possible, preferabl y within 
48 hours from the awareness of the abnormal results. The evaluation should include 
laboratory tests, detailed history , phy sical assessment and thepossibility of liver metastasis or 
new liver lesions, obstructions/compressions, etc.
1.Laboratory  tests should include ALT, AST, albumin, creatine kinase, total bilirubin, direct 
and indirect bilirubin, gamma -glutam yl transferase (GGT), prothrombin time 
(PT)/international normalized ratio (I NR) and alkaline phosphatase.
2.A detailed histo ry, including relevant information, such as review of ethanol, concomitant 
medications, herbal remedies, supplement consu mption, history  of any pre-existing liver 
conditions or risk factors, should be collected.
3.Further testing for acute hepatitis A, B, C or E infection and liver imaging (e.g.biliary 
tract) may  be warranted.
4.Obtain PK sample, as close as possible to last dose of study  drug, if PK analysis is 
performed in the stud y.
5.Additional testing for other hepatotropic viral infection (cytomegalovirus (CMV), Epstein-
Barr virus (EBV) or herpes simplex virus (HSV)) , autoimmune hepatitis or liver biops y 
may be considered as clinically  indicated or after consultation with specialist/hepatologist.
All cases confirmed on repeat testing meeting the laboratory  criteria defined above, with no 
other alternative cause for LFT abnormalities identified should be considered as “medical ly 
significant”, thus, met the definition of SAE (Section 8.2.1) and reported as SAE using the 
term “potential drug -induced liver injury ”. All events should be followed up with the outcome 
clearl y documented.
6.[ADDRESS_1018255] of care.

[COMPANY_001] Confidential Page 64
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
The patient must be told to notify  the investigational site about any new medications he/she 
takes after the start of the study  drug. All medications (other than study  drug) and significant 
non-drug therapi[INVESTIGATOR_014] (including physical therapy , herbal/natural medications and blood 
transfusions) administered during the study  must be listed on the Prior or Concomitant non-
drug therapi[INVESTIGATOR_014]/procedures CRF.
6.4.2 Permitted concomitant therapy  requiring caution and/or action 
Strong CYP3A4 inhibitors should be used with caution due to potential increase in 
midostaurin exposure. Alternative medi cinal products that do not strongly  inhibit CYP3A4 
activity  should be considered. In situations where satisfactory  therapeutic alternatives do not 
exist, patients should be closely  monitored for midostaurin
-related toxicity . 
Based on in vitro data, midostaurin and its active metabolites may  have the potential to inhibit 
P
-glycoprotein (P-gp), BCRP ,and OATP1B1. Midostaurin, CGP62221 and CGP52421 can 
potentially  induce the following CYP s: CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, 
CYP3A4 and inhibit the following ones: CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP2E1, 
CYP3A4/5. In absence of clinical data medicinal products with a narrow therapeutic range 
that are substrates of these CYPs should be used with caution when administered 
concomitantly  with midostaurin, and may  need dose adjustment to maintain optimal exposure .
Therefore medicinal products with a narrow therapeutic range that are substrates of CYP1A2, 
CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4/5, P-gp, BCRP or OATP1B1 
should be used with caution when administered concomitantly  with midostaurin and may  need 
dose adjustment to maintain optimal exposure.
A list of strong CYP3A4 inhibitors, substrates with narrow therapeutic index for CYP1A2, 
CYP2B6, CYP2C8, CYP2C9, CYP2C 19, CYP2D6, CYP2E 1, CYP3A and P -gp and 
substrates of BC RPand OATP1B1 is available in Appendix 1 .
6.4.3 Prohibited concomitant therapy
Strong CYP3A4 inducers: Concomitant use of midostaurin/placebo with strong inducers of 
CYP3A4 should be avoided . Strong CYP3A4 inducers decrease exposure of midostaurin and 
its active metabolites (CGP52421 and CGP62221). In a study  in healthy  subjects, 
coadministration of the strong CYP3A4 inducer rifampi[INVESTIGATOR_2513] (rifampin ,600mg daily ) to stead y 
state with a single dose of midostaurin decreased midostaurin Cmax by 73% and -AUC infby 
96% in average, respectively . CGP62221 exhibited a similar pattern. The mean AUC lastof 
CGP52421 decreased by 60%. In absence of clinical data, the impact of strong CYP3A4 
inducers on mido staurin exposure at steady -state was investigated based on physiologically -
based PK models. Exposure was predicted to be decreased b y 60%.
A list of strong inducers of CYP3A4 is available in Appendix 1 .
Other prohibited concomitant medications: If concomitant administration of drugs with a 
“known risk of torsades de pointes (TdP)”is required and cannot be avoided, then the study  
drug must be interrupted. If, based on the investigator assessment and clinical need, study 
treatment is resumed, close ECG monitoring is advised. Note that measurements of 
QTc≥480ms shall be centrally  verified on a copy  of a high quality  recording that includes time 
and voltage scales.

[COMPANY_001] Confidential Page 65
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
If during the course of the study , concomitant administration of a drug with ¨Possible riskof 
TdP ¨ or ¨Conditional risk of TdP¨ is required, based on the investigator assessment and 
clinical need, study  treatment may be continued with close ECG monitoring to ensure patient 
safet y. A list of drugs associated with QT prolongation and/or TdP is available online at 
[www.qtdrugs.org ].
As far as possible avoid co- administering drugs with a “Known”, “Possible”, or “Conditional” 
risk of TdP during the course of the stud y:
If concomitant administration of drugs with a “Known risk of TdP”is required and cannot 
be avoided, stud y drug must be interrupted. If, based on the investigator assessment and 
clinical need ,study  treatment is resumed, close ECG monitoring is advised. 
If during the course of the study , concomitant administration of a drug with ¨Possible risk¨ 
or ¨Conditional risk of TdP ¨ is required, based on the investigator assessment and clinical 
need, stud y treatment may be continued under close ECG monitoring to ensure patient 
safet y.
A list of drugs associated with QT prolongation and/or TdP is available online at 
[www.qtdrugs.org ]
6.4.4 Use of Bisphosphonates (or other concomitant agents ) 
Not Applicable .
6.[ADDRESS_1018256] Number (Subject No.), that is assigned 
when the patient is first enrolled for screening and is retained as the primary  identifier for the 
patient throughout his/her entire participation in the trial. The Subject No. consists of the 
Center Num ber (Center No.) (as assigned by [CONTACT_5359]) with a 
sequential subject number suffixed to it, so that each subject is numbered uniquely  across the 
entire database. Upon signing the informed consent form, the patient is assigned to the next 
sequential Subject No. available to the investigator through theClinical Data Management 
System interface.
The investigator or designated staff will contact [CONTACT_185686] (IRT)and 
provide the requested identify ing information for the patient to register them into IRT. Once 
assigned, the Subject No. must not be reused for any  other subject and the Subject No. for that 
individual must not be changed, even if the patient is re-screened. If the patient fails to be 
randomized or start treatment for any reason, the reason will be entered into the Disposition 
page.
IRT must be notified within 2 day s that the patient was not randomized.
6.5.2 Treatment assignment or randomization
Patients will be assigned to one of the 2 treatment arms, midostaurin or placebo ( Section 4.1
and Section 6.1) in a ratio of 1:1. 

[COMPANY_001] Confidential Page 66
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
Randomization will be stratified b yage(<60 versus  60 years).
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment is unbiased and is concealed from patients and investigator staff. A 
patient randomization list will be produced by [CONTACT_6609] a validated system that 
automates the random assignment of patient numbers to randomization numbers. These 
randomization numbers are linked to the different treatment arms, which in turn are linked to 
medication numbers. A separate medication randomization list will be produced by [CONTACT_744375] y Management using a validated system that 
automates the random assignment of medication numbers to medication packs containing 
each of the study  treatments.
On study  Day 8, all patients who fulfill all inclusion/exclusion criteria , including
demonstrated FLT3 -NM AML as confirmed by[CONTACT_744376] -designated laboratory , and who 
have begun induction chemotherapy  will be randomized via IRT to one of the treatment arms . 
The investigator or delegate will call or log on to the IRT and confirm that the patient fulfills 
all the inclusion/exclusion criteria. The IRT will assign a randomization number to the patient, 
which will be used to link the patient to a treatment arm and will specify  a unique medication 
number for the first package of study  drug to be dispensed to the patient. The randomization 
number will not be communicated to the caller.
6.5.[ADDRESS_1018257] to avoid the 
unnecessary  analysis of placebo samples. The identity of the study  drug will be concealed by 
[CONTACT_744377] (midostaurin or placebo) that is identical in packaging, labeling, 
schedule of administration, appearance, and odor. Confidentiality  of randomization data is 
required to limit the occurrence of potential bias arising from the influence that the knowledge 
of treatment may  have on the recruitment and allocation of patients.
Unblinding of study  drug assignment will only occur in the case of patient emergencies
(Section 8.3), at the time of the interim analysis (see Section 10.7), for regulatory  reporting 
purposes and at the conclusion of the study . 
In rare cases when unblinding occurs because of emergency  patient management, the actual
treatment arm will not be communicated to any [COMPANY_001] employ ee involved in the trial 
conduct in order to maintain their blinded status.
6.[ADDRESS_1018258] the patient or caregiver to take the 
study  drugs as per protocol. Study  drug(s) will be dispensed to the patient by [CONTACT_5361]. All dosages 
prescribed to the patient and all dose changes during the study 
must be r ecorded on the appropriate CRF.

[COMPANY_001] Confidential Page 67
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
Study  drug provided is midostaurin 25mg and matching placebo control. Study drug will be 
supplied by [CONTACT_744378]- resistant blisters. Each blister 
pack contains eight capsules, and each medication kit contains eight blisters for a total of 
sixty -four capsules per kit.
Study  treatment provided is daunorubicin/ idarubicin and cytarabine. They  will be procured 
locally  according to local practice and regulation, or supplied by  [CONTACT_5343] (or i ts designee).
Table 6-[ADDRESS_1018259] information
6.6.1 Study treatment packaging and labeling
Study  drug: midostaurin/placebo:
Midostaurin/placebo will be provided as global clinical blinded supply  and will be packed and 
labeled under the responsibility  of [COMPANY_001] Drug Supply  Management. 
Labels for midostaurin/placebo will compl y with the legal requirements of each country  and 
will include storage conditions and a unique medication number (corresponding to study 
treatment and strength).  Responsible site personnel will identify  the study  drug package(s) to 
be dispensed by [CONTACT_64084](s) assigned by [CONTACT_64085]. Site personnel will 
add the subject number on the label. The label has 2-parts (base plus tear-off label); 
immediately  before dispensing the package to the patient, site personnel will detach the outer 
part of the label from the package and affix it to the patient’s source document.
Chemotherapy : daunorubicin/idarubicin and cytarabine:
Daunorubicin/idarubicin and cytarabine will be procured locall y according to local practice 
and regulation, or supplied by  [CONTACT_5343] (or its designee).
6.6.[ADDRESS_1018260] access. Upon receipt, the study  treatment should be stored 
according to the instructions specified on the drug labels and in the Investigator’s Brochure 
for midostaurin/placebo or the package insert for daunorubicin/idarubicin and cy tarabine.
These instructions should be made clear to the patient for storage and self-administration of 
midostaurin/placebo at home.

[COMPANY_001] Confidential Page 68
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
Site staff will be responsible for managing re-supplies for the chemotherap y 
(daunorubicin/idarubicin and cy tarabine) 
Midostaurin/placebo will be managed b y IRT system. 
Table 6-4 Supply  and storage of study  treatments
Study treatments Supply Storage
Midostaurin/ Placebo Centrally supplied by [CONTACT_744379]/Idarubicin
CytarabineProcured locally according to 
local practice and regulation, 
or supplied by [CONTACT_5343] (or its 
designee).Refer to local product information
6.6.3 Study drug compliance and accountability
[IP_ADDRESS] Study drug compliance
Compliance will be assessed by [CONTACT_1755]/or study  personnel at each patient visit, 
and information provided by [CONTACT_5363]/or caregiver will be captured in the Drug 
Accountability  Form. This information must be captured in the source document at each 
patient visit.
[IP_ADDRESS] Study drug accountability
The investigator or designee must maintain an accurate record of the shipment and dispensing 
of study  treatment in a drug accountability  log. Drug accountability  will be noted by [CONTACT_744380] . Patients will be asked to return 
all unused study  treatment and packaging on a regular basis, at the end of the study  or at the 
time of study  treatment discontinuation.
At study  close-out, and, as appropriate during the course of the study , theinvestigator will 
return all used and unused study  treatment, packaging, drug labels, and a copy  of the 
completed drug accountability  log to the [COMPANY_001] (or Contract Research Organization ( CRO )) 
monitor or to the [COMPANY_001] address provided in the investig ator folder at each site.
[IP_ADDRESS] Handling of other study  treatment
Not applicable.
6.6.[ADDRESS_1018261] party , as appropriate. Arrange for drug supply  to be destroyed at the site only if 
permitted by  [CONTACT_64149] a prior agreement.
Drug supplies will be destroy ed only  after the approval of monitor and after the completion of 
drug accountability  reconciliation. 

[COMPANY_001] Confidential Page 69
Amended Oncology Protocol Version No. 01 (Clean ) Protocol No. CPKC412E2301
7 Visit schedule and assessments
7.1 Stud y flow and visit schedule
Table 7-1lists all of the assessments and indicates with an “X”, the visits when they are 
performed. All data obtained from these assessments must be sup
ported in the patient’s source 
documentation.
The table indicates which assessments produce data to be entered into the clinical database (D) 
or remain in source documents only (S) (“Category ” column). No CRF will be used as a 
source document. 
Allowed visit windows are specified as follows: 
Screening assessments listed below, must occur within 14 days prior to Day  1 as per Table 
7-1. 
During each induction and consolidation cy cle, PK and ECG assessments must be 
performed on the specified day . Local measurements of QTc ≥480ms will be centrally  
verified on a cop y of a high qualit y recording that includes time and voltage scales.
All other assessments 
should not exceed a 5 day  window to take into account scheduling 
over public holiday s if not explicitly  specified otherwise. 
Every  effort should be made to follow the schedule outlined in Table 7-1.

[COMPANY_001] Confidential Page 70
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 7-1 Visit evaluation schedule
A: Screening until end of consolidation phaseCategory
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
Informed 
consent
Obtain 
study  
Informed 
Consent D x
IRT
Registration D x
Randomizat
ion:
I1, D8: 
when FLT3 
mutation 
status is 
confirmedD x
I 1

[COMPANY_001] Confidential Page 71
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
Patient 
history
Diagnosis D x
Disease 
history D x
Demograph
yD x
Inclusion/ 
exclusion 
criteriaD x
Eligibility 
checklist
I1,D8D x x
FLT3 
mutation 
statusD x
Cytogenetic
s D x
Medical 
History D x

[COMPANY_001] Confidential Page 72
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-[ADDRESS_1018262]
ic 
medications D x
Prior/ 
concomitant 
medications 
and 
procedures 
including 
blood 
transfusions
.D x Continuous

[COMPANY_001] Confidential Page 73
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
Physical examination 
([IP_ADDRESS] )
Performanc
e statusD7.2.
2.4x x x (at 
EOT)x x x x (at 
EOT)
Height D7.2.
2.3x
Weight  D7.2.
2.3x x x (at 
EOT)x x (at 
EOT)
Vital signs D7.2.
2.2x x x x x xx (at 
EOT)x x x x x x x (at 
EOT)
Physical 
examinationS7.2.
2.1x x x x x x x x x x x (at 
EOT)x x x x x x x (at 
EOT)
Lab assessments
(see Table 7 -5)
Hematology D7.2.
2.5.
1x x x x x x x x x x x (at 
EOT)x x x x x x x (at 
EOT)
Chemistry
B: Tot 
Bilirubin 
onlyD7.2.
2.5.
2x x x
Bx
Bx x x x (at 
EOT)x x x x x x (at 
EOT)

[COMPANY_001] Confidential Page 74
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
Coagulation D7.2.
2.5.
3x x x x x x
Other 
hepatic 
tests in 
case of 
suspected 
DILI D6.3.
3.1If clinically indicated
Urinalysis 
dipstick and 
sedimentD7.2.
2.5.
4x If clinically indicated If clinically indicated
Serum (S) 
or Urine (U) 
Pregnancy 
test S7.2.
2.5.
5x
Sx
Ux (U at 
EOT)x
Ux (U at 
EOT)
Imaging/other 
assessments
Chest X -ray D7.2.
2.6x If clinically indicated
ECG ( Table 
7-7)D7.2.
2.7.
1x x
I1 x
I1 x
I1 x (at 
EOT)x x x (at 
EOT)
Cardiac D7.2. x If clinically indicated

[COMPANY_001] Confidential Page 75
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
MUGA/
ECHO2.7.
2
Efficacy / disease assessments   (see Section 7.2.1 for details)
Microscopic 
peripheral 
blood exam 
incl. full 
differential 
countD x x
(and up to 2 and 
3 weeks after day 
28 for induction1 
and 2 respectively 
for patients in CRi 
without adequate 
blood count 
recovery)x 
(at time 
of 
relapse)x
(and up to 
3 weeks 
after day 
28 for 
patients in 
CRi 
without 
adequate 
blood 
count 
recovery)x 
(at 
time 
relaps
e)

[COMPANY_001] Confidential Page 76
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
Microscopic 
exam of 
bone 
marrow 
aspi[INVESTIGATOR_337]/ 
biopsy for 
morphology 
&bone 
marrow 
differential 
countD x x x 
(at time 
of 
relapse)x x 
(at 
time of 
relaps
e)
Extramedull
ary disease 
assessment 
(physical 
exam and 
CNS 
symptom 
assessment
) D x x x x
Investigator 
assessment 
of Disease 
Response D x
(and up to 2 and 
3 weeks after day 
28 for induction1 
and 2 respectively 
for patients in CRi x x x
(and up to 
3 weeks 
after day 
28 for 
patients in x

[COMPANY_001] Confidential Page 77
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
without adequate 
blood count 
recovery)CRi 
without 
adequate 
blood 
count 
recovery)
BMA for 
Flow 
cytometry  
MRDD x x x 
(at time 
of 
relapse)x
(C1 only)x
(at 
time of 
relaps
e)
Safety
Adverse 
eventsD8.1 x Continuous
Pharmaco
kinetics
PK 
sampling 
(Tables 7 -8
& 7-9)D7.2.
3x
I 1x
I 1x
I 1x
I 1x
I 1x 
C
1
&
3x
C
1
&
3

[COMPANY_001] Confidential Page 78
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28

[COMPANY_001] Confidential Page 79
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
  Biomarkers ( 7.2.4 ) (for detailed biomarker collection plan, 
please refer to Table 7 -11)
BMA for 
DNA, and 
RNA 
analysis 
(MRD  D x x x 
(at time 
of 
relapse)x
(C1 only)x
(at 
time of 
relaps
e)
Whole 
blood for 
DNA and 
RNA 
analysis 
(MRD  D x x x
(at EOT)x
(C1 and 
C3) x
(at 
EOT)

[COMPANY_001] Confidential Page 80
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-[ADDRESS_1018263] -
Leu
EQ-5D-5LD7.2.
6x x x (at 
EOT)x x (at 
EOT)

[COMPANY_001] Confidential Page 81
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol Section 
Screening PhaseInduction Phase
Cycle 1 -2
End of Induction 
Phase / EOT
Prior to each cycle of 
Consolidation phaseConsolidation Phase/HSCT
Cycle 1 -4
End of Consolidation 
Phase / EOT
Visit name
[INVESTIGATOR_16852]
C
RINDUCTION C1 -C2 IND 
DISPOSI
TIONCONSOLIDATION C1 -C4 CON 
DISPO
SITION
Day of cycle 
-14 to -1
1
2
3
4
5 7 8
11 15
18 21
24
27
28
1
2
3
4
8
11
15
17
21
27
28
Disposition D x x x
IRT
Dispensatio
n 
Midostaurin/
PlaceboDx
(I
2 
on
ly)x
(I
1 
on
ly)x
Treatment 
Discontinua
tionDx (at 
EOT)x (at 
EOT)
Study  treatment 
administration
Midostaurin 
/ Placebo  DInduction 1: Continuous twice daily Day 8until 48 hrs 
prior to start of next cycle
Induction 2 : Continuous twice daily Day 4until 48 hrs 
prior to start of next cycleContinuous twice daily Day 4until 48 hrs prior to start of next 
cycle
Daunorubici
n/ Idarubicin 
I 2 <60 
years onlyD6.1x x x
CytarabineD6.1x x x x
I 1x
I 1x
I 1x x x

[COMPANY_001] Confidential Page 82
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
B: End of consolidation phase until end of study
Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018264] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018265])Surviva
l follow 
up (until 
[ADDRESS_1018266] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle 1 15
Patient history
Prior/concomitant medications 
and procedures including blood 
transfusions.D
continuous
Antineoplastic therapi[INVESTIGATOR_744332] D x Every 3 
monthsEvery  3 
months 
Transplant after discontinuation of 
study treatmentD x Every 3 
monthsEvery 3
months
Physical examination
Performance status D [IP_ADDRESS] x x x x
Weight D [IP_ADDRESS] x x x
Vital signs D [IP_ADDRESS] x x x x

[COMPANY_001] Confidential Page 83
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018267] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018268])Surviva
l follow 
up (until 
[ADDRESS_1018269] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle 1 15
Physical examination S [IP_ADDRESS] x x x x
Lab assessments (see Table 7 -5)
Hematology D [IP_ADDRESS].1 x x x
(C1 and C2 
post-
consolidation 
only if no 
grade 2 or 
higher 
anemia, 
thrombocyto
penia, or 
neutropenia )x Every 3 
months until 
relapse
Chemistry D [IP_ADDRESS].2 x x x
Other hepatic tests in case of 
suspected DILID 6.3.3.1If clinically indicated
Urinalysis dipstick and sediment D [IP_ADDRESS].4 If clinically indicated

[COMPANY_001] Confidential Page 84
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018270] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018271])Surviva
l follow 
up (until 
[ADDRESS_1018272] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle [ADDRESS_1018273] S [IP_ADDRESS].5 x x x
Imaging/other assessments
Chest X -ray D 7.2.2.6If clinically indicated
ECG (Table 7 -6) D [IP_ADDRESS].1 x x
(C 2 to C 12)Completion of C 12or at 
EOTx
Cardiac
MUGA/ECHOD [IP_ADDRESS].2If clinically indicated x
Safety
Adverse events D 8.1 Continuous
Pharmacokinetics
PK sampling (see Tables 7-8& 7-
9)D 7.2.3 x C4, C7, C1 0 Completion of C 12

[COMPANY_001] Confidential Page 85
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018274] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018275])Surviva
l follow 
up (until 
[ADDRESS_1018276] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle 1 15
Biomarkers ( 7.2.4 )(for detailed biomarker collection plan, please refer to Table 7 -11)
Bone marrow aspi[INVESTIGATOR_744333] (MRD  
)D x C4, C7, C10 Completion of C12/ at 
relapse3 months 
after end of 
post-
consolidatio
n  therapy 
and at 
relapse
Whole blood for DNA and RNA 
analysis (MRD  
)D x C4, C7, C10 Completion of C12/ at EOT Every 3 
months 
during years 
1 and 2 and 
then yearly

[COMPANY_001] Confidential Page 86
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018277] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018278])Surviva
l follow 
up (until 
[ADDRESS_1018279] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle 1 15
Efficacy / disease assessments (see Section 7.2.1 for details)
Microscopic peripheral blood 
exam incl. full differential countD x C1-C12 Completion of C12/ at 
relapseEvery 3 
months until 
relapse and 
when 
clinically 
indicated
Microscopic exam of Bone 
marrow aspi[INVESTIGATOR_337]/ biopsy for 
morphology & Bone marrow 
differential countD x C4, C7, C10 Completion of C12/ at 
relapse3 months 
after end of 
post-
consolidatio
n  therapy
and at 
relapse and
when 
clinically 
indicated
Extramedullary disease 
assessment (physical exam and D x C1-C12 Completion of C12/ at 
relapse3 months 
after end of 

[COMPANY_001] Confidential Page 87
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018280] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018281])Surviva
l follow 
up (until 
[ADDRESS_1018282] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle 1 15
CNS symptom assessment) post-
consolidatio
n  therapy 
and at 
relapse and
when 
clinically 
indicated
Investigator assessment of 
Disease Response D x C1-C12 Completion of C12/ at 
relapseEvery [ADDRESS_1018283] D x C4, C7, C10 Completion of C12/ at 
relapse3 months 
after end of 
post-
consolidatio
n  therapy 
and at 
relapse

[COMPANY_001] Confidential Page 88
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018284] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018285])Surviva
l follow 
up (until 
[ADDRESS_1018286] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle [ADDRESS_1018287] 2 
years and 
then yearly
Disposition D x x
IRT
Dispensation Midostaurin/ 
PlaceboD x
Treatment Discontinuation D x
Study  treatment  administration

[COMPANY_001] Confidential Page 89
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301Category
Protocol SectionPrior to 1st
cycle of post -
consolidation 
PhasePost -consolidation Phase 
Cycle [ADDRESS_1018288] -
consolidation Phase 
/EoT30 
day 
safety
follow 
up Post 
treatment 
follow up
(until [ADDRESS_1018289])Surviva
l follow 
up (until 
[ADDRESS_1018290] 
patient )
Visit name D  Post-Consolidation C1-C12
Day of cycle 1 15
Midostaurin/ Placebo  D continuous twice daily (from 
D1 to D28)
Follow -up
Efficacy Follow -up D every 3 
months
Survival Follow -up D every 3 
months

[COMPANY_001] Confidential Page 90
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
7.1.[ADDRESS_1018291] dose of 
study  treatment. ECG should be obtained within 3 day s prior to start of study  treatment. Local 
measurements of QTc ≥480ms will be centrally  verified on a copy of a high quality  recording 
that includes time and voltage scales.
Aspart of screening procedures, a bone marrow aspi[INVESTIGATOR_744334]3 mutation 
assessment .In case both sample types are collected/available, FLT3 screening will be 
preferentiall y performed only on the bone marrow sample; and the peripheral blood sample 
will be banked for future testing.   
Assessments done within four days prior to Day 1 (start of chemotherap y) as per local 
practice or under a local protocol, prior to signing the study  specific informed consent form 
and start of screening for the study , will not have to be repeated and results can be used for the 
study . At the discretion of the investigator, the final diagnosis of AML by [CONTACT_744372][INVESTIGATOR_744335] .
In some specific cases (and with [COMPANY_001]’ prior approval) , the FLT3 status may have been 
determined prior to screening in a [COMPANY_001] validated laboratory . In such cases, this previously 
obtained FLT3 result will be used for the study . Part of the remaining bone marrow sample 
should be provided to [COMPANY_001] for further analysesdefined in the protocol .  
 
At sites that also participate in the CPKC412A2220 (A2220) trial (aiming at patients with 
FLT3 mutated AML), patients who are screened in the A2220 trial and confirmed to be FLT3 
mutation nega tive(SR<0.05) may be offered the opportunity to join the E2301 trial provided 
they also meet all other inclusion criteria. To allow this, patients screened as part of A2220 
trial may be offered to sign E2301 informed consent at the same time as the one for A2220. 
Screening, baseline and the start of the first induction cycle will be performed under the 
A2220 protocol. All information obtained during that period will then be used for the E2301 
trial, samples collected under the A2220 trial would be used forfurther E2301 assessments. 
Some additional assessments will have to be performed for the E2301 trial, such as MRD flow 
cytometry  and ePROs. Patients are only considered for the E2301 trial if, under the A2220 
protoc ol, they are treated with the “RATIFY regimen” (i.e.,daunoru bicin or idarubicin/
cytarabine dos
ing regimen as described for the E2301 trial) during the first induction cycle
and are FLT3 -MN.
Re-screening is not allowed, and a patient who does not meet all inclusion/exclusion criteria 
will be considered to be a screen failure and cannot be randomized .

[COMPANY_001] Confidential Page 91
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
[IP_ADDRESS] Eligibility  screening 
Dosing with chemotherapy  may begin while FLT3 mutation results are pending. FLT3 
mutation results from the central laboratory  must be received by [CONTACT_2006] [ADDRESS_1018292] is eligible for randomization and to receive midostaurin/placebo.
Following registering in the IRT for screening, patient eligibility  will be checked once all 
screening procedures are completed (except FLT3 status). The eligibility  check will be 
embedded in the IRT s ystem. 
Please refer and compl y with detailed guidelines in the I RT manual.
[IP_ADDRESS] Information to be collected on screening failures
A patient who signs an informed consent 
but fails to begin chemotherap y for any reason will 
be considered as a screen failure. The reason for not being started on chemotherap y will be 
entered on the Disposition CRF. The demographic information, informed consent, and 
Inclusion/Exclusion CRF must also be completed for Screen Failure patients. FLT3 data will 
be collected for all patients including screen failures. No other data will be entered into the 
clinical database for patients who are screen failures, unless the patient experienced a Serious 
Adverse Event during the Screening Phase (see Section 
8for SAE reporting details).  If the 
patient fails to be randomized, the IRT must be notified within [ADDRESS_1018293] cy cle of induction will not be randomized and will then be discontinued from the study.
In addition to data collected at screeni ng, the reason for not being randomized will be entered 
on the disposition CRF, and AEs/SAEs will also be collected, if applicable.
No other data will be collected for those patients.
[IP_ADDRESS] Patient demographics and other baseline characteristics
The data to be c ollected on subject characteristics at screening includes:
Diagnosis and extent of cancer (WHO and French American British ( FAB )classification)
Demograph y (Age, gender, race and ethnicity , or as allowed by  [CONTACT_427])
Cytogenetics
Medical history
Prior antineoplastic medications
Prior and concomitant medications
Assessments to be performe d at screening/baseline include:
Physical examination (i.e., performance status Eastern Cooperative Oncology  Group 
(ECOG), height, weight, vital signs)
Extramedullary involvement

[COMPANY_001] Confidential Page 92
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Laboratory  assessments (i.e., hematology , chemistry , coagulation, urinal ysis, serum 
pregnancy  test)
Cardiovascular assessments (i.e., ECG; ECHO or MUGA)
Chest x -ray
Assessment of disease (in blood and bone marrow)
Biomarker assessments in blood and bone marrow (for FLT3 mutation status  
)
7.1.3 Treatment period
Patients will be assigned on Cycle 1 Day 8  of induction therapy  to midostaurin or placebo 
using a stratified randomization according to age.
Study treatment will begin on Day 1 of Cycle 1 with chemotherap y: daunorubicin from 
Day 1 to Day  3 and cy tarabine from Day  1 to Day 7. Study  treatment will continue on Day 
8 with m idostaurin/placebo until 48 hours prior to start of next cy cle.
Chemotherap y and midostaurin/placebo will be administered as indicated in Table [ADDRESS_1018294] experiences any of the following: persistent disease, relapse as 
determined by [CONTACT_1697], unacceptable toxici ty that precludes further treatment, 
pregnancy , start of non-protocol anti-cancer therapy , discontinuation at the discretion of 
the Investigator or patient, loss to follow -up, death, or study  termination by  [CONTACT_1034]. 
Visit frequency
Induction phase cycle 1: most assessments will be scheduled once or twice per week until 
hematology  recovery . This cycle may be longer than 28 days (until hematology  recovery  
occurs), and the assessments will be performed accordingl ybut cannot be longer than 43
days (28 days plus up to 14additional days for blood count recovery ) in total. If the 
patient has evidence of persistent leukemia on a bone marrow evaluation at the end of the 
first induction cycle, then a second cy cle of induction therapy  will be administered.
Induction phase cycle 2: assessments will be the same as for Cycle 1, except for the PK 
and study  drug dispensation. The maximum length of 
induction cycle 2 is 50days (28 days plus up to 21 additional days for blood count
recovery )
. For details of assessments in induction Cy cles 1 and 2, refer to Table 7 - 1.
Patients who achieve a CRor CRi with adequate blood count recovery will continue with 
consolidation therap yfor 3 to 4 cycleswith a maximum length of 50days(28 day s plus up 
to 21 additional days for  blood count recovery) each. Patients achieving CR/CRi with 
adequate blood count recovery  after induction cycle [ADDRESS_1018295] 3 cy cles of consolidation therapy .
Patients who remain in CR or CRi with adequate blood count recovery  after consolidation 
therap y will begin post-consolidation therap y for up to [ADDRESS_1018296]-
consolidation therap y will begin immediatel y (i.e. up to 48 hours) after the last dose of 
midostaurin/placebo during the last cycle of consolidation therap yand no later than [ADDRESS_1018297]- treatment follow -up.

[COMPANY_001] Confidential Page 93
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Patients in CR or CRi with adequate blood count recovery  may proceed to HSCT and will
enter the post-consolidation phase within 48 hours after the end of the consolidation phase .
Time windows for scheduling assessments
Every  effort should be made to follow the schedule of assessments as described in the 
protocol and especiall y during the induction and consolidation cycles for PK and ECG 
assessments.
All other assessments have a ± 5 day s window, unless otherwise indicated.
Patients who discontinue study  treatment must have an End of Treatment (EOT) visit 
performed ≤ [ADDRESS_1018298] udy treatment.
7.1.4 Discontinuation of study treatment
Patients may voluntarily  discontinue from thestudy  treatment for any reason at any time. If 
a patient decides to discontinue from the study treatment, the investigator should make a 
reasonable effort (e.g.,telephone, e-mail, letter) to understand the primary  reason for this 
decision and record this information in the patient’s chart and on the appropriate CRF pages.  
They  may be considered withdrawn if they state an intention to withdraw, fail to return for 
visits, or become lost to follow -up for an y other reason.
The investigator may  discontinue study  treatment for a given patient if he/she believes that 
continua tion would be detri mental to the patie nt’s well -being.
Study treatment must be discontinued und er the following circumstances: 
Emergence of specific adverse events or laboratory  abnormalities under some 
circumstances outlined in Section 6.3.
Failure to achieve CRor CR
iwith adequate blood count recovery in induction or relapse 
from CR or CRiwith adequate blood count recovery .
Pregnancy  (pregnancy  will be followed for outcome)
Any other protocol deviation that results in a significant ri sk to the patient’s saf ety
The appropriate personnel fr om the site and [COMPANY_001] will assess whether study  treatment 
should be discontinued for any patient whose treatment code has been broken inadvertentl y 
for an y reason.
Patie nts who discontinue study  treatment s should NOT be considered withdrawn from the 
study .They  should return for the assess ments indicated in Section 
7.2.1 . If they fail to return 
for these assess ments for unknown reasons, every  effort (e.g.,telephone, email, and letter) 
shoul d be made to contact [CONTACT_15026] 7.1.9 .
For patients who discontinue treatment for reasons other than documented failure to achieve 
CRor CRi with adequate blood count recovery in induction phase or relapse from CRor CRi 
with adequate blood recovery , death, loss to follow -up, or withdrawal of consent, will 
continue to be followed for efficacy  assessment and survival.
The investigator (or designee) must also contact [CONTACT_105253]’s
discontinuation from study  treatment.

[COMPANY_001] Confidential Page 94
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
[IP_ADDRESS] Replacement policy  
Not applicable
7.1.[ADDRESS_1018299]:
Does not want to participate in the study  anymore, and
Does not allow further collection of personal data
In this situation, the investigator should make a reasonable effort (e.g. telephone, e-mail, letter) 
to understand the primary reason for the subject’s decisio n to withdraw his/her consent and 
record this information. 
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing. 
Further attempts to contact [CONTACT_109032] -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table. 
[COMPANY_001] will continue to keep and use collected study  information (including any data 
resulting from the analysis of a subject’s samples until their time of withdrawal) according to 
applicable law.
For US and Japan: All biological samples not yet analyzed at the time of withdrawal may still 
be used for further testing/anal ysis in accordance with the terms of this protocol and of the 
informed consent form. 
For EU and RoW: All biological samples not yet analyzed at the time of withdrawal will no 
longer be used, unless permitted by [CONTACT_1289]. They  will be stored according to applicable 
legal requirements.
7.1.[ADDRESS_1018300] dose of study  treatment 
(including cy tarabine, daunorubicin/idarubicin or midostaurin/placebo).
Data collected should be added to the Adverse Events CRF and the Concomitant Medications 
CRF.
7.1.[ADDRESS_1018301]-treatment assessments as 
outline d in Section 7.1 until relapse or death.
During this phase, the following data will be collected:

[COMPANY_001] Confidential Page 95
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Antineoplastic therap y/transplantation after disco ntinuation of treatment: every  [ADDRESS_1018302] response, and relapse date etc...
The following assessments will be performed:
Physical examination for extramedullary  disease assessment , blood samples for 
hematology  : every 3mont hs 
Bone marrow aspi[INVESTIGATOR_337] /biopsy for disease assessment : after first [ADDRESS_1018303]-consolidation 
therap y and at relapse .
Questionnaires ( EQ5D -5L, FACT with FACT -Leu)  
 every [ADDRESS_1018304].
7.1.8 Survival follow  up
Patients will enter the survival follow -up phase once they complete the safet y follow up 
period ([ADDRESS_1018305] dose of midostaurin/placebo) in case of induction failure or have 
relapse during post-treatment follow -up.Patients will then be contact [CONTACT_80077]  3 
months +/- [ADDRESS_1018306] to fo llow- up
For patie nts whose status is unclear because they fail to appear for study  visits without stati ng 
an intention to withdraw consent, the investigator should show "due diligence" by [CONTACT_15027], family or family physician as agreed in the infor med consent and by [CONTACT_744381], e.g. dates of telephone calls, 
regis
tered letters, etc. A patie nt sho uld not be considered lost to follow -up until due diligence 
has been completed. Patients lost to follow up should be recorded as such on the appropriate 
Disposition CRF.
7.2 Assessment ty pes
7.2.1 Efficacy  assessments
Efficacy  assessments will be performed according to the IWG criteria for AML  (Cheson e t al 
2003, ELN 2017 / Döhner et 
al 2017 ). The investigator assessment will be used for the 
efficacy  anal yses.Response criteria in AML are described in Table 7 -2:
Table 7
-2 Response classification in A ML at a given evaluation time ( Cheson 
2003, ELN 2017 / Döhner et al 2017)
Response category Definition#
Complete remission 
(CR)Bone marrow 
< 5% blasts 
no blasts with Auer r ods 

[COMPANY_001] Confidential Page 96
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Response category Definition#
Peripheral blood 
neutrophils ≥ 1.0 x 109/L 
platelets ≥100 x 109/L
no blasts
No evidence of extramedullary disease (such as CNS or soft tissue 
involvement).
Transfusion independent (see Section [IP_ADDRESS] ). 
Complete remission 
with incomplete 
hematologic recovery 
(CRi)Bone marrow 
< 5% blasts
no blasts with Auer rods 
Peripheral blood#
neutrophils < 1.0 x 109/L and/or platelets < 100 x 109/L 
no blasts 
No evidence of extramedullary disease (such as CNS or soft tissue 
involvement).
CRiwith adequate blood count recovery is defined as the following:
Bone marrow 
< 5% blasts
no blasts with Auer rods 
Peripheral blood#
Neutrophils >=1.0 x 109/L and 50 x 109/L<=platelets < 100 x 109/L 
no blasts 
No evidence of extramedullary disease (such as CNS or soft tissue 
involvement).
Partial remission 
(PR)Bone marrow 
< 5% blasts AND presence of blasts with Auer rods 
OR
≥ 50% decrease from baseline in blasts in bone marrow AND blast count in
bone marrow is 5% to 25%
Peripheral blood 
neutrophils ≥ 1.0 x 109/L 
platelets ≥100 x 109/L 
no blasts 
No transfusion of neutrophils/platelets within 2days preceding the 
assessment (see Section 7. 2.1.6 ).
No Response Failure to attain the criteria needed for any response categories or relapse

[COMPANY_001] Confidential Page 97
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Response category Definition#
Relapse from CR or 
CRiOnly in patients with a CR or CRi with adequate blood count recover y. An y of 
the following:
Reappearance of blasts in peripheral blood OR 
≥ 5% blasts in bone marrow OR
(Re-)appearance of extramedullar y disease
Unknown In case the response assessment was not done or the assessment was 
incomplete .
# If not defined otherwise, all of the criteria apply.
Response assessment will be performed by [CONTACT_744382] 21-[ADDRESS_1018307]-consolidation phase s. Response assessment will 
be re-performed for patients achieving CRi without adequate blood count recovery  up to 3 
weeks after day 28 of each cycle.Moreover, patient can be assessed any time ifclinically 
indicated.
Treatment failure includes patients who failed to achieve a CR or CRi with adequate blood 
count recovery  up to the end of induction cycle 2. The following categories will only be 
assessed in case of induction treatment:
Category Definition
Primary refractory disease No CR nor CRi with adequate blood count recover y after 2 cycles of 
induction treatment; excluding patients with death in aplasia or death due 
to indeterminate cause
Death in aplasia Deaths occurring ≥7 daysfollowing completion of induction therapy while 
cytopenic; with an aplastic or hypoplastic bone marrow obtained within 7 
daysof death, without evidence of persistent leukemia (< 5% blasts in 
bone marrow, no Auer rods in blasts and/or no extramedullar y disease)
Death from indeterminate 
causeDeaths occurring before completion of therapy, or ,<7 d following its 
completion; or deaths occurring ≥[ADDRESS_1018308] induction cycle, a bone marrow aspi[INVESTIGATOR_337] /biopsy  will be 
performed to determine the presence of residual leukemia (5% blasts) according to the 
International Working Group (IWG) criteria for AML  (Cheson et al 2003, ELN 2017 / 
Döhner et 
al 2017 ). If the Day 21-28 bone marrow aspi[INVESTIGATOR_337] /biopsy shows <5% blasts and the 
response assessment is CR or CRi without adequate blood count recovery , then it is not 
necessary  to repeat bone marrow aspi[INVESTIGATOR_1516] /biopsy while patient is under platelet and/or 
neutrophil recovery  but a new blood count assessment will be performed to determine if the 
patient has achieved CR orCR
i with adequate blood count recovery to be able to move to 
consolidation phase . If the response is CRi without adequate blood count recovery  between
Day 21-28, the cy cle will be prolonged up to two weeks for blood count recovery (i.e. day  42). 
If the patient has reached CR or CRi with adequate blood count recovery, the patient will be 

[COMPANY_001] Confidential Page 98
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
able to move to consolidation phase . Otherwise, the patient will receive a second cycle of 
induction therap y.
If a patient receives a second course of induction therap y, a bone marrow aspi[INVESTIGATOR_1516] /biopsy 
between Day  21-[ADDRESS_1018309] treatment therapi[INVESTIGATOR_014] . Otherwise, the patient will move to 
consolidation phase. Of note, the bone marrow results obtained between Day 21-28 can be 
used retrospective lyto determine response level by D ay 49 (Day  28 plus 3 weeks) .
Therefore, themaximum duration of the induct ion phase cannot exceed 93 days:28 days 
(planned duration of cycle 1 )+ 14 day s (i.e. 2 weeks for blood count recovery  period )) + plus 
1 day  prior to the start of the next cy cle + 28 day s (planned duration of cycle 2 ) + 21 day s (i.e. 
2 weeks blood count recovery  period) ) + plus 1 day prior to the start of the next cy cle.
[IP_ADDRESS] Consolidation therapy:
A bone marrow and blood count examinatio n will be performed to evaluate for continued 
remission (CR or CRi with adequate blood count recovery )between Day 21-28 of each cycle 
of consolidation
.For each cycle, if the patient achieve sCR or CRi with adequate blood count 
recovery up to 3weeks after day 28 of each cycle, the patient will receive the next treatment 
cycle. Of note, the bone marrow results obtained between Day 21-28 can be used 
retrospectivel yto determine response level by  [CONTACT_4475] 49(Day  28 plus 3 weeks) .
[IP_ADDRESS] Post -Consolidation therapy :
A bone marrow examination will be performed to evaluate for continued remission (CR or 
CRi with adequate blood count recovery )prior the start of the post-consolidation therap y, at 
the start of Cycle 4, Cycle [ADDRESS_1018310]-consolidation 
therap y or at an y time at suspected 
relapse. 
[IP_ADDRESS] Post -treatment follow -up:
A bone marrow examination will be performed to evaluate for continued remission (CR or 
CRi with adequate blood count recovery ) [ADDRESS_1018311]-consolidation 
therap y. A bone marrow examination will also be performed at any  time of relapse.
[IP_ADDRESS] Assessment of minimum residual disease (MRD) in bone marrow
For the purpose of the secondary  MRD endpoint, MRD will be assessed by [CONTACT_4133], 
since th is technology  can be used for the large majority  of AML patients. Assessments will be 
performed at baseline during treatment phases indicated in Table 7-1and 7-3. Patients with 
leukemic blasts below 0.1% will be considered as MRD -negative based on leukemia -
associated immunophenoty pe (LAI P
).  
 
 

[COMPANY_001] Confidential Page 99
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
  
 
Table 7-[ADDRESS_1018312] sample collection plan
Sample Type Volume/visit Visit Time Point
Bone Marrow Samples 
Bone Marrow 
Aspi[INVESTIGATOR_744336]6ml*
*First BMA 
pull should be 
used for this 
assessmentScreening Anytime
Induction Phase [ADDRESS_1018313]- consolidation 
Phase C12 Day 28 Pre-dose
At relapse (at any phase of the 
study)Anytime
Post treatment Follow Up: [ADDRESS_1018314]-consolidation 
therapy, and at relapse Anytime
[IP_ADDRESS] Extramedullary  disease assessment
Extramedullary  involvement is to be assessed at baseline and at each visit for response 
assessment. Presence or absence and physical location of extramedullary  disease is to be 
captured in the CRF.
Extramedullary  disease is to be assessed via physical examination, cerebrospi[INVESTIGATOR_872] (CSF) 
assessment in case of symptoms suggestive of meningeosis leukemica, and if clinicall y 
appropriate relevant imaging techniques. In case of extramedullar y disease at baseline or (re-) 
appearance during the study , the lesions should be considered for confirmation by [CONTACT_744383] y and/or clinically feasible.
[IP_ADDRESS] Evaluation of transfusion dependency
Information on transfusion dependency  will beassessed at baseline as well as during the 
course of the trial for all patients. Transfusion of blood products will be recorded in a separate 
module of the CRF. The type of transfusion, start and end date as well as the volume of blood 
product will be captured at each visit with hematologic assessment.

[COMPANY_001] Confidential Page 100
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
A period of at least 2 days without any transfusion has been taken as a convention to define 
the status of transfusion independence to assess a CR or CRi with adequate blood count 
recovery .  A patient who has received a blood transfusion within 2 days preceding a response 
assessment (i.e. CR) will be considered transfusion dependent at the time of this response 
assessment.  
7.2.2 Safety  and tolerability  assessments
Safety  will be monitored by [CONTACT_217970], performance status, laboratory 
examinations, ECGs, Echo/MUGA as well as collecting of the adverse events at every  visit. 
Local measurements of QTc≥480ms shall be centrally  verified on a copy of the original high 
quality  recording that includes time and voltage scales. For details on AEs collection and 
reporting, refer to Section 8.
More frequent examinations may be performed at the investigator’s discretion, if clinically 
indicated.
[IP_ADDRESS] Physical examination
Significant findings that were present prior to the signing of informed consent must be 
included in the Medical History  page on the patient’s CRF. Significant new findings that 
begin or worsen after informed consent must be recorded on the Adve rse Event page of the 
patient’s CRF.
Physical examination will be performed as described in Table 7-1and will include the 
examination of general appearance, skin, neck (including Thyroid), eyes, ears, nose, throat, 
lungs, heart, abdomen, anus, back, lymph nodes, extremities, vascular and neurological 
assessments.
Information about the physical examination must be present in source documents at the study  
site. Significant findings that were present prior to the signing of informed consent must be 
included in the Medical History  CRF. Significant new findings that begin or worsen after 
informed consent must be recorded on the Adverse Events CRF. 
[IP_ADDRESS] Vital signs
Vital signs include blood pressure (supi[INVESTIGATOR_67529] n preferred), pulse measurement, and body 
temperature andwill be measured at screening and at subsequent time points as specified in 
Table 7-1. Data on vital signs will be tabulated and listed, notable values will be flagged.
[IP_ADDRESS] Height and weight
Height in centimeters (cm) will be measured at screening.
Body weight (to the nearest 0.1 kilogram [kg] in indoor clothing, but without shoes) will be 
meas ured at screening and at subsequent time points as specified in Table 7 -1.
[IP_ADDRESS] Performance status
ECOG Performance status scale will be performed as described in the Table 7-1. More 
frequent examinations may be performed at the investigator’s discretion, if medicall y 
indicated. ECOG performance status scale will be used as descri
bed in the Table 7-4.

[COMPANY_001] Confidential Page 101
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 7-4 ECOG performance status scale
Score Performance Status 
0 Fully active, able to carry on all pre disease 
performance without restriction 
1 Restricted in phy sically  strenuous activity but 
ambulatory and able to carry out work of a light or 
sedentary nature ,light housework, office work 
2 Ambulator y and capable of all self -care but 
unable to carry out any work activities. Up and 
about more than 50% of waking hours
3 Capable of only limited self -care, confined to bed 
or chair more than 50% of waking hours
4 Completely disabled. Cannot carry on any self -
care. Totally confined to bed or chair 
5 Dead 

[COMPANY_001] Confidential Page 102
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
[IP_ADDRESS] Laboratory  evaluations
Table 7-[ADDRESS_1018315] Name
[CONTACT_704228] (Local) Hgb, white blood cell ( WBC)with differential (including basophils, eosinophils, 
lymphocy tes, monocy tes, neutrophils, bands, metamyeloc ytes, m yelocytes, 
prom yelocytes blasts), atypi[INVESTIGATOR_70356] (e.g. LUC, er ythroblasts), platelets
Biochemistry  (Local) Albumin, alkaline phosphatase, ALT, AST, LDH, calcium, magnesium, 
phosphorous, sodium, potassium, creatinine, total bilirubin, direct bilirubin, total 
cholesterol, BUN/urea, uric acid, am ylase, lipase, glucose 
Coagulation (Local) International normalized ratio (INR), activated partial t hromboplastin time 
(aPTT)
Urinalysis (Local) Dipstick examination includes specific gravity, pH, glucose, protein, blood, 
bilirubin, ketones and WBCas clinically indicated
Other hepatic tests 
in case of suspected 
DILI (Local)GGT, alkaline phosphatase, other tests for diagnosis of acute hepatitis A, B, C 
or E infection or testing for hepatotropic viral infection or autoimmune hepatitis
Pregnancy Test 
(Local)Pregnancy test in serum (at screening) and urine
Clinical laboratory  anal yses are to be performed by  [CONTACT_12082]  (at the investigational’ 
site) according to the schedule of assessments and collection plan outlined respectively  in 
Table 7-1andTable [ADDRESS_1018316] be provided with a copy of the local laboratory ’s 
certification and a tabulation of the normal ranges and units of each parameters collected in 
the CRF. Any changes regarding normal ranges and units for laboratory  values assessed 
during the study  must be reported via an updated tabulation indicating the date of revalidation. 
Additionally , if at any time a patient has laboratory  parameters obtained from a different 
laboratory , [COMPANY_001] must be provided with a copy of the certification and a tabulation of the 
normal ranges and units for this laboratory  as well. The investigator is responsible for 
reviewing all laboratory  reports for patients in the study  and evaluating any abnormali ties for 
clinical significance.
At any time during the study , abnormal laboratory parameters which are clinically  significant 
and require an action to be taken with study  treatment (e.g.; require dose modification and/or 
interruption of study  treatment, lead to clinical symptoms or signs, or require therapeutic 
intervention), whether 
specificall y requested in the protocol or not will be recorded on the 
Adverse Events CRF. Laboratory  data will be summarized using the CTCAE version 5.0. 
Additional laboratory  evaluations are left to the discretion of the investigator.
[IP_ADDRESS].1
Hematology
Hematology  tests are to be performed by [CONTACT_744384] 7 - 1and Table 7 -6. 
More frequent hematology  testing may also be performed as medicall y necessary . Additional 
results from unscheduled hematology  lab evaluations should be recorded on the appropriate 
unscheduled visit CRF.

[COMPANY_001] Confidential Page 103
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 7-[ADDRESS_1018317] hematologic diagnostics
Sample Type Blood 
volume/visitVisit Time Point
Bone marrow by 
[CONTACT_9256]/aspi[INVESTIGATOR_744337]6 -8 bone 
marrow 
smearsScreening
Induction Phase 1 Day 21- 28
Induction Phase 2 Day 21- 28
Consolidation Phase C1 Day 21- 28
Consolidation Phase C2 Day 21-28
Consolidation Phase C3Day 21-28
Consolidation Phase C4 Day 21-28
Consolidation Phase (at time of 
relapse)
Prior to 1stcycle of post-
consolidation Phase
Post- consolidation Phase C4 Day [ADDRESS_1018318]- consolidation Phase (at 
relapse)
Post treatment  Follow Up: [ADDRESS_1018319]-consolidation 
therapy and at relapse
Peripheral blood 
smears for 
cytomorphology 
including microscopic 
differential count2 peripheral 
blood smearsScreening
Induction Phase 1 Day 21- 28
Induction Phase 2 Day 21- 28
Consolidation Phase C1 Day 21- 28
Consolidation Phase C2 Day 21- 28
Consolidation Phase C3 Day 21- 28
Consolidation Phase C4 Day 21- 28
Consolidation Phase (at time of 
relapse)
Prior to 1stcycle of post-
consolidation Phase
Post- consolidation Phase C2  Day [ADDRESS_1018320]- consolidation Phase C8 Day 1

[COMPANY_001] Confidential Page 104
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Sample Type Blood 
volume/visitVisit Time Point
Post- consolidation Phase C9 Day [ADDRESS_1018321]- consolidation Phase (at 
relapse)
Post treatment Follow Up, ever y 3 
months until relapse and when 
clinically indicated
Bone marrow for 
conventional 
metaphase 
cytogenetics 5 mL
(minimum)Screening
Bone marrow for 
immunophenotypi[INVESTIGATOR_007]5mL Screening
Bone marrow 
(preferably trephine) 
biopsy for histology 
and immunohistology1-2 cm 
trephineScreening (mandatory)
Optional in parallel to all bone 
marrow ( BM)aspi[INVESTIGATOR_744338] (e.g., for the 
purpose of immunohistochemically 
supported blast counting)
[IP_ADDRESS].2 Clinical chemistry
Clinical chemistry  tests are to be performed by [CONTACT_744385] 7 - 1and Table 7-5. 
More frequent clinical chemistry  testing may also be performed as medically  necessary . 
Additional results from unscheduled chemistry  lab evaluations should be recorded on the 
appropriate unscheduled visit CRF.
It should be noted in the patient’s CRF if the patient was fasting as the time of blood sampling.
[IP_ADDRESS].3 Coagulation
Coagulation analyses (INR and aPTT )are to be performed by [CONTACT_744386] 7-1and 
Table 7-5.
[IP_ADDRESS].4 Urinalysis 
Dipstick anal ysis (includes specific gravity , pH, glucose, protein, blood, bilirubin, ketones and 
WBC )is to be performed by [CONTACT_744387].

[COMPANY_001] Confidential Page 105
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Abnormal findings will be followed up with a microscopic analysis and/or additional 
assessments as clinicall y indicated. 
[IP_ADDRESS].[ADDRESS_1018322] dose of study  treatment (at day [ADDRESS_1018323] -consolidation cycles).
Urine pregnancy  tests will be required to be performed as well as at the End of Treatment visit
and at 30-day Safety follow up visit. Every  effort must be made for the women of child 
bearing potential to return to the site for the final pregnancy  test. However if the patient is 
unable to return then the patient will administer the urine pregnancy  test at home using the kit 
provided. For all pregnancy  test performed at home, the site personnel will follow up with the 
patient via telephone call to collect the date and the test results and document the information 
in the patient’s source documents. 
Women of child- bearing potential will be instructed to contact [CONTACT_744388]  (on treatment or during follow -up) should they have a positive 
pregnancy  test.
Male patients treated w ith idarubicin, daunorubicin or cytarabine should receive appropriate 
advice on the risk of infertility  and the option of sperm conservation. Midostaurin may  impair 
both male and female fertility  and this should be communicated to the patients. 
[IP_ADDRESS] Radiological examinations
Chest X -ray will be collect ed at baseline and during the stud y if clinically indicated.
[IP_ADDRESS] Cardiac assessments 
[IP_ADDRESS].1 Electrocardiogram (ECG)
A standard triplicate 12 lead ECG each 2 min apart will be performed according to the 
relevant Visit Evaluation Schedule ( Table 7 -1and Table 7-7).

[COMPANY_001] Confidential Page 106
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 7-7 Local ECG assessment monitoring schedule
Day Time ECG Type
Screening -3 to -1 Pre-dose 12 Lead 
Induction Phase 1 Day 8, Day 
11, Day 21Pre-dose (before PK)
Post- dose at 3 hours ± 0.5 hour (before PK)12 Lead 
Consolidation 
Phase, each c ycleDay 4, Day 
17Pre-dose (before PK)
Post- dose at 3 hours ± 0.5 hour (before PK)[ADDRESS_1018324]-consolidationPre-dose (before PK) [ADDRESS_1018325]- consolidation , 
cycle 2 to c ycle 12Day 1 Pre-dose (before PK) [ADDRESS_1018326]- consolidation , 
cycle 12
or 
at EOT (at any 
phase of the study)Day 28 Pre-dose (before PK)
Anytime12 Lead 
[ADDRESS_1018327] be made by a qualified physician and documented on the 
CRF . Each ECG tracing should be labeled with the study  number, patient initials (where 
regulations permit), subject number, date, and kept in the source documents at the study  site. 
Clinically  significant abnormalities present at screening should be reported on the Medical 
History  CRF. 
Standard 12 lead ECG recording will be performed after the patient has been resting for 
approximately  10 min prior to each ECG collection time point indicated in Table 7-7and 
prior to PK samples. Local measurements of QTc≥480ms shall be centrally  verified on a copy 
of the original high quality recording that includes time and voltage scales.
Dose adjustments in case of QT prolongation should be performed
 per Section 6.3.
Clinically  significant ECG abnormalities present at screening should be reported on the 
Medical History  CRF. New or worsened clinically  significant findings occurring after 
informed consent must be recorded on the Adverse Events CRF.
[IP_ADDRESS].2 Cardiac imaging -MUGA (multiple gated acquisition) scan or echocardiogram
Cardiac Imaging will be performed at screening , at the 30 day Safety Follow Up Visit and 
whenever clinicall y indicated. LVEF needs to be measured and reported at each cardiac 
imaging . 
Any clinically relevant abnormalities will be reported on the medical history  or AE 
page as applicable .
[IP_ADDRESS].3 Cardiac enzymes
Not applicable .

[COMPANY_001] Confidential Page 107
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
7.2.[ADDRESS_1018328] 60 patients randomized into the trial.Therefore there will be approximately
30 patients receiv ing midostaurin and contributing to the PK analysis. A detailed description 
of the sample collection is provided in Table 7-8. In this subset of patients, non-
compartmental PK parameters will be derived as described in Section 10.5.4 . 
The PK samples in the other patients will be collected according to the sampling scheme 
described in Table 7 -9. 
The whole set of concentrations will also be further analyzedusinga population PK approach
(Section 10.5.4). 
Table 7
-8 Pharmacokinetic blood collection log for Midostaurin, CGP52421 and 
CGP62221 –Full PK collection (N=60)
Dose Reference 
ID (2)PK Sample 
numberCycle (Period 
number)Study day 
for each 
cycleTime(1) Blood 
volume 
(mL)
1 101 Induction 1 
Cycle 1*8 Pre-dose 3 
1 102 Induction 1 
Cycle 1*8 1h 3 
1 103 Induction 1 
Cycle 1*[ADDRESS_1018329]- dose 3hrs 
+-0.5 hrs3 
1 104 Induction 1 
Cycle 1*8 6h 3 
1/ 111(3) 105 Induction 1 
Cycle 1*8 12h(prior to the 
evening dose of 
Midostaurin/ 
Placebo)3 
2/[ADDRESS_1018330]- dose 3hrs 
+-0.5 hrs3
3/301 108 Induction 1 
Cycle 115 Pre-dose 3 
4/401 109 Induction 1 
Cycle 118 Pre-dose 3 
5/[ADDRESS_1018331]- dose 3hrs 
+-0.5 hrs3
6/[ADDRESS_1018332]- dose 3hrs 
+-0.5 hrs3

[COMPANY_001] Confidential Page 108
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Dose Reference 
ID (2)PK Sample 
numberCycle (Period 
number)Study day 
for each 
cycleTime(1) Blood 
volume 
(mL)
7/[ADDRESS_1018333]- dose 3hrs 
+-0.5 hrs3
8/[ADDRESS_1018334]- dose 3hrs 
+-0.5 hrs3
9/[ADDRESS_1018335]- dose 3hrs 
+-0.5 hrs3
10/[ADDRESS_1018336]-
consolidation , 
cycle 1 Pre-dose 
 3 
11/[ADDRESS_1018337]- dose 3hrs 
+-0.5 hrs3 
12/[ADDRESS_1018338]-
consolidation , 
cycle 71 Pre-dose 3
13/[ADDRESS_1018339]-
consolidation , 
cycle 101 Pre-dose 3 
14/[ADDRESS_1018340]-
consolidation , 
cycle 1228 Pre-dose 3 
Total volume
Unscheduled samples
NA 100x NA NA Unscheduled
*: When m edically feasible full blood sample to be collected
(1): When PK is collected at the same time point as ECG, ECG should be done first. 
(2): Dose reference ID: The first number refers to the administration at the day, the second number 
refersto the administration the day before (The information has to be c ollected) with an exception on 
Day 1 (see below).
(3) The first number refers to the administration onDay1 morning dose , the second number refer sto 
the administration on Day1 evening dose.
Unscheduled blood samples will be uniquely, sequentially numbered 1001, 1002, …

[COMPANY_001] Confidential Page 109
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 7-9 Pharmacokinetic blood collection log for Midostaurin, CGP52421 and 
CGP62221 –Sparse PK collection
Dose Reference 
ID (2)PK Sample 
numberCycle (Period 
number)Study day 
for each 
cycleTime(1) Blood 
volume 
(mL)
1 201 Induction 1 
Cycle 1*8 Pre-dose 3 
1 202 Induction 1 
Cycle 1*[ADDRESS_1018341]- dose 3hrs 
+-0.5 hrs3 
2/[ADDRESS_1018342]- dose 3hrs 
+-0.5 hrs3
3/301 205 Induction 1 
Cycle 115 Pre-dose 3 
4/401 206 Induction 1 
Cycle 118 Pre-dose 3 
5/[ADDRESS_1018343]- dose 3hrs 
+-0.5 hrs3
6/[ADDRESS_1018344]- dose 3hrs 
+-0.5 hrs3
7/[ADDRESS_1018345]- dose 3hrs 
+-0.5 hrs3
8/[ADDRESS_1018346]- dose 3hrs 
+-0.5 hrs3
9/[ADDRESS_1018347]- dose 3hrs 
+-0.5 hrs3
10/[ADDRESS_1018348]-
consolidation , 
cycle 1 Pre-dose 
 3 
11/[ADDRESS_1018349]-
consolidation , 
cycle 41 Pre-dose 3 
12/[ADDRESS_1018350]-
consolidation , 
cycle 71 Pre-dose 3

[COMPANY_001] Confidential Page 110
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Dose Reference 
ID (2)PK Sample 
numberCycle (Period 
number)Study day 
for each 
cycleTime(1) Blood 
volume 
(mL)
13/[ADDRESS_1018351]-
consolidation , 
cycle 101 Pre-dose 3 
14/[ADDRESS_1018352]-
consolidation , 
cycle 1228 Pre-dose 3 
Total volume
Unscheduled samples
NA 200x NA NA Unscheduled
*: When m edically feasible full blood sample to be collected
(1): When PK is collected at the same time point as ECG, ECG should be done first. 
(2): Dose reference ID: The first number refers to the administration at the day, the second number 
refer to the administration the day before (The information has to be collected) 
Unscheduled blood samples will be uniquely, sequentially numbered 2001, 2002, …
Detailed instructions for the collection, handling, and shipment of PK samples will be 
provided in a separate document .
[IP_ADDRESS] Analytical method
Plasma concentrations of midostaurin and its active metabolites C GP62221 and C GP52421 
will be measured using a validated liquid chromatograph y-tandem mass spectrometry  (LC-
MS/MS) assay  with a lower limit of quantification (LLOQ) of approximately  10.0 ng/mL. 
Concentrations below the LLOQ will be reported as 0.00 ng/mL and missing samples will be 
labeled accordingl y.

[COMPANY_001] Confidential Page 111
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
7.2.4 Biomarkers
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7-11 Biomarker sample collection plan
Sample Type Blood 
volume/visitVisit Time Point
Samples for Molecular Screening
Bone Marrow 
Aspi[INVESTIGATOR_744339]3 
mutational testing *2 mL Screening (eligibility confirmation) Anytime, as early as 
possible after 
patient signed ICF
Peripheral Blood for 
FLT3 mutational 
testing *6mL Screening (eligibility confirmation) Anytime, as early as 
possible after 
patient signed ICF
*A bone marrow aspi[INVESTIGATOR_55536] a whole blood sample will be collected. In case both sample types 
are collected/available, FLT3 screening will be preferentially performed only on the bone 
marrow sample; and the peripheral blood sample will be banked for future testing
Bone M arrow Samples
Bone Marrow 
Aspi[INVESTIGATOR_744340] , 
DNA  (MRD and 
)[ADDRESS_1018353]- consolidation 
PhasePre-dose

[COMPANY_001] Confidential Page 112
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Sample Type Blood 
volume/visitVisit Time Point
Post- consolidation Phase C4 Day [ADDRESS_1018354]- consolidation 
Phase C12 Day 28 Pre-dose
At relapse (at any phase of the study) Anytime
Post treatment Follow Up: [ADDRESS_1018355]-consolidation 
therapy, and at relapse Anytime
Blood Samples 
Peripheral Blood
for RNA  and DNA  
analysis (MRD  
)16mL Screening Anytime
Induction Phase C1 Day [ADDRESS_1018356]- consolidation
Phase C12 Day 28 Pre-dose
EOT (at any phase of the study) Anytime
Every 3 months during years 1 and 2 
and then yearlyAnytime

[COMPANY_001] Confidential Page 113
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
[IP_ADDRESS] Additional biomarker assessments
 
 
 
 
 
 
 
 
 
 
 
 
 
7.2.6 Patient reported outcomes
Two questionnaires will be used in this study  to capture PROs: Functional Assessment of 
Cancer Therapy -Leukemia (FACT -Leu)and EQ-5D- 5L. Brief description of each 
questionnaire is given in the sections below.
The patient should be given the questionnaire(s) to be completed at the scheduled visit before 
other clinical assessments are conducted. Questionnaires should be completed in the language 
the respondent is most familiar with, at the scheduled visit before the patient sees the 
investigator for clinical assessments. The patient should be given sufficient space and time to 
complete the questionnaire. 

[COMPANY_001] Confidential Page 114
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Reason for missing data at scheduled visit will also be captured (‘patient refused due to poor 
health’, ‘patient refused (unrelated to health), ‘study  staff felt patient was too ill’, ‘patient 
missed appointment’, ‘other reasons’).
Data from both questionnaires will be captured electronicall y using dedicated devices. 
Instructions for operating the devices will be available to each study  site.  In addition detailed 
instructions relating to the administrative procedures of the questionnaires will be provided to 
the sites in a separate document. Patient’s refusal to complete all or any part of a 
questionnaire should be documented in the study  data capture s ystem. 
FACT -Leu
The FACT -Leu is a questionnaire to assess the quality  of life in patients with leukemia . It 
consists of a general quality  of life instrument (FACT -G) and a condition specific module Leu. 
The FACT -Leu is a fully validated QOL questionnaire applicable for patients with leukemia
and includes a module which assesses specific concerns of patients with leukemi a. The 
FACT -G has 27 statements that patients will need to endorse on a five -point scale (not at all, a 
little, somewhat, quite a bit, very much). The statements cover five subscales (Phy sical Well-
Being, Social/Famil y Well- Being, Emotional Well- Being, Functional Well- Being and 
Additional Concerns). The Leu module consists of 17 statements patients need to endorse on 
an identical five-point scale. The recall period is “Past 7 days”, and the questionnaire requires 
approximately  5 minutes to complete.
EQ-5D-5L
The EQ-5D is a widely  used, self-administered questionnaire designed to assess health status 
in adults. The EQ-
5D-5L essentially  consists of 2 pages: the EQ-5D descriptive system and 
the EQ visual analogue scale (EQ VAS).  The descriptive system comprise s five dimensions: 
mobility , self-care, usual activities, pain/discomfort and anxiety /depression. Each dimension 
has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme 
problems.
Patients rate each of these items: no problems, slight problems, moderate problems, severe 
problems and extreme problems. A composite health index is then defined by [CONTACT_744389]. The second section of the questionnaire measures self -rated (global) 
health status utilizin g a verticall y oriented visual analogue scale where 100 represents the 
“best possible health state” and 0 represents the “worst possible health state.” Respondents are 
asked to rate their current health by [CONTACT_1299] a mark along this continuum. The recall period is 
“today ,” and the questionnaire requires approximately  5 minutes to complete.
8 Safety  monitoring and reporting
8.1 Adverse events
8.1.1 Definitions and reporting
An adverse event is defined as the appearance of (or worsening of any pre-existing) 
undesirable sign(s), symptom(s), or medical condition(s) that occur after patient’s signed 
informed consent has been obtained.

[COMPANY_001] Confidential Page 115
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Abnormal laboratory  values or test results occurring after informed consent constitute adverse 
events only if they induce clinical signs or symptoms, are considered clinically  significant, 
require therapy  (e.g., hematologic abnormalit y that requires transfusion or hematological stem 
cell support), or require changes in study  medication(s).
Adverse events that begin or worsen after informed consent should be recorded in the Adverse 
Events CRF. Conditions that were alread y present at the time of informed consent should be 
recorded in the Medical History  CRF. Adverse event monitoring should be continued for at 
least [ADDRESS_1018357] dose ofstudy  treatment. Adverse events (including lab 
abnormalities that constitute AEs) should be described using a diagnosis whenever possible, 
rather than individual underly ing signs and symptoms. When a clear diagnosis cannot be 
identified, each sign or symp tom should be reported as a separate Adverse Event.
Adverse events will be assessed and graded according to the CTCAE version 5.0.
If CTCAE grading does not exist for an 
adverse event, the severit y of mild, moderate, severe, 
and life-threatening, death related to the AE corresponding respectivel y to Grades 1 - 5, will 
be used. Information about any deaths (related to an Adverse Event or not) will also be 
collected th rough a Death form.
The occurrence of adverse events should be sought by  [CONTACT_105]-directive quest ioning of the patient 
during the screening process after signing informed consent and at each visit during the study . 
Adverse events also may be detected when they are volunteered by [CONTACT_744390], or through phys ical examination, laboratory  test, or other 
assessments. As far as possible, each adverse event should be evaluated to determine:
1.The severit y grade (CTCAE Grade 1 -5)
2.Its duration ( start and end dates) 
3.Its relationship to the study  treatment ( related, n ot related )
4.Action taken with respect to study  treatment ( dose increased, dose not changed, dose 
reduced, drug interrupted, drug withdrawn, unknown, not applicable )
5.Whether medication or therap y was given (no concomitant medication/non -drug therap y, 
conco mitant medication/non -drug therap y)
6. Whether it is serious, where a SAE is defined as in Section 8.2.[ADDRESS_1018358] been met
7. Outcome (not recovered/not resolved, recovered/resolved, recovered/resolved with 
sequelae, fatal, unknown) 
8. If the event worsens, the event should be reported a second time in the CRF noting the 
start date when the event worsens in toxicity . For grade 3 and 4 adverse events only , if 
improvement to a lower grade is determined a new entry  for this event should be reported 
in the CRF noting the start date when the event improved from having been Grade 3 or 
Grade 4.
All adverse events should be treated appropriately . If a concomitant medication or non-drug 
therap y isgiven, this action should be recorded on the Adverse Event CRF.
Once an adverse event is detected, it should be followed until its resolution or until it is 
judged to be permanent, and assessment should be made at each visit (or more frequently , if 

[COMPANY_001] Confidential Page 116
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
necessary ) of any changes in severit y, the suspected relationship to the study  treatment, the 
interventions required to treat it, and the outcome.
Treatment failure or relapse (including fatal outcomes), if documented by [CONTACT_230784] a serious adverse event.
Adverse events separate from relapse or treatment failure will be reported as per usual 
guidelines used for such events with proper attribution regarding relatedness to the drug.
8.1.[ADDRESS_1018359] abnormalities
[IP_ADDRESS] Defin itions and reporting
Laboratory  abnormalities that constitute an AEin their own right (are considered clinicall y 
significant, induce clinical signs or sy mptoms, require concomitant therapy  or require changes 
in study  treatment), should be recorded on the AEs CRF. Whenever possible, a diagnosis, 
rather than a symptom should be provided (e.g. anemia instead of low hemoglobin). 
Laboratory  abnormalities that meet the criteria for Adverse Events should be followed until 
they have returned to normal or an adequa te explanation of the abnormality  is found. When an 
abnormal laboratory  or test result corresponds to a sign/s ymptom of an alread y reported 
adverse event, it is not necessary  to separately  record the lab/test result as an additional event.
Laboratory  abnormalities, that do not meet the definition of an adverse event, should not be 
reported as adverse events. A Grade 3 or 4 Event (severe) as per CTCAE does not 
automatically  indicate a SAE unless it meets the definition of serious as defined below and/or 
as per investigator’s discretion. A dose hold or medication for the lab abnormality  may be 
required by [CONTACT_64103], by [CONTACT_108], be 
an 
adverse event and must be reported as such.
8.1.[ADDRESS_1018360] (AESI ) are defined as events (serious or non-serious) which 
are ones of scientific and medical concern specific toMidostaurin
, for which ongoing 
monitoring and rapid communication by  [CONTACT_744391]. 
Such events may  require further investigation in order to ch aracterize and understand them.
AESI are defined on the basis of an ongoing review of the safet y data. AESI  are discussed in 
detail in the Investigator Brochure.
8.2 Serious adverse events
8.2.1 Definitions
Serious adverse event (SAE) is defined as one of the following:
Is fatal or life -threatening
Results in persistent or significant disability /incapacity
Constitutes a congenital anomaly /birth defect
Is medicall y significant, i.e., defined as an event that jeopardizes the patient or may 
require medical or surgical intervention to prevent one of the outcomes listed above

[COMPANY_001] Confidential Page 117
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Requires inpatient hospi[INVESTIGATOR_1081], 
Note that hospi[INVESTIGATOR_14944]:
Routine treatment or monitoring of the studied indication, not associated with any 
deterioration in condition 
Elective or pre-planned treatment for a pre-existing condition that is unrelated to the 
indication under study  and has not worsened since signing the informed consent
Social reasons and respi[INVESTIGATOR_064]’s 
general condition
Note that treatment on an emergency  outpatient basis that does notresult in hospi[INVESTIGATOR_286743] a SAE given above 
is not a serious adverse event.
8.2.[ADDRESS_1018361] be reported as follow -up to the original epi[INVESTIGATOR_5319] 24 
hours of the investigator receiving the follow -up information. An SAE occurring at a different 
time interval or otherwise considered completely  unrelated to a previously  reported one 
should be reported separately as a new event.
Any SAEs experienced after the 30 day safety evaluation follow -up period should only be 
reported to [COMPANY_001] if the investigator suspects a causal relationship to the study  treatme nt.  
Information about all SAEs is collected and recorded on the Serious Adverse Event Report 
Form; all applicable sections of the form must be completed in order to provide a clinically 
thorough report. The investigator must assess and record the relatio nship of each SAE to each 
specific study  treatment (if there is more than one study  treatment), complete the SAE Report 
Form in English, and submit the completed form within [ADDRESS_1018362] as the original SAE Report.  Each re-
occurrence, complication, or progression of the original event should be reported as a follow -
up to that event regardless of 
when it occurs. The follow -up information should describe 
whether the event has resolved or continues, if and how it was treated, whether the blind was 
broken or not, and whether the patient continued o r withdrew from study  participation.
If the SAE is not previously  documented in the Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the [COMPANY_001] study  treatment, an oncology  [COMPANY_001] 
Chief Medical Office and Patie nt Safety (CMO&PS) department associate may urgentl y require 
further information from the investigator for Health Authority  reporting. [COMPANY_001] may  need to 
issue an Investigator Notification (IN), to inform all investigators involved in any study with 
the same drug that this SAE has been reported. Suspected Unexpected Serious Adverse 

[COMPANY_001] Confidential Page 118
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Reactions (S[LOCATION_003]Rs) will be collected and reported to the competent authorities and relevant 
ethics committees in accordance with Directive 2001/20/EC or as per national regulatory 
requirements in participa ting countries.
8.[ADDRESS_1018363] often, study  treatment discontinuation and knowledge of the possible 
treatment assignments are sufficient to treat a study  patient who presents with an emergency 
condition. Emergency  code breaks are performed using the IRT. When the investigator 
contacts the IRT to unblind a patient, he/she must provide the requested patient identify ing
information and confirm the necessity  to unblind the patient. The investigator will then 
receive details of the drug treatment for the specified patient and a fax confirming this 
information. The system will automatically  inform the [COMPANY_001] monitor for the site and the 
Study  Lead that the code has been broken.
It is the investigator’s responsibility  to ensure that there is a procedure in place to allow access 
to the IRT in case of emergency . The investigator will inform the patient how to contact 
[CONTACT_5657]/her backup in cases of emergency  when he/she is unavailable. The protocol number, study 
treatment name [CONTACT_90228], subject number, and instructions for contact[CONTACT_744392] (CPO )(or any entity to which it has delegated responsibility  for 
emergency  code breaks) will be provided to the patient in case emergency  unblinding is 
required at a time when the investigator and backup are unavailable. However, if a mechanism 
is alread y in place to ensure that the investigator and/or back -up can always be reached in case 
of emergency  then the procedure above is not required.
The appropriate personnel fr om the site and [COMPANY_001] will assess whether study  treatment 
should be discontinued for any patient whose treatment code has been broken inadvertentl y 
for an y reason .
8.[ADDRESS_1018364] be reported to [COMPANY_001] within 24 hours of learning of its occurrence. The pregnancy 
should be followed up to deter mine outcome, including spontaneous or voluntary  termination, 
details of the birth, and the presence or absence of any  birth defects, congenital abnormalities, 
or maternal and/or newborn complications.
Pregnancy  should be recorded on a Clinical Trial Pregn ancy  Form and reported by [CONTACT_744393]&PS. Pregnancy  follow -up should be recorded on 
the same form and should include an assessment of the possible relationship to the study  
treatment for any pregnancy  outcome. Any SAE expe rienced during pregnancy  must be 
reported on the SAE Report Form.
Pregnancy  outcomes should be collected for the female partners of any males who took study 
treatment in this study . Consent to report information regarding these pregnancy  outcomes 
should be obtained from the mother.

[COMPANY_001] Confidential Page 119
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
If pregnancy  occurs in a patient in the study , the study treatment must be discontinued , 
though the patient may stay in the study  and follow the assessments, if she wishes to do so. 
All assessments that are considered as a risk during pregnancy  must not be performed. The 
patient may  continue all other protocol assessments.
Follow up of the pregnancy  (female patient or female partner of patient) should be according 
to the following schedule:
Tracking of pregnancy  cases occurs until after Expected Delivery  Date (EDD) for all 
prospective pregnancy  cases received from clinical studies (including pregnancies where 
the patient was exposed to placebo or comparator and pregnancies due to the conduct of 
the study ).
EDD +1 month (mandatory  for all cases). Requesting the pregnancy  outcome and other 
clinically  relevant pregnancy  data or changes in data.
EDD+2 month (mandatory
 if no answer is obtained after request at EDD+1 month). A 
reminder letter for the outcome.
The follow up at EDD+[ADDRESS_1018365] be collected.
The follow up at EDD+[ADDRESS_1018366] to follow -up (e.g. no respo nse after 3 attempts) this information
must be transferred to the Safet y Desk of the CPO.
8.[ADDRESS_1018367] patient. The 
DMC will be responsible to review safet y data approximately  every 6 m onths (after the first 
randomized patient has started study  treatment) . The DMC will also be responsible to review 
efficacy andsafety data, in the conduct of the interim analy sis as defined in the protocol. This 
includes but does not limit the role of the DMC to evaluate these data and to provide 
recommendations to the spon sor to continue, modify  or stop the study  early .
It is expected that the DMC will consist at a minimum of two physicians with appropriate 
disease area qualifications and 
one statistician. There will be a meeting with the DMC 

[COMPANY_001] Confidential Page 120
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
describing their roles and responsibilities and discussing potential data format and process 
issues prior to the finalization of DMC charter and the interim anal ysis plan.
It is envisioned that the DMC may  make five t ypes of recommendations, namely :
No safet y or efficacy issues, ethical to continue the study  as planned
Serious safet y concerns precluding further study treatment, regardless of efficacy
Overwhelming evidence for efficacy  making further participation in the study  unethical
Overwhelming evidence for futility , recommend stoppi [INVESTIGATOR_10098] .
Recommendation to continue the study  but proposing an amendment to the protocol (e.g., 
incorporate an additional safet y assessments)
If the study  is recommended to continue by [CONTACT_1363], no details about the results of the 
current interim anal ysis will be revealed prior to the next scheduled anal ysis.
8.7 Steering Committee 
The Steering Committee (SC) will be established comprising investigators participating in the 
trial and will not include the independent safet y committee or the [COMPANY_001] represe ntatives 
from the Clinical Trial Team.
The SC will ensure transparent management of the study  according to the protocol through 
recommending and approving modifications as circumstances require. The SC will review 
protocol amendments as appropriate. Togeth er with the clinical trial team, the SC will also 
develop recommendations for publications of study  results including authorship rules. The 
details of the role of the SCwill be defined in a SCcharter. The SC will not have access to 
un-blinded trial data prior to the primary  analy ses.
[ADDRESS_1018368] of the following:
What protected health information (PHI) will be collected from subjects in this study
Who will have access to that information and wh y
Who will use or disclose that information
The rights of a research subject to revoke their authorization for use of their PHI .
In the event that a subject revokes authorization to collect or use PHI, the investigator, by 
[CONTACT_5151], retains the ability  to use all information col lected prior to the revocation of subject 
authorization. For subjects that have revoked authorization to collect or use PHI, attempts 
should be made to obtain permission to collect follow -up safet y information (e.g. has the 
subject experienced an y new or w orsened AEs) at the end of their scheduled study  period.
The data collection system for this study  uses built-in security  features to encry pt all data for 
transmission in both directions, preventing unauthorized access to confidential participant 

[COMPANY_001] Confidential Page 121
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
informati on. Access to the system will be controlled by a sequence of individually  assigned 
user identification codes and passwords, made available only to authorized personnel who 
have c ompleted prerequisite training.
Subject Age will be recorded in the eCRF to establish that the subject satisfies protocol age 
requirements and to enable appropriate age-related normal ranges to be used in assessing 
laboratory  test results.
9.2 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, [COMPANY_001] 
personnel (or designated CRO) will review the protocol and CRFs with the investigators and 
their staff. During the study , the field monitor will visit the site regularly to check the 
completeness of patient records, the accuracy  of entries on the CRFs, the adherence to the 
protocol to Good Clinical Practice, the progress of enrollment, and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Key study 
personnel must be available to assist the field monitor during these visits.
The investigator must maintain source documents for each patient in the study , consisting of 
case and visit notes (hospi[INVESTIGATOR_5320]) containing demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or 
assessments. All information recorded on CRFs must be traceable to source documents in the 
patient's file. The investigator must also keep the original signed informed consent form (a 
signed cop y is given to the patient).
The investigator must give the monitor access to all relevant source documents to confirm 
their consistency  with the CRF entries. [COMPANY_001] monitoring standards require full verification 
for the presence of informed consent, adherence to the inclusion/exclusion criteria and 
documentation of SAEs. Additional checks of the consistency  of the source data with the 
CRFs are performed according to the stud y-specific monitoring plan.
9.3 Data collection
For studies using Electronic Data Capture (EDC), the designated investigator staff will enter 
the data required by [CONTACT_178209]. The eCRFs have been built using fully 
validated secure web-enabled software that conforms to [ADDRESS_1018369] certify  thatthe data entered into CRF are complete and accurate and 
that entry  and updates are performed in a timel y manner.
ECG data will be collected via 12-lead ECG machines and the data will be recorded on the 
CRF. 
PK  
samples (including FLT3 analy tics)drawn during the course of the study 
will be shipped by [CONTACT_373605] a [COMPANY_001] designated laboratory  for sample management and/or 
analysis.

[COMPANY_001] Confidential Page 122
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
PRO data must be recorded by [CONTACT_744394]. Paper que stionnaires as back -up might be allowed to use in exceptional cases.
9.4 Database management and quality  control
For studies using eCRFs, [COMPANY_001] personnel (or designated CRO) will review the data entered 
by [CONTACT_5375] . Electronic data queries stating the 
nature of the problem and requesting clarification will be created for discrepancies and 
missing values and sent to the investigational site via the EDC system. Designated 
investigator site staff are required to respon d promptly  to queries and to make any necessary 
changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using 
the WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical 
classification system. Medical history /current medical conditions and adverse events will be 
coded using the Medical dictionary  for regulatory  activities (MedDRA) terminology .
In terms of samples and/or data (e.g.  PK) that will be processed centrally  the 
results will be sent electronically  to [COMPANY_001].
PRO data will be entered into an electronic diary by [CONTACT_102]. The system will be supplied 
by a vendor(s), who will also manage the database. The database will be sent electronically  to 
[COMPANY_001] personnel.
Randomization codes and data about all study  treatments dispensed to the patient and all IRT 
assigned dosage changes will be tracked using an Interactive Response Technology . The 
system will be supplied by a vendor(s), who will also manage the database. The data will be 
sent electronically  to [COMPANY_001] personnel.
At the conclusion of the study , the occurrence of any emergency  code breaks will be 
determined after return of all code break reports and unused drug supplies to [COMPANY_001] 
personnel (or designated CRO). The occurrence of any  protocol violations will be dete rmined. 
After these actions have been completed and the data has been verified to be complete and 
accurate, the database will be declared locked and the treatment codes will be unblinded and 
made available for data analy sis. Authorization is required prior to making any database 
changes to locked data, by [CONTACT_744395], Global Head of Data Management and the Global Head of Clinical Development.
After database lock, the investigator will receive cop ies of the patient data for archiving at the 
investigational site.
[ADDRESS_1018370] interim analyses for OS if EFS statistically  significant will be performed by [CONTACT_744396] (CRO not involved 
with the conduct of the study ). The second OS interim analysis at the time of the final EFS 
analysis will beperformed by [CONTACT_744397] 123
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
significant . Investigators and patients will be kept blinded at the patient level in case the trial 
continues. 
The final EFS analysis will be conducted at the time when approx imately [ADDRESS_1018371] 
been observed. The final OS analy sis will be performed when there are approximately 
278deaths documented . Thesafety  analysis will be performed approximately  every 6 months 
by [CONTACT_744398] O S anal yses.
10.1 Analysis sets
10.1.1 Full A nalysis Set
The Full Analysis Set (FAS) comprises all patients to whom study  drug has been assigned by 
[CONTACT_17628]. According to the intent to treat principle, patients will be analyzed according 
to the treatment and strat umthey have been assigned to during the randomization procedure.
10.1.2 Safety  set
The Safety Set (SS) includes all patients who received at least one dose of study  treatment 
starting at day [ADDRESS_1018372] one dose of that treatment. 
Patients who started therapy  at day 1 but discontinued prior to randomizatio n at day 8 will be 
listed separatel y.
10.1.3 Per-Protocol set
The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant 
with requirements of the study  protocol (i.e.,without any major protocol deviation) .Protocol 
deviations leading to exclusion from the PPS will be justified and specified in the study  
Specification Document (SSD) and Statistical Analy sis Plan (SAP) documents prior to 
database lock.
10.1.4 Pharmacokinetic analy sis set
Pharmacokinetic A nalysis Set for all (PA S-all)
The Pharmacokinetic analy sis set for all (PAS -all) includes all subjects in the safet y set, and 
provide at least one evaluable PK concentration.
For a concentration to be evaluable: 
Dosing information must be properl y documented (data and time of administrati on)
the planned dose of midostaurin must be taken prior to sampling,
For pre -dose samples: no vomiting within 4 hours after the midostaurin dose prior to 
sampling, the sample is collected before the next dose administration.
For post -dose samples: no vomit ing within 4 hours after midostaurin dosing 
The PAS-all will be the primary  population used for all pharmacokinetic analy ses using 
trough concentration data.

[COMPANY_001] Confidential Page 124
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Pharmacokinetic analy sis set for full PK profile (PA S-full) 
The Pharmacokinetic analy sis set forfull PK profiles (PAS -full) includes all subjects in the 
PAS-all, who provide an evaluable PK profile. A profile is considered evaluable if all of the 
following conditions are satisfied:
Subject receives the planned first dose of midostaurin on C1D8 of In duction therapy
Subject did not vomit within [ADDRESS_1018373] dose of midostaurin on C1D8 of Induction 
therap y
Subject provides at least one primary  PK parameter (Cmax, AUC0 -t)
The PAS-full will be the primary  population used for all pharmacokinetic analyses based on 
full PK profile data.
Protocol deviations leading to exclusion from the PAS-all and PAS-full will be justified and 
specified in the study  Validation and Planning (VAP) and Statistical Analy sis Plan (SAP) 
documents.
10.2 Patient demographics/other baseline characteristics
Baseline demographics and disease characteristics data will be summarized descriptively  by
[CONTACT_64207]. Qualitative data, such as gender, race, etc., will be presented as
frequencies and percentages. Quantitative data, such as age, height, etc., will be summarized 
as mean, standard deviation, median, minimum, and maximum.
10.3 Treatments (study  treatment, concomitant therapi[INVESTIGATOR_014], compliance)
Data on the study  treatment administration will be summarized by [CONTACT_744399] y set. The duration of treatment and relative dose intensity  of each of the components of 
study  treatment will be summarized using descriptive statistics.
Concomitant medications and significant non-drug therapi[INVESTIGATOR_49344] (ATC) classification sy stem, by  [CONTACT_1570].
Any prior concomitant medications or significant non-drug therapi[INVESTIGATOR_744341] .
10.[ADDRESS_1018374]-
consolidation therapy
improves EFS in patients with newly  diagnosed FLT3 -MN (SR<0.05) AML.
The primary  endpoint is EFS as per investigator assessment and is defined as the time 
from the date of randomization to failure to obtain CR or CRiwith adequate blood count
recovery in induction, relapse after CR or CRi with adequate blood count recovery , or 
death due to an y cause, whichever occurs first.

[COMPANY_001] Confidential Page 125
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
10.4.[ADDRESS_1018375] (stratified according to randomization stratif ication factor of age (<60 vs. ≥ 60 years)) 
at the one-sided 2.5% level of significance: 
H01: θ1≥ 1vs. H a1: θ1< [ADDRESS_1018376] ratio (Midostaurin treatment arm vs. placebo arm) of EFS.
The primary  efficacy  endpoint EFS will be analy zed at the interim looksand final look of a 
group sequential design based on the FAS population according to the treatment group 
patients were randomized and the strata they  were assigned at randomization (i.e. age < 60 vs. 
>=60 years). EFS will be estimated using the Kaplan -Meier method . The median EFS along 
with 95% confid ence intervals will be presented by  [CONTACT_1570]. 
Under the proportional hazards assumption, a test based on the stratified log-rank test 
provides an asymptotically  equivalent result as that of the stratif ied Cox regression model 
which will be used to estimate the hazard ratio (HR) of EFS, along with 95% confidence 
interval (using the same strata information as above). 
10.4.2 Handling of missing values/censoring/discontinuations
In the primary  analysis, a patient who had not an EFS event at the date of the analy sis cut-off 
would have his/her EFS censored at the time of the last adequate response assessment before 
the cut -off date. 
A patient who failed to achieve CRor CRi with adequate blood count recovery  in ind uction , 
would have his/her EFS event due to induction failure documented at the date of 
randomization.
EFS events documented after the initiation ofHSCT ornew anti-neoplastic therap ywill be 
considered as EFS event for the primary  EFS analy sis.
If a
n EFS event is observed after two or more missing or non-adequate response assessments, 
then EFS will be censored at the last adequate response assessment before the EFS event. If 
an E FS event is observed after a single missing or non-adequate response assess ment, the 
actual date of event will be used .
An adequate response assessment is considered any disease assessment indica ting response 
status apart from “unknown” or “not done”.
10.4.3 Supportive analy ses
A supportive analysis on the primary  efficacy  variable using a stratified Cox’s proportional 
hazards model adjusting for time dependent covariates such as SCT and MRD and other 
potential prognostic factors will be performed. Other potential prognostic factors will be 
specified in the SAP document prior to database lock.
Subgroup analy ses based on age and gender etc. will be performed. There will be sensitivit y 
analyses for the EFS (e.g.,using different censoring techniques, per protocol set analy sis, 
etc...). More details on these will be available in SAP.

[COMPANY_001] Confidential Page 126
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
10.[ADDRESS_1018377]-consolidation therapy
improves OS in patients with newly  diagnosed FLT3 -MN (SR<0.05) AML.
Other secondary  efficacy  objectives are to compare CRor CRi with adequate blood count 
recovery  rate, MRD, DFS, Cumulative Incidence of Relapse (CIR), Cumulative Incidence of 
Disease (CID )and health -related quality  of life and symptoms of AML in patients treated 
with midostaurin in combination with daunorubicin or idarubicin /cytarabine versus those 
treated with placebo in combination with daunorubicin or idarubicin/cy tarabine.
The seconda ry safety /PK objective is to assess safet y, pharmacokinetic of midostaurin in 
combination with daunorubicin or idarubicin /cytarabine versus placebo in combination with 
daunorubicin or idarubicin /cytarabine.
Population and groupi[INVESTIGATOR_744342]. For all safet y analyses, the
safet y set will be used. Subgroup analyses will be performed by [CONTACT_654] (<60 versus ≥60 years) ,
ELN risk group (Favorable/ Intermediate/ Adverse ) etc.... All listings and tables will be 
presented b y treatment group.
10.5.1 Key secondary  objective(s)
The key secondary  objective of the study  is to determine if the addition of midostaurin to 
standard induction and consolidation therapy , followed by [CONTACT_744348]-consolidation
therap y improves OS in patients with newly  diagnosed FLT3 -MN (SR<0.05) AML.  
OS is defined as the time from date of randomization to date of death due to any cause. If a 
patient is not known to have died, survival will be censored at the date of last contact. No 
censoring will be done in case of HSCT.
Assuming proportional hazards model for OS, the following statistical hypothesis for OS will 
be tested using a stratified log-rank test (stratified according to 
randomization stratification 
factor of age) at the one-sided 2.5% level of significance: 
H02: θ2≥ 1vs. H a2: θ2< [ADDRESS_1018378] ratio ( Midostaurin treatment arm vs. placebo arm) of OS.
The analy ses for OS will be based on the FAS population according to the treatment group 
patients were randomized and the strata they  were assigned at ra ndomization. 
The final OS analy sis will not be performed at the time point of the final EFS analy sis, but 
after additional follow up. Therefore, a three -look design is considered for OSfollowing a 
separate group -sequential plan.
The OS will be hierarchically  tested in the following way : 
1.The first potential time point for OS anal ysis will be at the time of the 2ndEFS interim 
analysis, where approximately  79deaths are expected. If EFS is statistically  significant at 
this stage, O S will also be tested. If OS is not statistically  significant at this stage, the 2nd

[COMPANY_001] Confidential Page 127
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
OS analy sis will be planned at approximately  190 deaths (i.e. at time of EFS final 
analysis). If OS is not statistically  significant at this stage, a final anal ysis is pla nned at 
approximately  [ADDRESS_1018379] been recorded. 
3.If EFS is not statistically  signifi cant at the final analy sis
, then OS will not be tested. 
The type I error probability  will be controlled by [CONTACT_2329] a separate Haybittle -Peto boundary
independent of the one used for the primary  efficacy  analysis of EFS at 2.5% level of 
significance. This guarantees 
the prote ction of the overall level α = 2.5% ( one- sided) across 
the two hypotheses and the repeated testing of the OS hypotheses in the interim and the final 
analyses. 
OS will be estimated using the Kaplan -Meier method. The median OS along with 95%
confidence intervals will be presented by [CONTACT_1570]. The stratified Cox regression 
model will be used to estimate the HR of OS, along with 95% confidence interval. All OS 
analyses will be based on the FAS.
10.5.2 Other secondary  efficacy  objectives
[IP_ADDRESS] CR/CR irate, Time to CR or CRi w ith adequate blood count recover y, 
Disease Free survival (DFS) , Cumulative Incidence of Relapse (CIR) 
and Cumulative Incidence of Death (CID)
Other secondary  efficacy  variables include CRor CRi with adequate blood count recover y
rate, DFS, CIR and CID. The assessment of these endpoints will be based on the IWGcriteria
for AML (Cheson et al 2003, EL N 2017 / Döhner et al 2017 )as per investigator assessment.
CR/CR iwith adequate blood count recovery rate will be analy zed using Cochran -Mantel -
Haenszel test based on strata at randomization. Estimated CR/CRi rate along with 
corresponding 95% confidence intervals will be presented by [CONTACT_504176], and by 
[CONTACT_1570].
Time to CR or CRi with adequate blood count recovery is defined as the time from 
randomization to CR or CRi with adequate blood count recovery  whichever occurs first. 
Patients without experiencing CR, CRi with adequate blood count recovery will becensored 
according to the following events:
Patients experiencing induction failure will be censored at maximum follow -up (i.e. date 
of FPFV to date of LPLV used for the anal ysis).
Patients not experiencing induction failure and who did not die (any  cause ) will be 
censored at their last adequate response assessment date which is different from “unknown” 
or “not done”.

[COMPANY_001] Confidential Page 128
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
DFS is defined as the time from CRor CRi with adequate blood count recovery  to relapse or 
death due to any cause. Patient who did not relap se nor die will be censored at the last 
adequate response assessment.
DFS will be estimated using the Kaplan -Meier method. The median DFS along with 95%
confidence intervals will be presented by [CONTACT_1570]. The stratified Cox regression will 
be used to estimate the HR of DFS, along with 95% confidence interval.
Cumulative Incidence of Relapse (CIR)is defined for patients with CRor CRi with adequate 
blood count recovery  and is time from achieving the CRor CRi with adequat e blood count 
recovery  until the onset of relapse from CRor CRi with adequate blood recovery . Patients 
without relapse are censored at the last adequate response assessment. Patients who died 
without relapse are counted as a competing cause of failure.
Cumulative Incidence of Relapse (CIR)will be estimated using the Kaplan -Meier method. 
The median CIR along with 95% confidence intervals will be presented by [CONTACT_1570]. 
The stratified Cox regression will be used to estimate the HR of CIR, along with 95%
confidence interval.
Cumulative Incidence of Death (CID) is defined for all patients achieving CR or CRi with 
adequate blood count recovery  measured from the date of achievement of CR or CR iuntil the 
date of death due to any reason. Patients not known to have died are censored on the last 
contact [CONTACT_568]. Patients who experienced relapse are counted as a competing cause of failure.
CID will be estimated using the Kaplan -Meier method. The median CID along with 95%
confidence intervals will be presented by[CONTACT_1570]. The stratified Cox regression will 
be used to estimate the HR of CI D, along with 95% confidence interval.
The rate of CR/CRi with adequate blood count recovery  will be analyzed based on the FAS. 
However, DFS, 
Cumulative Incidence of Relapse (CIR)and Cumulative Incidence of Death 
(CID) will be analyzed based on data from responders (CR or CRi with adequate blood count 
recovery ) in the FAS. Assessment of relapse from CRor CRiwith adequate blood count 
recovery , DFS, CI Rand CI Dwill not consider whether a patient received HSCT.
[IP_ADDRESS] MRD negative status
The percentage of patients with MRD negative bone marrow will be summarized along with 
exact 95% CI by [CONTACT_744400]. Importantly , comparisons of the 
MRD level s between the end of theconsolidation phase during the post-consolidation phase 
will be performed by  [CONTACT_6660].
The time to MRD negative status is defined as the time from randomization to first occurrence
of MRD negativity . Patients without reaching MRD negative status level will be censored 
according to the following events:
Patients experiencing induction failure will be censored at maximum follow -up (i.e. date 
of FPFV to date of LPLV used for the anal ysis).
Patients not experiencing induction failure and who did not die (any  cause) will be 
censored at their last adequate MRD assessment. 

[COMPANY_001] Confidential Page 129
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Moreover, the kinetics of MRD levels will be display ed in terms of boxplot by [CONTACT_744401] .
[IP_ADDRESS] Time to neutrophil/platelet recovery
The time to neutrophil recovery  will be assessed for the following criteria: 
Number of day s from start of treatment to the first day  neutrophils ≥0.5 x 109/L 
Number of day s from start of treatment tothe first day  neutrophils ≥1.0 x 109/L.
Similarly , the time to platelet recovery  will be assessed for the following criteria:
Number of day s from start of treatment to the first day  platelets ≥50 x 109/L
Number of day s from start of treatment tothe first day  platelets ≥100 x 109/L.
Moreover, the time to adequ ate blood count recovery  will be assessed as:
Number of day s from start of treatment tothe first day  platelets ≥50 x 109/L and the first 
day neutrophils ≥1.0 x 109/L.
In addition, data on transfusion will be summarized by  [CONTACT_1570].
The median time to platelet and to neutrophil recovery  along with their corresponding 95% 
confidence intervals will be presented by [CONTACT_1570].
10.5.3 Safety  objectives
[IP_ADDRESS] Analysis set and groupi[INVESTIGATOR_63964] y analyses, the safet y set will be used. All listings and tables will be presented by 
[CONTACT_1570] .
The overall observation period will be divided into three mutually  exclusive segments:
1. P re-treatment period: from day  of patient’s informed consent to the day  before first dose 
of study  treatment
2.
On-treatment period: from day  of first dose of study  medication to [ADDRESS_1018380]-treatment period: starting at day  [ADDRESS_1018381]-treatment period will be flagged in all the listings. 
[IP_ADDRESS] Adverse events (A Es)
Summary  tables for AEs will include only AEs that started or worsened during the on-
treatment period, the treatment
-emergent AEs.
The incidence of treatment- emergent adverse eve nts (new or worsening from baseline) will be 
summarized by [CONTACT_30826], severit y (based on CTCAE grades 
version 5.0), t ype of adverse event, relation to study treatment

[COMPANY_001] Confidential Page 130
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Serious adverse events, non-serious adverse events during the on-treatment period will be 
tabulated.
All deaths (on
-treatment and post -treatment) will be summarized.
All AEs, deaths and serious adverse events (including those from the pre and post-treatment 
periods) will be listed and those collected during the pre-treatment and post-treatment period 
will be flagged.
AESI  will be analyzed. Such categories consist of one or more well-defined safet y events 
which are similar in nature and for which there is a specific clinical interest in connection with 
the investi gational treatment(s).
AESI will be defined at the project level and may be regularl y updated based on emergent 
data. For each specified AESI , number and percentage of patients with at least one event part 
of the AESI will be reported.
[IP_ADDRESS] Laboratory  abnormal ities
Grading of laboratory  values will be assigned programmatically  as per national cancer 
institute (NCI)CTCAE [version 5.0].The calculation of CTCAE grades will be based on the 
observed laboratory  values only , clinical assessments will not be taken in
to account.
CTCAE Grade 0 will be assigned for all non -missing values not graded as 1 or higher. 
For laboratory  tests where grades are not defined by [CONTACT_3989] 5.0, results will be categorized 
as low/normal/high based on laboratory  normal ranges .
The following by-treatment summaries will be generated separately  for hematology , 
biochemistry  and urinary laboratory  tests
Worst post -
baseline CTCAE grade (regardless of the baseline status). Each patient will be 
counted only  once for the worst grade observed post-baseline.
Shift tables using CTCAE grades to compare baseline to the worst on -treatment value
For laboratory  tests where CTCAE grades are not defined, shift tables using the 
low/normal/high/(low and high) classification to compare baseline to the wor st on-
treatment value.
Listing of all laboratory  data with values flagged to show the corresponding CTCAE 
grades and the classifications relative to the laboratory normal ranges.
In addition to the above mentioned tables and listings, other exploratory  analyses, for example 
figures plotting time course of raw or change in laboratory  tests over time or box plots may  be 
specified in the SAP
[IP_ADDRESS] Other safety  data
ECG values and Vital signs will be listed and summarized by  [CONTACT_1570].
ECG
Listing of ECG evalu ations for all patients with at least one abnormality .

[COMPANY_001] Confidential Page 131
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Change from baseline (QTcF andVital signs )
Shift table baseline to worst on -treatment result.
Table with descriptive statistics at baseline, one or several post -baseline time points and 
change from ba seline to this/these post -baseline time points.
[IP_ADDRESS] Supportive analy ses for secondary  objectives 
Subgroup analyses will be provided for specific secondary  variables based on age, gender, 
race, etc. will be performed as appropriate, more details will be provided in the SAP.
10.5.4 Pharmacokinetics
Plasma 
concentration s: Plasma concentrations will be summarized by [CONTACT_744402]. Summary  statistics will include n (number of values to be reported), arithmetic and 
geometric mean, median, SD, CV, and geome tric CV, minimum and maximum. 
Concentrations below the LLOQ will be treated as zero in summary  statistics except for 
geometric mean. Zero concentrations will not be included in the geometric mean calculation. 
For Tmax, the median and range will be provided .
Non-compartmental analysis (NCA): PK parameters for midostaurin and the active 
metabolites will be determined using non-compartmental method(s) using Phoenix 
WinNonlin (Version 6.4 or later-Certara L.P.) for the patients who had full PK sampling on 
Cycle 1 Day  8 of the induction therapy . 
Concentration data from patients who underwent sparse sampling onl y will be anal yzed where 
possible, and relevant NCA parameters determined.
PK parameters listed in Table 10-1will be estimated and reported, when feasible (dependent 
on sampling scheme, and validity  of samples) . 
AUC0 -t and Cmax are defined as primary  parameters (contributing to PAS -
full definition). 
All PK parameters will be determined when possible .In addition, and when feasible, analysis 
of data from all subjects (frequently  and less frequently  sampled) for PK parameters at stead y 
state (Table 10 -1)will be performed.
NCA PK parameters and all concentrations will be summarized and reported. Summary
statistics will include n (number of values to be reported), arithmetic and geometric mean, 
median, SD, CV, geometric CV, minimum and maximum. 
Population pharmacokinetic (PopPK) analysis: the PK samples of the PAS-all will be 
analyzed using a population PK approach. Comparisons of new data with predicted exposures 
from existing models will be provided through visual predictive checks (VPCs). Further
details of the analy sis as well as the results will be reported in a stand- alone analysis plan and 
report independent of this clinical study  report. In addition, comparisons of individual 
predicted patient parameters with those observed will be conducted and reported in the CSR. 
Further details will be provided in the SAP.
Exposure -response analyses for relevan t efficacy endpoints (including CR , CRi with adequate 
blood count recovery andEFS, plus investigation of further endpoints such as MRD )and 
safet y endpoints (including QT and AEs)will be further discussed as appropriate in the SAP.

[COMPANY_001] Confidential Page 132
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 10-1 Noncompartmental pharmacokinetic parameters
AUC 0-t The AUC from time zero to a measurable concentration sampling time (t) (mass x 
time x volume -1).
Note: as the last sampling time is at [ADDRESS_1018382] dose (tlast) (mass x time x volume-1)
Cmax The maximum (peak) observed plasma, blood, serum, or other body  fluid drug 
concentration after the first dose administration (mass x volume-1)
Cmin Minimal observed pre -dose concentration (when feasible)
C3h Concentration at [ADDRESS_1018383] -dose (when feasible)
Tmax The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug 
concentration after single dose administration (time)
 
 
 
 
 
 
 
 
 
 
10.5.[ADDRESS_1018384] -Leu and EQ5D -5L, will be generated in accordance with the 
respective scoring manual. 
A table of decomposition of patients will be created at each visit depi[INVESTIGATOR_744343] ‘number of 
patients in the analy ses’, ‘patients died’, ‘patients achieved CR/CRi’, ‘patient refused data due 
to poor health’, ‘patient refused (unrelated to health), ‘study  staff felt patient was too ill’, 
‘patient missed appointment’, ‘other reasons’) .
Descriptive statistics (mean, standard deviation, median, minimum, and maximum) will be 
used to summarize the scored scales at each scheduled assessment time point for the FACT -
Leu and EQ5D -5L (VAS) by [CONTACT_2939]. Additionally , change from baseline in the scores 
at the time of each assessment will be summarized. Patients with an evaluable basel ine score 
and at least one evaluable post baseline score during the treatment period will be included in 
the change from baseline anal yses. 
Mixed models for repeated measures (MMRM) will be used to estimate the treatment effect 
on the FACT -Leu scores over time. MMRM are commonly  used to analyze longitudinal data 
from randomized trials under the missing -at-random (MAR) assumption. The MMRM will 

[COMPANY_001] Confidential Page 133
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
include fixed -effect covariates for treatment, study  visit (time), and interaction of treatment 
and time; other fixed covariates may include baseline score and randomization stratification 
factors.  A  s ubject -specific random effect will be included in the model.  Change from 
baseline score will serve as the dependent variable. Least squares estimates and 
accompan ying 95% CIs for change scores by [CONTACT_744403]. As a 
sensitivity  analysis to the MMRM, pattern-mixture models will be used to examine the 
missing mechanism and explore the plausibility of the MAR assumption.  
Analy sis will be carried out for all patients as well as excluding those received HSCT.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 134
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

[COMPANY_001] Confidential Page 135
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
 
 
 
 
 
 
 
 
 
 
10.7 Interim analy ses
10.7.1 Event free survival ( EFS)
The efficacy  analyses will be based on FAS and are event driven. The final EFS analysis will
be performed when there are approximately  285 EFS events. Two interim analy ses will be 
performed when approximately  40% and 75% of [ADDRESS_1018385] 
patient randomized in the study  assuming an increasing recruitment rate to reach 30 
patients / month in month 6. The primary  intent of the first interim analysis is to allow the 
study  to stop early for lack of efficacy  (futility ). There is no intent to carry out an analysis to 
declare superior efficacy at the time of the first interim analysis. At least, 283 patients (56%) 
are expected to be randomized at the time of the interim futility  analysis, i.e., when 
approximately  
114EFS events have occurred. The 2ndinterim analy sis will allow the study  to 
stop early  for outstanding efficacy . The 2ndinterim analy sis will only be carried out after all 
patients have been randomized.
A user-defined gamma spending function (γ = - 1.2) will be used as a beta-spending function 
to determine the non-binding futility  boundary  at the time of the 1stinterim analy sis. The 
futility  boundary  at the first interim is calculated as hazard ratio of 0.97. The observed 
(i.e.,
nomina l) p-value has to be greater than p=0.44 (one-sided) to conclude futility . Since the 
observed number of EFS events at the interim analyses may not exactly  be equal to the 

[COMPANY_001] Confidential Page 136
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
planned number of events, the futility  boundary will need to be re-calculated (or updated) 
based on the actual number of observed events. Therefore, the observed p-value (or Z -test 
statistic) at the first interim analy sis will be compared with the updated futility  boundary .
A Haybittle -Peto stoppi[INVESTIGATOR_744344] 
(Peto et al 1976). At the second interim analysis, the observed p -value has to be less than 
p=0.0001 (i.e.HR<0 .601) in order to conclude superior efficacy . If the study  continues, the 
final analysis will beperformed when approximately  [ADDRESS_1018386] version 6.4 . The following are a few key operational 
characteristics: The cumulative probability  to detect an efficacious treatment by [CONTACT_744404] 90%; while the cumulative probability  of erroneousl y detecting a non-efficacious
treatment by [CONTACT_744405] 2.4%. If the null hypothesis is true then cumulative 
probability  to stop the trial at the first interim analy sis for lack of efficacy  is 55. 8%.

[COMPANY_001] Confidential Page 137
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Table 10-2 Simulated cumulative probabilities to stop for efficacy  or futility  by [CONTACT_941]
1stinterim (IA1), the 2ndinterim (IA2)or the final EFS (FA) analy ses
Hazard 
ratioAnalysis Average 
sample 
sizeAverage
Time
(months)Simulated cum. prob. stop due to
Efficacy Futility
0.675IA 1
IA 2
FA282
502
[ZIP_CODE].9
20
38.80.0149
0.1983
0.9000.025
NA
NA
0.8375IA1
IA2
FA264
502
[ZIP_CODE].3
20
310.0003
0.009
0.3120.213
NA
NA
1.0IA1
IA2
FA249
502
[ZIP_CODE].8
20
26.50
0.0001
0.0240.558
NA
NA
* In the middle of H 0and H A; cum. prob.: cumulative probability
Note: Simulation is performed with software package [East version 6.4] with number of 
simulations = 10,000 and randomization seed =[ADDRESS_1018387] (apart from the 
independent statistician and DMC members) until EFS is found to be significant or study 
needs to be terminated due to safet y or lack of efficacy.
10.7.2 Key secondary  endpoint: Overall survival (OS)
OS will be compared between the two treatment groups, provided the primary endpoint EFS is 
statistically  significant favoring the active treatment group. A hierarchical testing procedure will 
be adopted and the statistical tests for OS will be performed only if the primary  efficacy 
endpoint EF S is statistically  significant.
Three analyses areplanned for OS; at the time of the interim and final EFS analyse
s(provided 
EFS is significant), at which point a total of approximately  79 and 190deaths are expected 
(
28% and 68% information fraction respectivel y) and a final OS analysis when approximately 
278deaths are expected (expected 64months from date of f irstpatient to be randomized).
AHaybittle -Peto boundary  as implemented in East version 6. 4
(Peto et al 1976 ) , independent 
of the Hay bittle -Peto boundary used for EFS , along with the testing strategy  outlined below will 
be used to maintain the overall type I error probability .This guarantees 
the protection of the 
(2.5%) overall level of significance across the two hypotheses and the repeated testing of the 
OS hy potheses in the interim and the final analysis(Glimm 2010 ).
The trial allows for the stoppi[INVESTIGATOR_744345] a superior OS result, provided the primar y 
endpoint E FS has already  been shown to be statistically  significant favouring the test 

[COMPANY_001] Confidential Page 138
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
treatment group . Further, the exact nominal p-values that will need to be observed to declare 
statistical significance at the time of these analyses for OS will depend on the number of OS 
events that have 
been observed at the time of these analyses and theα for OS alread y spent at 
the time of earlier analy ses.Given the hierarchical testing strategy  of EFS and OS, the design 
concerning OS analyses will have the following characteristics based on simulations in
software package [East 6.4].The probabilitie s shown in Table 10-3are conditional
probabilities (conditional on EFS being statistically  significant) not marginal probabilities.
Table 10 -
3 S imulated probabilities to stop for efficacy  on overall survival at 2nd
EFS interim (1stOS interim (IA OS1)) , final EFS (2ndOS interim (IA OS2))
analy sis or final OS analy sis(FAOS)
Hazard 
ratioAnalysis Average 
sample 
sizeAverage
Time
(months)Simulated cum. 
prob . stop due to
Efficacy
0.714IAOS1
IAOS2
FAOS502
502
[ZIP_CODE]
38
640.010
0.074
0.799
0.857IAOS1
IAOS2
FAOS502
502
[ZIP_CODE]
35
580.001 8
0.0050
0.327
1.0IAOS1
IAOS2
FAOS502
502
[ZIP_CODE]
34
540
0.0001
0.026
* Probabilities are reported as if OS was tested alone, regard less the testing strategy with EFS. The true 
probabilities should take i nto account the probability of EFS at each look. 
Note: Simulation is performed with software package [East 6.4 ]with number of simulations = 10,000 and 
randomization seed =2301.
At the time of interim analy sis for EFS, an interim analy sis for the key secondary  endpoint of 
OS will be performed by [CONTACT_55467]. Unblinded results from the interim 
analysis for EFS and corresponding interim analysis for OS will not be communicated to the 
Sponsor's clinical team or to any party involved in the study  conduct (apart from the 
independent statistician and DMC members) until the DMC has determined that either (i) EFS 
analysis has crossed the pre-specif ied boundary for efficacy , or (ii) the study  needs to be 
terminated due to any cause including futility or safet y reasons. Further details will be 
described in the DMC Charter.
At the time of the primary analyses, both EFS and interim OS analysis will be performed by 
[CONTACT_1034]'s clinical team. Investigators and patients will remain blinded to study  treatment 
and all patients will continue to be followed for OS until the final analysis (or earlier if OS 
reaches statistic al significance at an y of the interim analy ses).

[COMPANY_001] Confidential Page 139
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
10.8 Sample size calculation
The assumption of median EFS of 12.0 months for the control treatment arm for sample size 
calculations is based on available data for patients with FLT-MN (Bacher et al 2008). It is 
expected that treatment with test treatment arm will result in a 37.5% reduction in the hazard 
rate (corresponding to an increase in median 
EFS from 12.0 months to 17.8 months under the 
exponential model assumption). 
If the true hazard ratio is 0.675, a total of [ADDRESS_1018388] 90% power at 
an one
-sided overall 2.5% level of significance to reject the null hypothesis (HR≥1)using a 
log-rank test and a 2-look group sequential design with Haybittle -Peto bounda ry to determine 
efficacy  boundary  and 
gamma spending function (γ = -1.2) to determine the non-binding 
futility  boundary . Considering a recruitment period of approximately  20months assuming an 
increasing recruitment rate to reach 30 patients / month in month 6, 502 patients will need to 
be randomized to the two treatment arms in a 1:1 ratio. Assuming about approximately  
10% 
patients will be lost to follow -
up for EFS, a total of [ADDRESS_1018389] patient randomized inthe study . The sample 
size calculation was conducted with software package [East 6.4] .
10.9 Power for analy sis of key secondary  endpoint
OS will be compared between the two treatment groups, provided that the primary  endpoint 
EFS is statistically  significant. Based on available data ( Gale et al 2008 ), the median OS in the 
control treatment arm is expected to be around 30 months. It is hy pothesized that Midostaurin
treatment arm will result in a28.6% reduction in the hazard rate for overall survival 
(corresponding to an increase in median survival by12 months (from 30 to 42 months) under 
the exponential model assumption). If the true hazard ratio is 0.714, a total of [ADDRESS_1018390] 80% power at an one-sided overall 2.5% level of significance 
to reject the null hypotheses (HR≥
1) using a log-rank test and a 3-look group sequential 
design conditionall y to a significant improved EFS befor e or at the same time of analy ses 
testing OS.Based on the same number of patients that are planned to be enrolled in this study 
to detect the primary  endpoint, it is estimated that these [ADDRESS_1018391] been conducted. The power calculation was conducted with software 
package [ East 6.4] .
11 Ethical considerations and admini strative procedures
11.1 Regulatory  and ethical compliance
This clinical study  was designed, shall be implemented and reported in accordance with the 
international conference on harmonization (ICH)Harmonized Tripartite Guidelines for Good 
Clinical Practice (GCP) , with applicable local regulations (including European Directive 
2001/20/EC and US Code of Federal Regulations Title 21), and with the ethical principles laid 
down in the Declaration of Helsinki.

[COMPANY_001] Confidential Page 140
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
11.2 Responsibilities of the investigator and IRB/IEC/REB
The protocol and the proposed informed consent form must be reviewed and approved by a 
properl y constituted Institutional Review Board/I ndependent Ethics Committee/Research 
Ethics Board (IRB/IEC/REB) before study  start. Prior to study  start, the investigat or is 
required to sign a protocol signature [CONTACT_5389]/her agreement to conduct the study 
in accordance with these documents and all of the instructions and procedures found in this 
protocol and to give access to all relevant data and records to [COMPANY_001] (or CRO) monitors, 
auditors, [COMPANY_001] Clinical Quality  Assurance representatives, designated agents of [COMPANY_001], 
IRBs/IECs/REBs and regulatory  authorities as required.
11.3 Informed consent procedures
Eligible patients may only be included in the study  after providing written (witnessed, where 
required b y law or regulation), I RB/IEC/REB -approved informed consent
Informed consent must be obtained before conducting any study -specific procedures (i.e. all 
of the procedures described in the protocol). The process of obtaining informed consent 
should be documented in the patient source documents. The date when a subject’s Informed 
Consent was actuall y obtained will be captured in their CRFs.
[COMPANY_001] will provide to investigators, in a separate document, a proposed informed consent 
form (ICF) that is considered appropriate for this study  and complies with the ICH GCP 
guideline and regulatory  requirements. Any changes to this ICF suggested by [CONTACT_5381]/IEC/REB, and a copy of the 
approved version must be provided to the [COMPANY_001] (or CRO) monitor after IRB/IEC/REB 
approval.
Women of child bearing potential should be informed that taking the study  medication may 
involve unknown risks to the fetus if pregnancy  were to occur during the study  and agree that 
in order to participate in the study  they must adhere to the contraception requirement for the 
duration of the study . Male patients treated with idarubicin, daunorubicin or cy tarabine should 
receive appropriate advice on the risk of infertility  and the option of sperm conservation. 
Midostaurin may impair both male and female fertility  and this should be communicated to 
the patients. If there is any question that the patient will not reliabl y comply , they should not 
be entered in the study .
Additional consent form 
Not applicable .
11.4 Discontinuation of the study
[COMPANY_001] reserves the right to discontinue this study  under the conditions specified in the 
clinical study  agreement. Specific conditions for termin ating the study  are outlined in Section 
4.4.

[COMPANY_001] Confidential Page 141
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
11.5 Publication of study  protocol and results
[COMPANY_001] is committed to following high ethical standards for reporting study  results for its 
innovative medicine, including the timel y communication and publication of clinical trial 
results, whatever their outcome. [COMPANY_001] assures that the key  design elements of this protocol 
will be posted on the publicly  accessible database, e.g., www.clinicaltrials.gov before study
start. In addition, results of interventional clinical trials in adult patients are posted on 
www.novartisclinicaltrials.com, a publicl y accessible database of clinical study  results within 
1 year of study  completion (i.e., last patient last visit ( LPLV)), those for interventional clinical 
trials involving pediatric patients within 6 months of study  completion.
[COMPANY_001] follows the International Committee of Medical Journal Editors (ICMJE )authorship 
guidelines (www.icmje.org) and other specific guidelines of the journal or congress to which 
the publication will be submitted
Authors will not receive remuneration for their writing of a publication, either directl y from 
[COMPANY_001] or through the professional medical writing agency . Author(s) may be requested to
present poster or oral presentation at scientific congress; however, there will be no 
honorarium provided for such presentations.
As part of its commitment to full transparency in publications, [COMPANY_001] supports the full 
disclosure of all funding sources for the study  and publications, as well as any actual and 
potential conflicts of interest of financial and non-financial nature by [CONTACT_15064], including 
medical writing/editorial support, if applicable.
For the [COMPANY_001] Guidelines for the Publication of Results from [COMPANY_001] -sponsored Research, 
please refer to www.novartis.com.
11.[ADDRESS_1018392] keepi[INVESTIGATOR_5324], in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory and institutional 
requirements for the protection of confidentiality of subjects. As part of participating in a 
[COMPANY_001] -sponsored study , each site will permit authorized representatives of the sponsor(s) 
and regulatory  agencies to examine (and when required by [CONTACT_1289], to copy) clinical 
records for the purposes of qualit y assurance reviews, audits and evaluation of the study 
safet y and progress.
Source data are all information, original records of clinic al findings, observations, or other 
activities in a clinical trial necessary  for the reconstruction and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, hospi[INVESTIGATOR_2553], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or 
evaluation checklists, pharmacy  dispensing records, recorded data from automated 
instruments, copi[INVESTIGATOR_10379], 
microfiches, photogr aphic negatives, microfilm or magnetic media, x-rays, and subject files 
and records kept at the pharmacy , at the laboratories, and medico- technical departments 
involved in the clinical trial.

[COMPANY_001] Confidential Page 142
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Data collection is the responsibility  of the clinical trial staf f at the site under the supervision of 
the site Principal Investigator. The study  CRF is the primary  data collection instrument for the 
study . The investigator should ensure the accuracy , completeness, legibility , and timeliness of 
the data reported in the CRFs and all other required reports. Data reported on the CRF, that 
are derived from source documents, should be consistent with the source documents or the 
discrepancies should be explained. All data requested on the CRF must be recorded. Any 
missing data must be explained . For electronic CRFs an audit trail will be maintained by [CONTACT_28049]. 
The investigator/institution should maintain the trial documents as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8) and as required by 
[CONTACT_64122]/or guidelines. The investigator/institution should take measures to 
prevent accidental or premature destruction of these documents.
Essential documents (written and electronic) should be retained for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial unless Sponsor provides written 
permission to dispose of them or, requires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines.
11.[ADDRESS_1018393] ensure anon ymity of the patients; patients must not be identified by 
[CONTACT_64123]. Signed informed consent forms and patient 
enrollment log must be kept strictly  confidential to enable patient identification at the site.
11.8 Audits and inspections
Source data/documents must be available to inspections by [CONTACT_5385].
11.[ADDRESS_1018394] 
be considered a protocol amendment, and unless such an amendment is agreed upon by 
[CONTACT_6669]/IEC/REB it cannot be implemented. All significant 
protocol deviations will be recorded and reported in the CSR.
12.[ADDRESS_1018395] be approved by [CONTACT_5343], Health Authorities where required, and the IRB/IEC/REB. 

[COMPANY_001] Confidential Page 143
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Only  amendments that are required for patient safety  may be implemente d prior to 
IRB/IEC/REB approval. Notwithstanding the need for approval of formal protocol 
amendments, the investigator is expected to take any immediate action required for the safet y 
of any patient included in this study , even if this action represents a deviation from the 
protocol. In such cases, [COMPANY_001] should be notified of this action and the IRB/IEC at the study 
site should be informed according to local regulations but not later than 10 working day s.

[COMPANY_001] Confidential Page 144
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
13 References (available upon request)
Arber D, Oraz i A, Hasserjian R, et al (2016) The 2016 revision to the World Health 
Organization classification of my eloid neoplasms and acute leukemia. Blood; 127(20):2391-
2405. 
Bacher U, Haferlach C, Kern W, et al (2008) Prognosis relevance of FLT3 -TKD mutations in 
AML: the combination matters –an analy sis of 3082 patients. Blood 111:2527 -2537.
Brunet S, Labopin M, Esteve J, et al (2012) Impact of FLT3 Internal Tandem Duplication on 
the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute 
Myeloid Leukemia in First Remission: A Retrospective Anal ysis. J Clin Oncol; 30:735 -741. 
Brunet S, Martino R, Sierra J (2013) Hematopoietic transplantation for acute my eloid 
leukemia with internal tandem duplication of FLT3 gene (FLT3/ITD). Curr Opin Oncol;
25:195 -204.
Cheson BD, Bennett JM, Kopeck y KJ, et al (2003) Revised Recommendations of the 
International Working Group for Diagnosis, Standardization of Response Criteria, Treatment 
Outcomes, and Reporting Standards for Therapeutic Trials in Acute M yeloid Leukemia. J 
Clin Oncol; 21:4642 -9.
Christopeit M, Kröger N, Haferlach T, et al (2014) Relapse assessment following allogeneic 
SCT in patients with MDS and AML . Ann Hematol; 93:1097-1110.
DeZern A, Sung A, Kim S, et al (2011) Role of allogeneic transplanta tion for FLT3/ITD acute 
myeloid leukemia: Outcomes from 133 consecutive newl y-diagnosed patients from a single 
institution. Biol Blood Marrow Transplant; 17(9): 1404–1409.
Döhner H , Estey  E , Grimwade D , etal (2017) Diagnosis and management of AML in adult s: 
[ADDRESS_1018396] recommendations from an international expert panel. Blood;129(4): 424-447.
Gale RE, Green C, Allen C
,et al (2008) The impact of FLT3 internal tandem duplication 
mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young 
adult patients with acute my eloid leukemia. Blood ; 11(1): 2776-2784.
Hourigan CS, Gale RP, Gormley  NJ et al (2017) Measurable residual disease testing in acute 
myeloid leukaemia . Leukemia; 
31: 1482–1490.
Ivey A, Hills R.K., Simpson M.A., et al (2016) Assessment of Minimal Residual Disease in 
Standard
-Risk AML . N Engl J Med; 374: 422-33.
Kantarjian H, O’brien S, Cortes J, et al (2006) Results of intensive chemotherap y in 998 
patients age 65 years or older with acute m yeloid leukemia or high -
risk my elody splastic 
syndrome : predictive prognosis models for outcome. Cancer; 106(5): 1090 -
1098.
Kayser S, Döhner K, Krauter J, et al (2010) I mpact of allogeneic transplantation from 
matched related and unrelated donors on clinical outcome in y ounger adult A ML patients with 
FLT3 internal tandem duplications. Blood; 116(21) Abst 909.
Kayser S, Levis MJ (2014) FLT3 t yrosine kinase inhibitors in acute my eloid leukemia: 
clinical implications and limitations. L euk Ly mphoma; 55: 243-55.
Kottaridis PD, Gale RE, Frew ME, et al (2001) The presence of a FLT3 internal tandem 
duplication in patients with acute m yeloid leukemia (AML) adds important prognostic 

[COMPANY_001] Confidential Page 145
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
information to cy togenetic risk group and response to the first cy cle of chemotherapy : 
analysis of 854 patients from the [LOCATION_008] Medical Research Council AML  10 and 12 
trials. Blood; 98(6): 1752-9.
Levis M, Pham R, Smith BD, et al (2004) In vitro studies of a FLT3 inhibitor combined with 
chemotherap y: sequence of administration is important to achieve s ynergisti c cytotoxic effects. 
Blood; 104(4): 1145-50.
 
Ommen H (2
016) Monitoring minimal residual disease in acture m yeloid leukemia: a review 
of the current evolving strategies. Ther Adv Hematol; 7(1) 3-16.
Papaemmanuil E, Gerstung M, Bullinger L, et al (2016) Genomic Classification and 
Prognosis in Acute M yeloid L euke mia. N Engl J Med; 374(23): 2209-21.
Peto R, Pi[INVESTIGATOR_2531] M, Armitage P, et al (1976) Design and anal ysis of randomized clinical trials 
requiring prolonged observation of each patient. I. I ntroduction and design. Br J Cancer; 34(6):
585-612. 
Pratcorona M, Brunet S, Nomded´eu J, et al (2013) Favorable outcome of patients with acute 
myeloid leukemia harboring a low -allelic burden FLT3 -ITD mutation and concomitant NPM1 
mutation: relevance to post- remission therap y. Blood; 121(14): 2734-38.
Pratz KW and L uger DM (2014
) Will FL T3 Inhibitors Fulfill Their Promise in AML ? Curr 
Opin Hematol; 21(2): 72 –78.
Röllig C, Bornhäuser M, Kramer M, et al (2015) Allogeneic stem -cell transplantation in 
patients with NPM1 -mutated acute my eloid leukemia: results from a prospective donor versus 
no-donor anal ysis of patients after upfront HLA t ypi[INVESTIGATOR_744346] -AML 2003 trial. J 
Clin Oncol.; 33(13): 1519.
Sato T, Yang X, Knapper S, et al (2011) FLT3 ligand impedes the efficacy  of FLT3 inhibitors 
in vitro and in vivo. Blood; 117(12): 328
6-3293.
Schiller GJ (2014) Evolving treatment strategies in patients with high -
risk acute m yeloid 
leukemia. Leuk Lymphoma; 55(11): 2438-48.
Schlenk RF, Kay ser S, Bullinger L, et al (2014) Differential impact of allelic ratio and 
insertion site in FL T3-ITD
–positive AML  with respect to allogeneic transplantation. 
Blood;124: 3441-9.
Stone MR, DeAngelo DJ, Klimek V, et al (2005) Patients with acute my eloid leukemia and an 
activating mutation in FLT3 respond to a small -molecule FLT3 ty rosine kinase inhibitor, 
PKC412. Blood; 105(1): 54-60.
Stone MR, Mandrekar SJ, Sanford BL, et al. (2017) 
Midostaurin plus chemotherap y for acute 
myeloid leukemia with a FLT3 mutation. N Engl J Med ; 377: 454-464.
Steudel C, Mohr B, et al (2002) Anal ysis of FLT3 -activating mutations i
n 979 patients with 
acute m yelogenous leukemia: association with FAB subtypes and identification of subgroups 
with poor prognosis. Blood; 99(12): 4326-35.

[COMPANY_001] Confidential Page 146
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Terwijn M, van Putten WL , et al (2013) High prognostic impact of flow cy tometric minimal 
residual disease detection in acute m yeloid leukemia: data from the HOVON/SAKK AML 
42A study .J Clin Oncol.;31(31):3889-97.
Thiede C, Steudel C, Mohr B, et al (2002) Analy sis of FLT3 -activating mutations in 979 
patients with acute m yelogenous leukemia: association with FAB subt ypes and identification
of subgroups with poor prognosis . Blood: 99(12):4326-4335
Weisberg E, Boulton C, Kelly  LM, et al (2002) Inhibition of mutant FL T3 receptors in 
leukemia cells b y the small molecule tyrosine kinase inhibitor PKC412. Canc er Cell; 1: 433-
443

[COMPANY_001] Confidential Page 147
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
14 Appendices
14.1 Appendix 1 –Concomitant medications
The following lists are not comprehensive and are only meant to be used as a guide. The lists 
are based on the [COMPANY_001] PK Sciences’ guidance, Drug -Drug Interaction and Co-Medication 
Considerations (v0 7, release date: Jan 2018), which was compi[INVESTIGATOR_583651]’s P450 Drug Interaction Table 
(http://medicine.iupui.edu/clinpharm/ddis/main -table/) and supp
lemented with the FDA Draft 
Guidance for Industry , Drug Interaction Studies –Study  Design, Data Anal ysis, and 
Implications for Dosing and Labeling (February  2 012) 
(http://.fda.gov/downloads/drugs/guidancecomplianceregulatory information/guidances/ucm29
2362.pdf), and the Universit y of Washington’s Drug Interaction Database 
(http://www.druginteractioninfo.org/ ). 
For current lists of medications that may cause QT prolongation and/or torsades de pointes 
(TdP), refer to the CredibleMeds®website (www.qtdrugs.or g/)
. Please contact [CONTACT_436704].
14.1.[ADDRESS_1018397] of prohibited medications
Strong inducers of CYP3A4 carbamazepi[INVESTIGATOR_050], enzalutamide, lumacaftor, phenobarbital, phenytoin, rifabutin, 
rifampi[INVESTIGATOR_2513] (rifampin), mitotane, St. John’s wort (Hypericum perforatum)1
Medications with a known risk 
for QT prolongation2amidarone, anagrelide, arsenic trioxide, astemizole, azithromycin, chloroquine, 
chlorpromazine, cilostazol, cisapride, citalopram, clarithromycin, disopyramide, 
dofetilide, domperidone, donep ezil, dronedarone, droperidol, erythromycin, 
escitalopram, flecainide, fluconazole, gatifloxacin, halofantrine, haloperidol, 
ibutilide, levofloxacin, levomepromazine, levosulpi[INVESTIGATOR_14956], methadone, 
moxifloxacin, ondansetron, oxaliplatin, papaverine HCl (intra -coronary), 
pentamidine, pi[INVESTIGATOR_3924], procainamide, propofol, quinidine, roxithromycin, 
sevoflurane, sotalol, sulpi[INVESTIGATOR_14956], sultopride, terlipressin, terodiline, thioridazine, 
vandetanib
[ADDRESS_1018398] provided is as of January 2018.Check https www c rediblemeds.org/healthcare -providers/drug -list for the 
most updated list. 
14.1.2 Permitted medications to be used with caution
Strong inhibitors of CYP3A ombitasvir/paritaprevir/dasabuvir/ritonavir (Viekira Pak)1, indinavir/ritonavir1, 
tipranavir/ritonavir1, ritonavir, cobicistat, indinavir, ketoconazole, 
troleandomycin, telaprevir, danoprevir/ritonavir1, elvitegravir/ritonavir1, 
saquinavir/ritonavir1, lopi[INVESTIGATOR_054]/ritonavir1, itraconazole, voriconazole, mibefradil,  
posaconazole, telithromycin, grapefruit juice2, conivaptan, nefazodone, 
nelfinavir, idelalisib, boceprevir, atazanavir/ritonavir1, darunavir/ritonavir1
Substrates with narrow therapeutic index (NTI)
CYP1A2 theophylline, tizanidine (also sensitive)
CYP2B6 No substrate with narrow therapeutic index known.
CYP2C8 paclitaxel
CYP2C9 (S)-warfarin
CYP2C19 (S)-mephenytoin (also sensitive) 

[COMPANY_001] Confidential Page 148
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
CYP2E1 No substrate with narrow therapeutic index known.
CYP3A alfentanil ,cyclosporine, dihydroergotamine, ergotamine, fentanyl, sirolimus, 
tacrolimus
Transporter substrates
NTI substrates of P-gp3cyclosporine, digoxin, fentanyl, p aclitaxel, sirolimus, tacrolimus
BCRP substrates atorvastatin daunorubicin, doxorubicin, hematoporphyrin, imatinib, 
methotrexate, mitoxantrone, pi[INVESTIGATOR_2830], rosuvastatin, SN -38 (irino tecan), 
ethinyl estradiol, simvastatin, sulfasalazine, sofosbuvir, topotecan, 
sulfasalazine, tenofovir, topotecan.
OATP1B1 substrates (including 
OATP1B3, and OATP2B1 
substrates)aliskiren, ambrisentan, anacetrapib, atenolol, asunaprevir, atrasentan, 
atorv astatin, bosentan, bromociptine, caspofungin, cerivastatin, celiprolol, 
danoprevir, d igoxin, docetaxel, eliglustat, e pangliflozin, ezetimibe, fimasartan, 
fexofenadine, fluvastatin, glyburide, maraviroc, methotrexate, sn -38, 
rosuvastatin, saquinavir, simvas tatin acid, paritaprevir, pi[INVESTIGATOR_2830], 
pravastatin, repaglinide, rosuvastatin, simvastatin, valsartan, olmesartan, 
telmisartan, montelukast, ticlopi[INVESTIGATOR_5325], thyroxine
1Combination ritonavir -boosted regimens are listed here in the DDI memo as strong CYP3A i nhibitors (to avoid 
potential confusion), even though some are considered moderate CYP3A inhibitors in the UW  DDI Database. 
2The effect of grapefruit juice varies widely among brands and is concentration -, dose -, and preparation -
dependent. Studies have s hown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation 
was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was 
used (e.g., low dose, single strength). 
3These drugs have both a narrow therapeutic index and an in vivo DDI outcome partly ascribed to P -gp inhibition 
or induction that exceeds 20% change in AUC.

[COMPANY_001] Confidential Page 149
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
14.2 Appendix 2 –FACT-Leu questionnaire 
FACT -Leu (Version 4)
English (Universal)
Copyright 1987, 199719November [ADDRESS_1018399] pain .......................................................................... 0 1 2 3 4
GP5 Iambothered by[CONTACT_744406] ......................... 0 1 2 3 4
GP6 Ifeelill............................................................................... 0 1 2 3 4
GP7 Iamforced to spend time in bed........................................ 0 1 2 3 4
SOCIAL/FAMILY WELL -BEING Not
at allAlittle
bitSome -
whatQuite
a bitVery
much
GS1 Ifeelclose to myfriends .................................................... 0 1 2 3 4
GS2 Igetemotional support from myfamily ............................ 0 1 2 3 4
GS3 Igetsupport from myfriends............................................. 0 1 2 3 4
GS4 Myfamily hasaccepted myillness .................................... 0 1 2 3 4
GS5 Iamsatisfied with family communication about my
illness.................................................................................. 0 1 2 3 4
GS6 Ifeelclose to mypartner (orthe person who is mymain
support) .............................................................................. 0 1 2 3 4
Q1 Regardless ofyour current level ofsexual activity, please
answer thefollowing question. Ifyou prefer notto answer it,
please mark thisbox and go to thenext section.
GS7 Iamsatisfied with mysexlife............................................ 0 1 2 3 4

[COMPANY_001] Confidential Page 150
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Please select onenumber perlinetoindicate your response asitapplies tothepast 7days.
EMOTIONAL WELL- BEING Not
at allAlittle
bitSome-
whatQuite
a bitVery
much
GE1 Ifeelsad.............................................................................. [ADDRESS_1018400] my illness .................. 0 1 2 3 4
GE4 Ifeelnervous ....................................................................... 0 1 2 3 4
GE5 Iworry about dying............................................................. 0 1 2 3 4
GE6 Iworry that mycondition will getworse ............................ 0 1 2 3 4
FUNCTIONAL WELL -BEING Not
at allAlittle
bitSome-
whatQuite
a bitVery
much
GF1 Iamable to work (include work athome) .......................... 0 1 2 3 4
GF2 Mywork (include work at home) is fulfilling..................... [ADDRESS_1018401] accepted myillness................................................... 0 1 2 3 4
GF5 Iamsleepi[INVESTIGATOR_102641] ............................................................... 0 1 2 3 4
GF6 Iamenjoy ing the things Iusually dofor fun ...................... 0 1 2 3 4
GF7 Iamcontent with the quality ofmyliferight now.............. 0 1 2 3 4

[COMPANY_001] Confidential Page 151
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Please select onenumber perlinetoindicate your response asitapplies tothepast 7days .
ADDITIONAL CONCERNS Not
at allAlittle
bitSome -
whatQuite
a bitVery
much
BRM3 Iambothered by[CONTACT_260788] (epi[INVESTIGATOR_744347]) ....................................................................... [ADDRESS_1018402] night sweats ............................................................. 0 1 2 3 4
LEU1 Iambothered by[CONTACT_744407] (e.g., neck, armpi[INVESTIGATOR_10022], or groin) .............................. [ADDRESS_1018403] emotional ups and downs ........................................ 0 1 2 3 4
LEU7 Ifeelisolated from others because ofmyillness or
treatment............................................................................. 0 1 2 3 4

[COMPANY_001] Confidential Page 152
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
14.3 Appendix 3 –EQ-5D -5L questionnaire 
Health Questionnaire
English version forthe[LOCATION_003]
[LOCATION_003] (English) ©2009 EuroQol Group. EQ-5D™ isatrade mark oftheEuroQol Group

[COMPANY_001] Confidential Page 153
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301
Under each heading, please check theONE boxthatbest describes your health TODAY
MOBILITY
Ihave noproblems walking 
Ihave slight problems walking 
Ihave moderate problems walking 
Ihave severe problems walking 
Iamunable towalk 
SELF -CARE
Ihave noproblems washing ordressing myself 
Ihave slight problems washing ordressing myself 
Ihave moderate problems washingor dressing myself        
Ihave severe problems washing ordressing myself 
Iamunable towash ordressmyself 
USUA LACTIVITIES (e.g. work, study, housework,
family orleisure activities)
Ihave noproblems doing myusual activities 
Ihave slight problems doing myusual activities 
Ihave moderate problems doing myusual activities 
Ihave severe problems doing myusual activities 
Iamunable todomyusual activities 
PAIN/DISCOMFORT
Ihave nopain or discomfort 
Ihave slight pain or discomfort 
Ihave moderate pain ordiscomfort 
Ihave severe pain ordiscomfort 
Ihave extreme pain ordiscomfort 
ANXIETY /DEPRESSION
Iamnotanxious or depressed 
Iamslightly anxious ordepressed 
Iammoderately anxious or depressed 
Iamseverely anxious or depressed 
Iamextremely anxious ordepressed 

[COMPANY_001] Confidential Page 154
Amended Oncology Protocol Version No. 0 1 (Clean ) Protocol No. CPKC412E2301



Wewould liketoknow how good orbadyour health is
TODAY.
This scale isnumbered from 0to100.
100means thebest health youcanimagine.
0means theworst health youcanimagine.
Mark anXonthescale toindicate how your health isTODAY.
Now, please write thenumber you marked onthescale in the
boxbelow.Thebest health
youcanimagine
100
95
90
85
80
75
70
65
60
55
YOUR HEALTH TODAY = [ADDRESS_1018404] health
youcanimagine
